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The incubation of rat jejunal slices in Kreb/s-Ringer 
bicarbonate buffer (RRS) resulted in a time dependent release 
of soluble sialyltransferase (STase) into the incubation 
medium for up to 6 h. However, the STase released was 
susceptible to proteolysis and in order to measure the STase 
activity released there was a requirement for either heat-
inactivated serum, 0: 1 proteinase inhibitor (AlP!) or 0:1 
antiplasmin in the incubation medium. Trypsin and plasmin 
activities higher in medium obtained from KRB 
incubations, compared to incubations where KRB 
supplemented with either heat-inactivated horse serum (HHS) 
heat inactivated rat serum (HRS). 
Addition of heparin to jejunal incubations supplemented 
with HRS or HHS resulted in decreased STase activity and 
increased trypsin and plasmin activities in the medium. It was 
determined that the heparin-binding fraction (HSF) from HHS or 
HRS was the serum component required in order to measure STase 
activity in the medium. 
HSF exhibited inhibitory activity towards trypsin and 
plasmin, but did not inhibit either elastase, thrombin, 
chymotrypsin, kallikrein or papain. A trypsin-binding protein 
(TBPl was isolated from HSF by trypsin agarose affinity 
ill 
chromatography. TBP was able to inhibit trypsin and plasmin 
and on 50s-Page showed a single major band and an apparent 
molecular weight of 67 kOa. When TBP was used to supplement 
jejunal incubations, it was as effective as HSF in protecting 
the STase activity released during jejunal incubations. 
Galactosyltransferase (GTase), which was also released in 
the soluble form during jejunal incubations, was not dependent 
on the proteolytic activity of the medium. GTase activity in 
the incubation medium remained similar whether incubations 
were carried out in KRB alone or in KRB supplemented with 
either HHS, HRS, HBF or TBP. Addition of heparin to 
incubations in either KRB or KRB supplemented with HRS did not 
a decrease in GTase activity, further suggesting that, 
GTase in contrast to STase was not dependent on the 
proteolytic activity of the medium. 
Heat-inactivated serum from turpentine treated rats had 
higher trypsin and plasmin inhibitory activities compared to 
heat-inactivated control rat serum. When heat-inactivated 
serum from turpentine treated rats was used to supplement KRB 
during jejunal incubations there was an increase in the STase 
activity released into the medium compared to incubations 
where heat-inactivated serum from control rats was used. In 
contrast, GTase activity remained similar whether 
incubations were carried out in KRB alone or in KRB 
iY 
supplemented with heat-inactivated serum from either control 
turpentine treated rats. 
Trypsin and plasmin when added individually to a mixture 
of pure STase (5) and GTase preferentially inhibited STase 
activity. This effect was observed for both the STases used 
(a2-6(N) and a2-J [0]) . TBP was able to protect STase against 
the action of trypsin and plasmin. 
Serum from turpentine treated and control rats when 
incubated for 4 h at 37°C showed a progressive decline in 
STase activity over the time of incubation. Trypsin and 
plasmin inhibitory activities also decreased over the 4 h of 
incubation. Serum STase, as well as trypsin and plasmin 
inhibitory activities remained higher in the turpentine 
treated rats compared to control rats. However, serum GTase 
activity was similar in both groups. 
In incubations with hepatocytes, STase activity released 
into the medium was also dependent on the balance between 
trypsin and plasmin inhibitory/ trypsin and plasmin activities 
of the incubation medium. STase activity was higher in the 
medium when heat-inactivated serum from either turpentine 
treated or control rats, HBF or TBP were used as supplements 
compared to incubations carried out in buffer alone. GTase 
activity remained similar when incubations were carried out in 
buffer alone or in buffer supplemented with antiproteases. 
y 
The results indicate that increased STase activity was 
associated with increased trypsin and plasmin inhibitory 
activities or decreased trypsin and plasmin activities. This 
effect was not observed for GTase activity. Soluble STase is 
susceptible to proteolysis and trypsin and plasmin inhibitors 
therefore play a key role in determining measurable STase 
activity. 
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CHAPTER I. INTRODUCTION 
SECTION 1. GLYCOPROTEINS: FUNCTIONS, SYNTHESIS AND STRUCTURE 
1.1.1. Glycoproteins: occurrence and functions 
Glycoproteins are the products ensuing from the covalent 
association via a glycosidic linkage, between a carbohydrate 
(or glycan) and a protein [Marks et al., 1962; Neuberger et 
al., 1966 J . Glycoproteins are ubiquitous compounds found in a 
large variety of living organisms (Table 1.1). They occur in 
membrane-bound as well as soluble forms, in intracellular and 
extracellular fluids. Examples include enzymes, hormones, 
immunoglobulin, lectins, circulatory and membrane proteins 
( Spiro, 1963, 1966; Sharon and Lis, 1981; Schachter, 1984; 
Cumming, 1992]. 
The carbohydrate moieties of glycoproteins have been 
implicated in a number of biochemical fUnctions [Sharon and 
Lis, 1981; Berger et al., 1982; Schachter et aI, 1982; 
Schachter, 1984; Cumming, 1992; Roth, 1993]. These functions 
include (1) influence on the physical properties of proteins, 
(2) determination of blood group antigenicity, (3) protection 
against proteolysis of the polypeptide moiety, (4) control of 
the lifetime of circulatory proteins, (5) role in biological 
functions such as membrane recognition and uptake of 
glycoproteins by cells and (6) involvement in cell-cell 
interactions and cellular differentiation. 
TABLE 1.1. Examples at glycaprateins. Examples of commonly 
occurring glycoproteins are shown in the table. [Adapted from 
Sharon and Lis, 1981]. 
Glycoproteins Source Molecular Carbohydrate 
weight content ,., 
enzymes 
alkaline mouse liver 130 000 I. 
phosphatase 
hormones 
erythropoietin human urine 34 000 29 
aeabr4lle proteins human 
_ glycophor in erythrocytes 31 000 60 
serua proteins 
IgG immunoglobulin human serum 150 000 10 
structural 
proteins rat skin 300 000 A.' 
collagen 
I .1. 2. Glycopeptide-linkages and glycan structures 
I .1. 2 .A. Types of glycopeptide-linkages 
Glycoproteins are classified according to the linkage 
formed between the oligosaccharide (or glycopeptide) and the 
amino acid. Two types of linkages predominate, namely the N-
type and o-type glycosidic linkages respectively. In N-linked 
glycoproteins, an N-acetylglucosamine (GlcNAc) residue in the 
glycopeptide is linked N-glycosidically to an asparagine (Asn) 
residue in the polypeptide (Figure 1.1). Most N-linked 
glycoproteins share a common pentasaccharide core comprised of 
three mannose (Man) residues and two GlcNAc residues, linked 
to an Asn (Figure 1.1). Examples of N-linked glycoproteins 
include serum proteins (such as a 1 proteinase inhibitor 
(AIPI], transferrin, a 1 acid glycoprotein {AGP}) , enzymes 
(such as alkaline phosphatase, amylases), hormones (such as 
thyroglobulin, chorionic gonadotrophin), membrane proteins 
(such as glycosyltransferases) and receptor proteins (such as 
rhodopsin) (Kornfeld and Kornfeld, 1980; Sharon and Lis, 1981; 
Berger et aI., 1982; Schachter et aI., 1982; Cumming, 1992]. 
The most prevalent o-type linkage is that which 
between N-acetylgalactosamine (GalNAc) O-glycosidically linked 
to the hydroxyl groups of either a serine (ser) or threonine 
(Thr) residue on the polypeptide (Figure 1.2). Examples of 
molecules with this kind of oligosaccharide linkage include 
- Asn -
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GJcIIAc 
- Asn -
A: COMPLEX-TYPE 
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Figure 1.1 . Typical structures of N- linked carbohydrate 
chains 
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Figure 1.1. Typical structures of "-linked carbohydrate 
chains. Examples of a complex-type glycan (A), high mannose-
type glycan (B), hybrid-type glycan (e) shown in the 
figure and are the type of the glycan structures found in N-
linked glycoproteins. N-linked glycoproteins share a common 
penta saccharide core comprising of Man1GlcNAc2, which is 
indicated in the boxed area. (Adapted from Sharon and Lis, 
1981; Roth, 1987]. 
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Figure 1. 2. Typical structures of O-linked carbohydrate 
chains 
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Figure 1.2. Typical structures of O-linked carbohydrate 
chains. A, Band C denote the typical core structures found in 
a-linked oligosaccharides, whereas D, E, F and G show the 
structures of various a-linked glycan chains. [Adapted from 
Roth, 1987]. 
5-S 
the mucins found lining the mucous epithelia of the 
respiratory, genito-urinary and gastro-intestinal systems 
[ Berger et al . , 1982; Schachter et al., 1982]. This type of 0-
linkage can also occur together with a N-glycosidic linkage in 
a glycoprotein (for example fetuin and immunoglobulin). Other 
O-glycosidic type linkages include those occurring in collagen 
and basement membranes, consisting of short carbohydrate 
chains, such as the glucosyl-galactosyl-hydroxylysine and 
galactosyl-hydroxylysine linkages respectively. Another 0-
glyc osidic linkage is that seen in proteoglycans where 
o ligosaccharides are attached to polypeptides by a xylosyl-Ser 
linkage. This introduction will focus mainly on some of the 
general features of N- and O-linked glycoproteins and/ or 
oligosaccharides. 
1.1.2. B. Glycan structure 
Studies elucidating the oligosaccharide structure of a 
particular glycoprotein are complicated by a number of factors 
( Sharon and Lis, 1981; Kornfeld and Kornfeld, 1980, 1985; 
Schachter, 1984; Cumming, 1992; Roth, 1993). One of these 
factors is the complex nature of the glycopeptide chains 
resulting from the linkages the glycan residues form. For 
instance, many of the sugar chains are branched and do not 
necessarily show repeating patterns. Another factor is 
"microheterogeneity" which is a common phenomenon, whereby a 
particular glycoprotein can occur in forms that vary from each 
other by the structure of one or more of their glycopeptide 
chains. 
In the past few decades, advances have been made in the 
methods available for the study of glycopeptide structure 
[Kornfeld and Kornfeld, 1980; Sharon and Lis, 1981; Berger et 
al., 1982; Schachter, 1984]. In order to accomplish the 
detailed characterisation of a particular oligosaccharide unit 
a combination of techniques is generally used. A first step 
usually involves purification of the glycoprotein, followed by 
proteolytic digestion and isolation of the oligosaccharides. 
The glycan moieties of glycoproteins can be isolated using 
chromatographic methods such as gel filtration, ion exchange, 
gas-liquid, high performance and affinity chromatography 
[Kornfeld and Kornfeld, 1980; Sharon and Lis, 1981; Blake and 
Goldstein, 1982; Finne and Krasius, 1982; Wells et al., 1982; 
Yamashita et aI, 1982; cumming, 1992]. Affinity chromatography 
using lectins as ads or bents is widely used for the isolation 
of glycoproteins. Among the most frequently used lectins 
concanavalin A (Con A) which is specific for mannose (Man) and 
glucose (Glc) residues; soybean agglutinin which is specific 
for GlcNAc and galactose (Gal) residues; wheat germ agglutinin 
which is specific for GlcNAc and sialic acid (also known as N-
acetylneuramininc acid {NeuAc}) and peanut agglutinin which is 
specific for Gal. 
One of the easiest features to elucidate is probably the 
carbohydrate-peptide linkage. This is because the N- and 0-
glycan linkages differ in their stability towards hydrolysis 
by acid or alkali (Takasaki et al., 1982]. O-linked glycans 
can be easily released by mild treatment with alkali/ 
borohydride. N-linked glycans generally require stronger 
conditions such as alkaline hydrolysis, trifluoroacetolysis 
and hydraz inolysis. 
Methylation analysis, initially introduced by Haworth and 
coworkers in the 1930s and later modified by Hakamori and 
coworkers, is commonly used in the elucidation of glycopeptide 
structure [ Hakamori and Jeanloz, 1961: reviewed by Sharon and 
Lis, 1981 and references cited therein; Berger et al 1982; 
Kornfeld, 1982]. This technique involves methylation of all 
free hydroxyl groups, followed by acid hydrolysis during which 
the glycosidic linkages are cleaved, whereas the methyl 
linkages remain intact. The product formed is a mixture o! 
partially methylated sugars with free hydroxyl groups. These 
hydroxyls mark the position where the sugars were linked in 
the starting material. Further analysis of the sugars and 
sugar linkages can then be carried out using other techniques, 
including chromatography, electroscopic methods or 
spectroscopy [ Sharon and Lis., 1981; Wells et al., 1982; 
Schachter, 1984 ] . 
The sequence of sugars in glycopeptides as well as their 
configuration can also be determined using glycosidases 
[Kornfeld and Kornfeld, 1980; Schachter et al., 1983; Takasaki 
et: al., 1982]. Exoglycosidases such as sialidase, (3-
galactosidase and cr-mannosidase sequentially remove the 
corresponding monosaccharides from the non reducing end of 
glycan chains. Endoglycosidases can cleave aN-linked 
oligosaccharide from a glycoprotein leaving a GlcNAc residue 
attached to the polypeptide. 
other techniques such NMR spectrometry are also used 
to study the anomeric linkages, nature and relative 
proportions of the sugars [Dabrowski et al., 1980; Carver and 
Grey, 1981; Schachter, 1984]. One of the major advantages of 
these techniques is their non-destructive character. 
1.1.3. Glycosyltransferases and glycoprotein synthesis 
I.1.3.A. Glycosyltransferases 
The glycosyltransferases are a group of enzymes which 
play a key role in the synthesis of glycopeptide chains. 
Inside the cell these enzymes are present bound to membranes 
in the Goigi apparatus and endoplasmic reticulum (ER) [Beyer 
et al., 1979, 1981; Berger et al., 1982]. The fUnction of 
these enzymes is to catalyse the transfer of a sugar residue 
from a donor to an acceptor. The donor is generally a 
nucleotide diphospho sugar except for the reaction catalysed 
by sialyltransferase (STase) where the donor is CMP-NeuAc 
(CMP-sialic acid). The acceptor can be an oligosaccharide 
either in the free form or linked covalently to protein 
[Berger et al., 1982; Schachter, 1984; Hirschberg and snider, 
1987; Roth, 1987; Finne and Colley, 1989]. A typical reaction 
catalysed by a glycosyltransferase with STase as an example is 
shown in Figure 1. 3. These enzymes operate in a concerted 
fashion, the product of each glycosyltransferase reaction 
serving as the substrate for the next enzyme. The nature of 
these enzymes and the reactions they catalyse ensures that out 
of a large number of structures theoretically possible only a 
limited set of glycopeptide chains are actually produced. On 
the basis of the type of sugar transferred, 
glycosyltransferases can be grouped into families (eg. STases, 
galactosyltransferases [GTaSeS], fucosyltransferases etc.). 
The individual enzymes in each family can be distinguished by 
their specificity for the acceptor substrates and the type of 
anomeric linkage formed in the product. The reaction shown in 
Figure 1. 3 is typical for STase which catalyses the addition 
of the terminal NeUAc onto N-linked oligosaccharides. The 
enzyme preferentially utilises the sequence Gal.B1-4GlcNAC in 
the acceptor and is not active for other sequences such 
Gal.B1 .... 3GlcNAC or Gal.Bl .... 3GalNAc [Beyer et al.. 1981; Joziasse 
et al., 1987]. 
1.1.3.B. Subcellular localization of oligosaccharide synthesis 
Some differences exist between the synthesis of N- and 0-
linked glycans which will be addressed along with glycopeptide 
synthesis in the following sections. The enzymes involved in 
10 
CMP-NeuAc + Ga lSl-4GlcNAc 
donor 
t 
acceptor 
NeuAca2 ..... 6GalSl-4GlcNAc + CMP 
product 
Figure 1.3. Example of a reaction catalysed by STase 
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Figure 1.3. Example ot a reaction catalysed by STase. The 
reaction shown is typical for the a2-6 STase which catalyses 
the addition of terminal NeuAc onto N-linked glycan chains, 
resulting in the formation of NeuAc cr2-6 Gal linkage. (Adapted 
from Beyer et al., 1981] . 
the early stages of glycan synthesis are localized in the rough 
endoplasmic reticulum (RER) whereas those associated with the 
later stages of glycan synthesis are localized in the Golgi 
apparatus ( Schachter, 1978; Roth et al., 1985b; Roth, 
1987 ) . N-Glycosylation is believed to be cotranslational or to 
occur shortly after completion of the polypeptide chain [Li et 
al., 1978 a,b; Schachter, 1978, 1984; Kornfeld and Kornfeld, 
1985 ) . Unlike N-glycosylation, the events involved in 0-
glycosylation are not clearly defined. It is believed that 0-
glycosylation is a cotranslational event, which takes place in 
the smooth endoplasmic reticulum (SER) and Golgi [Sharon and 
Lis 1981; Berger et al., 1982]. The later events associated 
with the maturation of both N- and 0- linked glycans take 
place in the ER and Golgi apparatus . Translational and initial 
glycosylation occurs in the RER after which the glycoproteins 
translocate via the SER to the Golgi apparatus. The 
glycoprotein moiety undergoes processing and may undergo 
modification by phosphorylation and further glycosylation 
[Reitman and Kornfeld, 1981; Goldberg and Kornfeld, 1983]. 
Lastly near or at the trans region of the Golgi, sorting takes 
place and the proteins are packaged for secretion to the blood 
stream, or transport to either the lysosomes or other membrane 
locations (Figure 1.4) (Berger et al., 1982; Hirschberg and 
Snider, 1987]. 
12 
Figure 1.4. Subcellular localizatio synthesis n of glycopeptide 
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Figure 1. 4. Subcellular local i zation of glycope ptide 
synthesis . The various cellular compartments wherein 
glycopeptide synthesis occurs are shown in the figure. 
(Adapted from Berger et aL , 1982] . 
KEY: - ( ~ ) glycoprotein . 
1)-a 
1.1.3. c. synthesis of N-l inked qly cans 
OJ Synthesis of the lipid-linked orecursor chain· The 
assembly of the precursor oligosaccharide takes place on a 
\ lipid-carrier' known as dolichol (Dol), an a-saturated 
polyisoprenoid [Chapman et aI., 1979; Parodi and Leloir, 1979; 
Berger et al., 1982; Schachter, 1984]. The oligosaccharide is 
linked to Dol via a pyrophosphate group. Dol is also involved 
in the synthesis of the sugar donors, Ool- P- Man and ool-P- Glc 
which are lipid linked sugars required in the later stages of 
the biosynthesis of the precursor sugar chain (Spiro et al., 
1976 a,b]. The first steps in the synthesis of the lipid 
linked oligosaccharide are the formation of GlcNAc-PP- Ool and 
its conversion to GlcNAc,81 ..... 4GlcNAc- PP- Ool. The next step 
involves the addition of a ,8 Man residue donated by GOP-Man 
giving rise to the product Man,81 ..... 4GlcNAc,81 ..... 4GlcNAc- PP- Ool. 
Elongation of this trisaccharide takes place by the highly 
ordered addition of a Man and a Glc residues. The end product 
is a lipid linked species Glc) Ma~ GlcNAc2- PP- Dol (Figure 
1. 5]. The completed oligosaccharide is transferred en bloc to 
the protein. 
Oi J. Glycosylation of proteins: The transfer of the 
oligosaccharide to an Asn residue on a nascent polypeptide 
chain occurs in the RER [Czichi and Lennarz, 1977; Schachter, 
1978; Kornfeld and Kornfeld , 1985]. It is thought that the 
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Figure 1.5. proposed structure of t he lipid- linked 
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Figure 1. s. proposed structure of the lipid-linked 
oligosaccharide precursor of Asn-linked glycans. 
The structure of the dolichol-linked oligosaccharide precursor 
involved in the synthesis of N-linked glycoprotein chains is 
shown in the figure. (Adapted from Roth, 1987]. 
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terminal Glc residues on the saccharide function as a signal 
for transfer to the protein (Kaplan et al., 1987; Robbins et 
al., 1977; Truco and Robbins, 1979; Allen et al., 1984 J. This 
reaction is catalysed by oligosaccharyltransferase, 
enzymewhich preferentially acts on glycosylated lipid-linked 
liposaccharides compared to unglycosylated lipid derivatives. 
In order for the carbohydrate transfer or attachment to 
occur, there is a requirement for the sequence Asn-X-Ser (Thr) 
on the polypeptide chain where X can be any amino acid. This 
however is not the sale requirement as other factors including 
sufficient exposure of the tripeptide sequence of the acceptor 
protein also considered to influence carbohydrate 
attachment. Fragmented or denatured peptides are considered to 
be better acceptors for glycosylation compared to folded 
polypeptide chains [Schachter, 1978; Berger et al., 1982; 
Green, 1982; Pollack and Atkinson, 1983; Trimble et al., 1983; 
Schachter, 1984; Kornfeld and Kornfeld, 1985 J • 
(iii). Processing of the protein-linked oligosaccharide' Once 
the oligosaccharide is transferred onto the polypeptide chain, 
the carbohydrate portion of the "newly formed glycoprotein" 
undergoes extensive processing (Figure 1.6). The processing 
begins with the removal of the Glu residues by glucosidases 
[Grina and Robbins, 1979; Ugalde et al., 1980]. The distal 
glucose is removed by microsomal a-glucosidase I, 
glucosidase II then removes the two remaining Glu residues 
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Figure 1.6. processing of the Asn-linked oligosaccharides. 
Schematic diagram showing the processing reactions occurring 
in the ER during the synthesis of Asn-linked oligosaccharides. 
[Adapted from Roth, 1987]. 
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giving a glycopeptide .... ith the structure Ma~GlcNAcl ' A large 
number of glycoproteins at this stage go through " mannose-
trimming". The Man9GlcNAc2 intermediate undergoes processing by 
the removal of the 0:1 ..... 2 linked mannose residues, catalysed by 
o:-mannosidases which are located in the Golgi. In the 
order for the Man~GlcNac2 pentasaccharide or core structure to 
be formed two different mannosidases are needed [Tabas et al., 
1981; Tabas and Kornfeld, 1979; Tulsiani et aI., 1982; Allen 
et al., 1984]. The MansGlcNAc1 glycopeptide linked to protein 
can be converted into either a complex-type or a hybrid-type 
glyc an (Figures 1. 7 and 1.8). Some glycoproteins contain 
carbohydrate moieties which after the removal of Glc do not 
get processed to the same extent as complex- and hybrid - type 
glycans. This results in the formation of high- Man structures 
containing between 5 to 9 Man residues (Trimble et al., 1983]. 
A number of factors govern the extent and processing of the 
individual glycosylation stages [Wilson et al., 1981; 
Kornfeld, 1982; Schachter, 1984]. These include (1) the 
conformational exposure of the glycosylation site, (2) the 
activity of the enzymes catalysing the . various reactions and , 
(3) the transit time through the ER and Golgi. 
civ!. Conversion to either complex-type or hybrid-type 
structures: GlcNAc-transferase I plays a key role in the 
formation of complex- and hybrid-type glycans from the 
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Figure 1.7. Terminal steps involved in the synthesis of 
complex-type glycans 
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Figure 1.7. Terminal steps involved in the synthesis of 
complex-type glycans. Some of the terminal steps involved in 
the formation of complex-type glycans are shown in the figure. 
[Adapted from Roth, 1987]. 
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Figure 1.8. proposed mechanism involved in the formation of 
hybrid-type glycans. The steps leading to the formation of 
hybrid-type glycans are shown in the figure. [Adapted from 
Kornfeld, 1982]. 
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Man5GlcNAC:! intermediate. This enzyme attaches GlcNAc in a ,81 ..... 2 
linkage to Man (Figure 1. 7) to give the structure GlCNAC-Man,-
GlcNAc2-R. At least five of the enzymes that take part in the 
synthesis of the glycan chain require prior action by GlcNAc 
transferase I [Harpaz and Schachter, 1980 a,b; Hasilik et al., 
1981}. The formation of complex type glycans involves cr-
mannosidase II which catalyses the removal of the two 
remaining a-linked Man residues. The resulting glycopeptide 
GlcNAcMan3GlcNAc-R is converted by GlcNAc-transferase II into 
a biantennary structure [Bendiak and Schachter, 1987 a,b}. 
Further branching takes place through the action of GlcNAc-
transferases IV and v [Schachter, 1978, 1984). Gal is then 
added in a /31 ..... 4 linkage to GlcNAc at the Man a1 ..... 3 branch of 
the biantennary glycans [Hanover and Lennarz, 1981; Hubbard 
and Ivatt, 1981; Berger et al., 1982; Hirschberg and snider, 
1987]. The complex-type structures can undergo fucosylation at 
the core GlcNAc. Finally NeUAc (in either a cr2"'3 or a2 ..... 6 
linkage) is added to the terminal Gal residues, or L-Fuc is 
added to the subterminal GlcNAc residue in a a1 ..... 3 linkage. 
Addition of aNeUAc, aFuc or aGal blockt the further extension 
of the sugar chains [paulson et al., 1978). 
Hybrid-type carbohydrate structures are produced in 
those tissues where GlcNAc-transferase III is active (Figure 
1. 8). The enzyme transfers GlcNAc in ,81-4 linkage to the 
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branching (J Man. This bisecting GlcNAc hinders access to the 
GlcNAcS recognition site [Harpaz and Schachter, 1980 a,b; 
Narasimhan, 1982). This in turn prevents action of a 
mannosidase II resulting in the synthesis of hybrid-type 
oligosacchar ides. 
tv). Is there a requirement for elaborate processing? 
The complex processing pathway(s) are thought to be 
a mechanism whereby the cell is able to generate a variety of 
glycan structures, without the need for developing new 
pathways for the biosynthesis of lipid-linked oligosaccharides 
[Berger et aI., 1982; Kornfeld, 1982; Roth, 1987). The 
processing pathway is therefore a means by which at least five 
different classes of N-linked glycans can be produced from a 
single precursor [Figure 1.9). 
I.1.3.D. synthesis or O-linked glycans 
The biosynthesis of O-linked glycans differs from N-
linked glycans [Schachter, 1978; Berger et al., 1982; Roth, 
1987). O-linked carbohydrate chains are synthesized one 
residue at a time directly onto the protein backbone. So far 
there seems to be no evidence to indil=!ate involvement of a , 
lipid-linked intermediate. The factors which ultimately 
control and determine the structures of O-glycopeptides 
not clearly defined. Some of the reactions involved in the 
synthesis of 0 glycans have been studied and these studies 
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4PC-cA.. ..... 
Figure 1. 9. Different kinds of glycans formed from a common 
lipid-linked oligosaccharide 
Figure 1. I). Different kinds of glycans formed from a cOJllllon 
lipid-linked oligosaccharide. The figure shows a summary of 
the different types of glycans which are known to be formed 
from a common lipid-linked oligosaccharide. [Adapted from 
Kornfeld, 1982]. 
KEY: ( A) glucose, (0) mannose, (.) N-acetylglucosamine, 
( • ) galactose, (...L.. ) asparagine. 
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have provided valuable information regarding the synthetic 
process(es) of O-linked oligosaccharides. 
The initial step is the transfer of GalNAc from UDP-
GalNAc to either a Ser or Thr residue on the polypeptide chain 
of a protein and this reaction is catalysed by the enzyme UDP-
GalNAC: polypeptide transferase. [Hill et al., 1977; 
schachter, 1978; Berger et al., 1982, Roth, 1987]. 
UDP-GalNAc + HO-(ThrjSer) --- GalNAca-O-(ThrjSer) + UDP 
The GalNAc-transferase involved in O-glycosylation is mainly 
located in the SER and Golgi apparatus and recognises Ser and 
Thr residUes [Hill et al., 1977). The product of one 
glycosyltransferase serves as the acceptor substrate for the 
next reaction. 
In a particular tissue, the structure of O-linked glycans 
is determined by the relative activities of the 
glycosyltransferases and the substrate specificities of the 
particular tissue. The ordered addition of sugar residues 
results in the formation of a well def f ned glycan structure. 
In mucins the synthesis of sialylated oligosaccharides 
proceeds in an ordered fashion by the additions of Fuc, GalNAc 
and NeuAc to Gal!31-3GalNAC-R chains [Hill et al., 1977; Berger 
et al., 1982). The addition of NeuAc to the oligosaccharide 
GaiNAcal-R appears to block elongation of this chain. The 
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length of the glycan chain thus depends on the stage where 
NeuAc is introduced into the glycan [Berger et al., 1982]. A 
proposed scheme for the biosynthesis of the porcine mucin 
pentasaccharide is shown in Figure 1.10. After the formation 
of the glycan chain GalNAcaThr/Ser, either Gal or NeuAc can be 
transferred next. It has been shown that Gal requires to be 
added next, and that the addition of NeuAc before Gal 
terminates the oligosaccharide as a disaccharide [Schachter, 
1978; Schachter and Roseman, 1980]. The steps involved in 
glycosylation after the formation of the sequence Gal,B1-3 
GalNacaThr/ser have been studied [Beyer et al., 1981] . Three 
homogeneous glycosyltransferases purified from porcine 
submaxillary glands were used and the possible tri - and 
tetrasaccharide intermediates en route to the completed 
pentasaccharide tested substrates . The 
glycosyltransferases used were those which catalysed the 
addition of the non-reducing terminal NeuAc, Fuc a nd GalNAc 
and the results are summarized in Figure 1.10 (8). These 
studies indicated that the preferred order of addition is 
NeuAc, Fue and GalNac respectively. The NeuAc was added first 
i 
as fucosylated substrates are poor substrates for STase and 
the GalNAc added last since GalNAc-transferase requires the 
Fucal-2Gal sequence as a substrate. 
Some studies indicate that there is genetic control at 
the level of the expression of the number a nd type of 
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GalNAc ~ Gal....!'!.!... GalNAc It Thr/ Ser A 
iltH tl12-6 
Puc NeuAc 
Figure 1.10. Proposed stages in the synthesis of a - linked 
oligosaccharide chains 
Figure 1.10. proposed stages in the synthesis of O-linked 
oligosaccharide chains. Panel A shows the structure of the 
completed mucin penta saccharide . Panel B shows the 
biosynthesis. The preferred addition of sugars is shown in the 
centre. Alternate pathways branching to the sides result in 
dead end products because of the inability of 
glycosyltransferases to carry out the reactions shown by 
hatched or solid blocks. (Adapted from Berger et al., 1982]. 
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glycosyltransferases which are produced in a cell. The genetic 
basis for the A, Band 0 blood groups is determined by the 
carbohydrate structures present the red cell 
glycoconjugates [Schachter and Roseman, 1980; Beyer et al., 
1981; Keshavara et aL, 1992). All three blood group 
structures share a terminal precursor sequence 
Fucal-2Gal. Blood group A is determined by an additional 
GalNAc residue GalNAcal-3 (Fucal-2)Gal and blood group B by an 
additional Gal residue Galal-3 (Fucal-2) Gal. 
SECTION 2. SIALYLTRANSFERASES (STASES) 
1.2.1. Nature and cellular localization of STases 
I.2.1.A. specificity of STases 
STases are a family of glycosyltransferases which 
catalyse the transfer of NeUAc from CMP-NeuAc, to usually 
terminal positions on the carbohydrate residues of suitable 
acceptors [Beyer et al., 1981]. The acceptor can be an 
oligosaccharide either in the free form or attached to a 
protein. 
The hallmark of glycosyltransferases is thought to be 
their specificity which forms the basis' of the one-enzyme one-
linkage hypothesis. Each STase exhibits high specificity for 
the protein acceptor, the nucleotide sugar, the linkage which 
is formed (a2--3, a2-6, a2-8) and the structure of the acceptor 
molecule. The reaction shown in Figure 1.11 is typical for the 
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CMP-NeuAc + GalBl-tGlcNAc - - - .. NeuAca2 .. 6GalBl-tGlcNAc + CMP 
DONOR ACCEPTOR PRODUCT 
Figure 1.11. Example of a reaction catalysed by STase 
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Figure 1.11. Example ot a reaction catalysed by BTase. An 
example of a reaction catalysed by STase is shown. CMP-NeUAc 
is the nucleotide sugar donor, Gal(j1 ..... 4GlcNAc is the required 
sugar sequence in the acceptor. The product formed will have 
NeuAc linked 02-6 to a Gal residue. [Adapted from Beyer et 
al., 19B1). 
STase which catalyses the addition of NeuAc onto N-linked 
oligosaccharides. The enzyme preferentially utilises the 
sequence Gal.B1-4GlcNAc in the acceptor and is not active for 
other sequences such as Galf3'1-3GlcNAc and Gal.B1-3GaINAC (Beyer 
et al., 1981: Bergh et al., 1983; Joziasse et al., 1987; Van 
den Eijnden et al., 1977, 1980; Nemansky et al., 1992]. The 
specificity of STase is believed to extend to structural 
features beyond the terminal N-acetyllactosamine units on the 
oligosaccharide chains of acceptor proteins. studies by Van 
den Eijnden and coworkers (1980] showed that .B-galactoside 
cr2-6STase from bovine colostrum preferentially transferred 
NeuAc to the Gal{j1-4GlcNAqSl-2Mancrl .... 3Man branch of crIAGP. The 
branch with the sequence Gal.B1-4GlcNAc.Bl .... 4Mancr1 .... 3Man was of 
intermediate preference, whereas the least preferred branch 
was that with the sequence Gal.B1-4GlcNAc{jl-2Mana:1-6Man. 
Evidence not conforming to the one-enzyme one-linkage 
hypothesis also exists in the literature. For example studies 
have shown that the Gal.B1-4GlcNAca:2 .... 6 STase from rat liver was 
able to sialylate the disaccharide Man.B1-4 GlcNAc and the 
trisaccharide Man.B1-4GlcNAc.B1-4GlcNAC lvan Pelt et al. ,1989]. 
I 
In eucaryotic cells five NeuAc linkages predominate 
namely (1) NeuAca:2-6Gal (2) NeuAca:2 ..... 3Gal (3) NeuAca:2-6GaINAc 
(4) NeuAca:2-6GlcNAc and (5)NeuAca:2 ..... 8NeuAc (Sadler et al., 1979; 
Beyer et al., 1981; weinstein et al., 1982 a,b; Finne et al., 
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1983; McCoy et a1., 1985; Broquet et a1., 1991]. 
1.2.1.8. Distribution of aTas. within the cell 
STases in cells are found located predominantly in the 
Golgi apparatus, but enzyme activities have also been detected 
in ER and plasma membranes (Berger and Hesford, 1985; Roth et 
al., 1986; Taatjes et al., 1987; Bosshart and Berger, 1992; 
Tang et al., 1992]. There is evidence that in mouse and rat 
hepatocytes Gal02-6 STase is found within the trans Golgi 
cisternae and the trans tubular network [Carey and Hirschberg, 
1981; Roth, 1987]. In intestinal goblet cells, STase was found 
to be distributed in the trans cisternae of the Golgi 
apparatus staCk, brush border and plasma membranes [Roth et 
a1., 1986: Stitcher et a1., 1991]. The presence of two 0-
glycan STases have been reported in rat brain, with the a:2-3 
STase located towards the lumen and the 02-6 STase located 
towards the cytoplasmic side of the Golgi membranes 
[Baubichon-Cortay et al., 1986b]. 
Drugs and related agents can cause redistribution of 
STase in cellular membranes. For instance, in experiments with 
cuI tured hepatocytes it observed that malignant 
i 
transformation caused a reorganization of (trans) Golgi 
apparatus elements containing STase, leading to a more 
extensive distribution compared to intact hepatocytes (Taatjes 
et al., 1987]. Experiments by Tang and coworkers (1992) with 
CHO cells transfected with cDNA of the rat STase have revealed 
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that the STase expressed was found localized in the trans-
Golgi, but upon treatment with brefeldin A was redistributed 
into the ER. STases have been found in the outer membranes of 
mouse liver mitochondria [Gateau et al., 1980], rat liver 
nuclei [Richard et al., 1975] and synaptosomes (Breen and 
Regan, 1986]. 
STases have also been found localised to internal 
membranes other than the Golgi and ER. The presence of ecto-
STases has been demonstrated in a variety of cells including 
platelets (Bauvois et al., 1981], lymphocytes (Hoflack et al., 
1979], lymphoblasts (DucDeudon et al., 1984], neuronal cells 
[Matsui et al., 1983, 1986] and mucosal cells of the small 
intestine [Taatjes et al., 1988]. 
1.2.2. STases in tissues and extracellular fluids 
I . 2.2.A. Distribution of STase in tissues 
STase activities have been detected in a variety of 
mammalian tissues including rat mammary glands [Jourdian et 
al., 1963; Roseman et al., 1966; Carlson et al., 197Ja], 
sheep submaxillary glands (Roseman et al., 1966; Carlson et 
al., 1973b], embryonic chicken brain (Roseman et al., 1966], 
.. 
rat and calf liver (van den Eijnden and Schiphorst, 1981; 
Paulson et al., 1982; 1984], rat and chicken brain (Dall'Olio, 
1990; Van den Eijnden and Schiphorst, 1981] and mouse kidney 
(Bardos et al., 1980]. STases are also present in blood cells 
such as platelets (Bauvois et al., 1982), leucocytes and 
31 
lymphocytes [Hoflack et al., 1979; Baker et al., 1987]. It is 
thought that in order to synthesize all the sialo-
oligosaccharide sequences known, more than 15 STases are 
required [Schauer, 1982]. A number of STases have been 
purified including ,8Gala:2 ..... 6 STase from rat liver [Weinstein 
et al., 1982a, bJ, ,8GaINAca:2-6 STase from porcine submaxillary 
glands [Sadler et al., 1979], ,8Gala2 ..... 3 STase from human 
placenta [Joziasse et al., 1985bJ, ,BGala:2 ..... 6 and ,BGala2 ..... 3 
STases from human platelets [Bauvois et al., 1982]. 
The primary sequence of ,8Gal a:2 ..... 6 STase (E.C.2.4.99.1) 
from rat liver has been determined from the nucleotide 
sequence of eDNA and was compared with five other cloned 
glycosyl transferases [Weinstein et al., 1987; Paulson and 
Colley, 1989]. The six enzymes studied by these researchers 
showed a lmost no sequence homology. However, they shared a 
homologous amino terminal Nlt.J tail on the cytoplasmic side of 
the membrane, a 16-20 amino acid anchor domain in the membrane 
and a large carboxyl terminal catalytic domain on the lumenal 
side of the Golgi membrane (Figure 1.12). 
The stem region is thought to art as a flexible hold 
leaving the catalytic region exposed, thereby enabling it to 
glycosylate carbohydrate moieties of membrane-bound proteins 
as well as other proteins of the secretory pathway enroute 
through the Golgi apparatus [Weinstein et al., 1987; Paulson 
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cataJytic 
domain 
Figure 1.12. proposed topography of STase 
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Figure 1.12. Proposed topography ot BTase. Terminal 
glycosyltransferases are believed to share a common topography 
in the Golgi apparatus. The enzyme molecule is thought to 
consist of a short NH2-terminal cytoplasmic tail, a signal 
anchor domain which spans the membrane, an extended stem 
region, and a large COOH-terminal catalytic domain oriented 
within the lumen of the Golgi cisternae. proteolytic cleavage 
of the membrane anchor is believed to release the molecule in 
the soluble form. [Adapted from Paulson and colley, 1989). 
and Colley, 1989]. Recent studies suggest that the signal 
anchor domain as well as a second region of Galcr:2 ..... 6 STase, 
probably the stem region, contain sequences which playa role 
in the Golgi apparatus localization [Colley et al., 1989, 
1992] . 
1. 2 .2 . B . So luble STas e s 
Soluble forms of STases exist in body fluids including 
milk, serum, colostrum and intestinal lymph [Hudgin and 
Schachter, 1971a,b; Kim et al., 1972a,b; Mookerjea et al., 
1972; Paulson et al., 1977; Joziasse et al., 1987; Ratnam et 
al., 1981]. These enzymes are believed to originate due to 
proteolytic release from their membrane-bound forms [Paulson 
and Colley, 1989; Broquet et al., 1991). Results obtained from 
NH2 terminal analysis of the soluble forms of STase have 
revealed a lumenal stem region which separates the catalytic 
domain from the transmembrane domain and is exposed to 
prot eases (Weinstein et al., 1987; Colley et al., 1989; 
Gillespie et al., 1992). Other studies have shown that a 
cathepsin-D-like protease is involved in the release of STase 
from hepatocyte membranes [Lammers and Jamieson, 1988, 1990; 
.. 
Mccaffrey and Jamieson, 1993]. 
Some pathological conditions associated with 
increases in activities of STase(s) in both tissue(s) and body 
fluids. Turpentine induced inflammation in the rat is 
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accompanied by increased STase activity in liver and serum 
[ Kaplan et a1., 1983; Fraser et a1., 1984). Hepatocytes and 
liver slices in culture have been shown to release soluble 
STase into the incubation medium [Kaplan et a1., 1983; Van 
Dijk et a1., 1986). In the rat colchicine injection resulted 
in increased STase activity in intestine, intestinal lymph and 
serum [ Fraser et a1., 1980; Ratnam et a1., 1981, 1987). Chu 
and coworkers [1988 ) have demonstrated that thermal injury in 
the r at caused increased STase activity in small intestine 
and serum. Liver is thought to be the major source of soluble 
STase activity in tissue fluids especially blood. The presence 
of STase in blood cells such as platelets [Bauvois et a1., 
1981, 1982], granulocytes and lymphocytes [Hoflack et al., 
1979; Baker et al., 1987 ] suggests that these may also 
contribute to the STase activity present in blood. The 
increased activity of STase observed in small intestine as 
well as serum, following thermal injury and colchicine 
injection suggest that the intestine could be a possible 
source of soluble STase activity. 
Although it is clear that STase activity can be detected 
f 
in extracellular fluids, as well as in cell/tissue culture 
mediUm, the factors which control the levels of soluble STase 
are not clearly defined. Also, the conditions which govern the 
release of the membrane-bound STase and the subsequent levels 
of soluble STase activity are poorly understood. 
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The release of STase from the membranes could be due to 
a number of factors. For example, the STase activity detected 
in tissue fluids or incubation media could be the result of 
release of surface materials from membranes. It has been 
proposed that STase is a secretory protein which may explain 
its association with plasma membranes [Bosshart and Beyer, 
1992 J. Release of STase into the incubation media and/ or 
tissue fluids could also occur as the result of cell damage, 
due to either pathological processes or normal wear and tear 
of cells. STases however are membrane-bound proteins, and 
detection in the soluble form would still require these 
membrane-bound molecules to be dislodged from the membrane. 
There is evidence that proteolytic cleavage of the STase 
occurs near the membrane domain which causes the molecule to 
be released from the membranes. This protease activity has 
been described as a cathepsin-D like activity [Lammers and 
Jamieson, 1986,1988, 1990 J • 
1.2.3. Regulation of STase activity 
A number of pathophysiological conditions are associated 
with changes in sialylation and/or STa~e activities (Paulson 
and Colley, 1989; Broquet et aI., 1991; Jamieson et aI., 
1993}. changes in sialylation occur during development and 
differentiation as is evident in the rat intestine [Taatjes et 
al., 1987; Chu et aI., 1988; Taatjes and Roth, 1988] and in 
oncogenic transformation, resulting in modified circulating or 
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membrane glycoproteins (Miyagi et a1., 1988; Passaniti and 
Hart, 1988]. There are many ways whereby regulation of STase 
can occur, some of which are described below. 
(aJ. Effect of cytokines and glucocorticoids: During 
turpentine induced inflammation in the rat, there is an 
increase in serum I3Gal a2 .... 6 STase activity (Kaplan et al., 
1983; Fraser et al., 1984). Jamieson and his coworkers have 
reported that a cathepsin D-like protease activity in Golgi 
membranes is increased during the acute phase response, which 
in turn caused an increased release of STase from hepatocyte 
membranes (Lammers and Jamieson, 1986, 1988, 1990; Mccaffrey 
and Jamieson, 1993]. 
Dexamethasone caused increased release of soluble STase 
activity during experiments with cultured hepatocytes (Van 
Dijk et a1., 1986] and intestinal tissue (Kolinska et a1., 
1990). wang and coworkers have demonstrated that in hepatoma 
cells dexamethasone caused an increase in STase activity [wang 
et a1., 1989, 1990a,b]. The effect of glucocorticoids and 
cytokines on STase is thought to be due to the increased 
synthesis of mRNA (O'Hanlon et al., 1989; wang et al., 1989, 
f 
1990a]. In experiments with FAZA cells, dexamethasone caused 
an increase in STase activity in both the cells and incubation 
medium {Harder et a1., 1990]. 
(bl. Drugs and other agents: Drugs and other reagents which 
cause "specific effects" on metabolism are also known to 
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affect STase activity. It has been shown that STase activities 
in liver and serum were increased when FAZA hepatoma cells 
were treated with phorbol ester ( Harder et a1., 1990). 
Colchicine injection in the rat resulted in increased STase 
activity in intestine, intestinal lymph and serum (FraSer et 
al., 1980; Ratnam et al., 1981, 1987 ) . Retinoic acid is 
thought to stimulate STase production in melanoma cell lines 
(Deutsch and Lotan, 1983; Lotan et a1., 1988). 
re I. Regulation of STase through gene expression: The cloning 
of the Gal/3 1- 4GlcNAca2-6 STase (Weinstein et al., 1987], 
Gal/31- 3 ( 4) GlcNAca2 ..... 3 STase (Wen et a1., 1992) and 
Gal/31 ..... 3GalNAc a2 ..... 3 STase (Gillespie et al., 1992] have helped 
in better understanding the regulation of STase. Lee and 
coworkers ( 1989 ) have demonstrated that the terminal sequence 
of Chinese Hamster ovary (CHO) cell glycoproteins can be 
altered by expression of a Gala/32 ..... 6 STase. The wild type cells 
normally produce oligosaccharide chains terminating in an a2-3 
NeuAc linkage and do not possess the /3Gal a2-6 STase. A 
modified cell line of CHO transfected with cDNA coding for 
/3Gala2-6STase was able to synthesise . the a2-6 linkage by , 
competing with the a2-3 STase. 
Recent studies by Wang et al (1990b] have shown that the 
hepatic STase transcript and the related kidney mRNAs are 
transcribed from different initiation sites . Also physically 
distinct promoter elements regulate the transcriptional 
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initiation of the STase isoforms. 
IdJ Effect of developmental factors: Changes associated with 
tissue development are often accompanied by changes in either 
STase or NeuAc. For example in the newborn rat cr2 ..... 3 STase 
activity in liver was high compared to a2-6 STase activity, 
when lactose was used as an acceptor [Hudgin and Schachter, 
1972]. In the adult rat however 02 ..... 6 STase predominated 
indicating that a shift from a2 ..... 3 STase to 02 ..... 6 STase occurred 
during aging. Assays with lactosamine, revealed a higher 
proportion of 02-6 STase, compared to 02-3 STase in large 
intestine of the newborn rat [Dall'Olio et al., 1990J. During 
maturation the a2 ..... 6 STase decreased resulting in a reversal of 
the ratio. 
Experiments have shown that in the suckling rat, NeuAc in 
the small intestine was distributed in the apical and 
basolateral plasma membranes of the epithelial cells, as well 
as the mucous of the goblet cells [Taatjes and Roth, 1990]. 
During the weaning period NeuAc was detectable throughout the 
villus. In the adult rat, NeUAc could not be detected in the 
epithelial cells but was present in the. goblet cell mucous of , 
the lamina propia as well as in the smooth muscle cells 
[Taatjes and Roth, 1990]. In contrast, the distribution of Fuc 
was opposite to that of NeuAc. In the suckling rat, Fuc in the 
small intestine was restricted to the goblet cells, whereas in 
the adult, Fuc was present in the apical and basolateral 
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plasma membranes of both epithelial and goblet cells. The 
results showed that a shift from sialylation to fucosylation 
occurred during the weaning phase of development. 
reI Effectors acting directly on STase: Studies by Scudder et 
al., (1982) have shown that the 0: 2-6 STase of bovine 
colostrum was stimulated by a bovine heart lectin. Five plant 
lectins tested showed very little or no activation of the 0:2-6 
STase activity. 
Detergents such as Triton X-IOO have been shown to 
activate the Gal 0:2-3 STase. A similar effect on the Gal 0:2-) 
STase was observed with lysophosphatidylcholine [Westcott and 
Hill, 1985 J. Other studies have indicated that the same lipid 
could have opposite effects on STases from the same tissue. 
For example it has been shown that lysophosphatidylcholine 
(1) inhibits the Gal 0:2-3 STase sialylating the o-glycans from 
rat brain and (2) strongly activates the GalNAc-Ser 0:2 .... 6 STase 
(Baubichon-Cortay et al., 1986a]. The GalNAc-Ser 0:2 .... 6 STase on 
the other hand was inhibited by thiol reagents such as N-
ethylmaleimide unlike the Gal 0:2 .... 3 STase [Baubichon-Cortay et 
al., 1989]. 
.-
rfl Regulation through enzyme specificity: Regulation can also 
occur as a result of enzyme specificity. Purified 0:2 .... 3 and 
0:2"'6 STases from rat liver were able to sialylate N-glycans 
from rat liver but could not sialylate O-glycan branches 
[Paulson et aI, 1982]. Though each of the enzymes was able to 
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sialylate the Gal ,s1 .... 4GlcNAc sequence only the 02-3 STase ..... as 
able to sialylate the Gal,sI .... 3GlcNAc structure. Studies by 
Joziasse et al (1985a, b] have sho ..... n that the a2 .... 6 STase from 
bovine colostrum preferentially sialylated the Manal .... 3Man 
branch of a biantennary glycopeptide of the lactosamine type. 
For bi, tri and tetra saccharides the Gal,sI- 4GlcNActh-2Manal .... 3 
branch ..... as preferentially sialylated [Joziasse et al., 1987]. 
In Q-linked glycoprotein structures such as Gala! .... 3 
GaINAc-Ser, the sialylation of the GalNAc residue through the 
02--6 NeuAc generally occurs follo ..... ing sialylation of the Gal 
residue by an 02 .... 3 linkage. This has been demonstrated in 
fetal calf liver [ Bergh et al., 1983; De Heig et al., 1986] 
and rat brain ( Baubichon-Cortay et al., 1986a, 1989] . 
faJ Effect of serum on STase activity released during 
cell / tissue cui ture experiments: In experiments ..... ith 
hepatocytes it was observed that the STase activity released 
into the incubation medium was increased when heat-inactivated 
serum was used to supplement incubations (VanDijk et al., 
1986 J . Ratnam et al., ( 1987J reported that the addition of 
heat-inactivated serum to the incubation medium caused a , 
release of STase from rat intestinal slices. other researchers 
have shown that in experiments with intestinal cultures, an 
increased release of STase into the culture medium .... as 
observed when the incubations were supplemented .... ith heat-
inactivated serum (Kolinska et al., 1990]. 
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1.2.". STase in small intestine 
I.2.4.A. The small intestine 
The small intestine stretches from the pylorus to the 
ileocecal valve and is divided into the duodenum, jejunum and 
ileum (Cheng, 1981a,bi cheng and Leblond, 1981a,b,c; Moog, 
1981; Neutra and Padykula, 1984]. The anatomy of the small 
intestine is similar in all mammalian species. The mucosa 
forms the innermost layer and is in contact with the lumen 
(Figures 1.13 and 1.14). The submucosa underlays the mucosa 
and is rich in blood vessels and lymphatics. The next layer is 
a muscular layer made up of smooth or involuntary muscles. The 
outer surface is covered over most of its area by the visceral 
peritoneum or serous layer (serosa), in which run the blood 
vessels and lymphatics. The arterial supply comes from the 
branches of the superior mesenteric artery. The venous 
drainage leads into the portal vein, which takes the blood 
from the intestine to the liver (Figures 1-13 and 1-14). 
The mucosa is made up of folds and from it project 
tiny finger like projections known as the villi 
(Figures 1-13 and 1-14). The crypts of Liberkuhn lie between , 
the bases of the villi. It is from the crypts that the 
columnar epithelial cells which cover the surface of the villi 
arise. These cells which constantly produced in the 
crypts, move up the villus and are ultimately shed from its 
tips. Many of the epithelial cells have an absorptive 
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Figure 1_13 _ Anatomical structure of the small intestine 
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Figura 1.13. Anatomical structure of the small intestine. The 
wall of the intestine is made up of four concentric layers, 
comprised of three outer layers:- the serosa, the muscularis 
and the submucosa, which surround the innermost layer the 
Several projections the villi extend from the 
intestinal surface increasing its absorptive area. [Adapted 
from Moog, 1981]_ 
43-8 
Figure 1. 14" Structure of a villus 
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Figure 1.14. structure of a villus. The structure of a villus 
is shown in the figure. The villi extend into the interior 
space from the surrounding surface, inside each villus is a 
dense network of blood and lymph vessels. [Adapted from Moog, 
1981) . 
function. 
The main fUnctions of the intestine are (1) to allow 
enzymatic breakdown of the larger dietary components such as 
proteins, fats and polysaccharides, a process occurring 
largely in the lumen, (2) to complete digestion by breakdown 
of the smaller molecules resulting from the preliminary 
digestive processes, a process occurring mainly in the brush 
border and (3) to absorb the final products of digestion. A 
major part of luminal digestion is brought about by the 
enzymes of pancreatic secretions which act upon the products 
of digestion. The mucosal cells in the duodenum and upper 
jejunum release enterokinase which converts trypsinogen to the 
acti ve enzyme trypsin by the removal of terminal 
hexapeptide. Trypsin is also an important activator of other 
proteolytic enzyme precursors. The brush border enzymes 
include maltase, isomaltase, sucrase, lactase and T amylase, 
which are involved in carbohydrate digestion; aminopeptidases 
and several dipeptidases, which are involved in oligopeptide 
digestion. 
1.2.4.B. The small intestine as a mOdel1 for the study of 
STasel sialoglycoconjugates 
The intestine is an interesting tissue for the study of 
STase andl or NeuAc for a number of reasons. Glycoconjugates 
are both abundant and widespread in the intestine. The mucosal 
and epithelial cells of the gastrointestinal tract are rich in 
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both secretory and structural glycoproteins [Rubio et 
al., 1964; Galand and Forstner, 1974; Neutra and padykula, 
1984]. The digestive enzymes including maltase, sucrase and 
alkaline phosphatase are glycoproteins [Rubio et al., 1964; 
Yeh and Moog, 1975J. The lining of the intestinal cells has a 
high mucin content. Gastrointestinal mucins are glycoproteins 
with structural diversity whose main fUnction is to provide 
protection. Glycoconjugates in the intestine also 
constituents of both plasma and endoplasmic membranes, as well 
being cellular components of the mucous. 
STases and NeuAc are thought to play important roles in 
cell differentiation and recognition, which is yet another 
reason that the intestine is a good model for their study. 
The rate of cell turnover in the intestinal mucosa is rapid as 
surface epithelial cells are shed by being sloughed off into 
the lumen and are replaced by new cells proliferating and 
migrating from the crypts [Cheng, 1981a,b; Cheng and Leblond, 
1981a,b,c] . 
I . 2.4.C. Expression of BTasel sialoglycocon ; ugates in sma ll 
intestine 
A number of investigators have sought to measure and 
compare STase activity between differentiated villus and 
undifferentiated crypt cells. The method used by Weiser 
(197Jb) involved the use of citrate and EDTA to separate as 
well as dissociate cells resulting in epithelial cell 
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fractions which defined a gradient from villus tips to crypts. 
The results indicated that higher STase activity was present 
in the villus cells compared to crypt cells. Kim and coworkers 
in 1975 used a method based on planar tissue sections to 
separate crypt and villus cells and found that STase 
enriched in crypt cells. The discrepancy between the two 
groups is thought to be the result of the different methods 
employed for the separation of crypt and villus cells. Other 
studies have confirmed the results of Kim et al., [1975], 
indicating that the crypt cells contained higher STase 
compared to villus cells [Martin and Louisot, 1976, BioI et 
al., 1987]. 
The studies cited above did not make any distinction 
between the type of STase activity measured (that is 0-2 ..... 6 
0:2-3 STase). A number of more recent studies have focused 
studying the distribution of specific STases in the 
intestine. In the small intestine STase was found to be 
predominantly that which catalysed the cr2 ..... 6 NeuAc linkage on 
lactosamine which was used as the oligosaccharide acceptor 
(Dall 'Olio et al., 1990]. By contrast In the large intestine 
the STase activity was of the 0:2-3 type. Immunochemical 
studies using an antibody directed towards the polypeptide 
portion of the 0:2-6Galjll-4 GlcNAc STase molecule have shown 
that the enzyme was present in a number of post-Golgi 
apparatus structures including mucous droplets and plasma 
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membranes [Taatjes et al., 1988). The presence of STase in the 
goblet cell mucous and the absorptive cells are thought to be 
markers for the differentiated state of the small intestinal 
epithelium (Taatjes et al., 1988]. These results suggest that 
both the "ecto-STase" in plasma membranes of intestinal cells 
and that released from Golgi membranes could be secreted with 
the goblet cell mucous. 
Bennett and coworkers (1987) have shown that NeuAc was 
distributed throughout the small intestine at the microvillar 
surface of the crypt and villus columnar cells. Other studies 
have shown that in the lower half of the crypt region NeuAc 
was present in the apical and basolateral membranes. 
1.2.4. D. changes in STasel sialoqlycoconiugates during 
development 
Numerous studies have shown that in the pre-weaning rat, 
STase activity in the small intestine was increased compared 
to the adult and then declined after weaning [Chu and Walker, 
1986; BioI et al., 1987, 1992; Taatjes and Roth, 1990]. These 
studies also revealed that during the weaning phase there was 
a shift from sialylation to fucosyla \ ion in the intestinal 
microvillar glycoconjugates . Immunological studies using a 
lectin specific for the NeUAccr2 ..... 6Gal have shown that in the 
suckling rat, NeuAc was present in the apical as well as 
basolateral plasma membranes, in both epithelial and goblet 
cells throughout the villi [Taatjes and Roth, 1990]. In the 
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adult rat NeuAc was not detectable in the plasma membranes of 
epithelial cells but abundant staining was detected in the 
goblet cell mucous, cells of the lamina propia and smooth 
muscle cells. 
I.2.4.E. Alterations in sm.all intestinal STase 
The role of NeuAc/sialoglycoconjugates in colon during 
pathological conditions has been more extensively studied 
compared to small intestine [Kim and Isaacs, 1975; Whitehead 
et al., 1979; Irimura et al., 1988; Dall'Olio et al., 1992]. 
This is due to the fact that STase and NeuAc metabolism are 
altered during colon cancer, a disorder which is associated 
with a high mortality rate. 
There are indications that STase in small i n testine also 
plays an important role in pathophysiological conditions. 
Increased STase activity in small intestinal mucosa and serum 
have been observed following thermal injury in the rat [Chu et 
al., 1988]. Colchicine injection in the rat, resulted in 
increased STase activity in small intestine, intestinal lymph 
and serum (Fraser et aL, 1980; Ratnam et al., 1987]. 
Increases in STase activity and s~alylation, 
I 
in small 
intestine have been reported following hydrocortisone 
injection in the rat (Kolinska et aL, 1988, 1990]. 
Dexamethasone also increased the amount of soluble STase 
activity which was released during jejunal culture experiments 
(Kolinska et aI., 1989, 1990]. 
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SECTION 3. GALACTOSYLTRANSFERASES (GTASESl 
I. 3 .1. Membrane-bound GTases: Goigi and cell surface enzymes 
GTases catalyse the transfer of Gal from UDP-Gal onto 
suitable carbohydrate residues on glycoproteins [Schachter et 
aI., 1970; Schachter and Roseman, 1980; Beyer et aI., 1981: 
Berger et aI., 1987a; Yadav and Brew, 1991]. Among mammalian 
glycosyltransferases, GTases are the most widely studied 
enzymes with ,s1 ..... 4GTaSe (,s1 ..... 4GlcNAc GTase) being the most 
extensively studied glycosyltransferase. 
GTases are widely distributed in both mammalian tissues 
well as extracellular fluids, existing in both membrane-
bound and soluble forms [Kim et aI., 1972a, b; Pierce et e1., 
1980; Pestalozzi et aI., 1982; Ram and Mungal, 1985]. In the 
cell, GTases are found on Golgi and cell membranes . For 
example, in human ovarian adenocarcinoma cells two distinct 
subcellular populations of GTase were observed, one within the 
trans-Goigi compartment and one on the plasma membrane (Sichel 
et al., 1991]. Some studies have shown that a longer GTase 
protein containing a unique 13 amino acid peptide 
preferentially targeted to the plasma ,.membrane, whereas the 
shorter GTase protein without the 13 amino acid peptide 
retained in the Goigi apparatus ( LopeZ et aI., 1991]. The 
cytoplasmic (or N-terminal) half of the transmembrane domain 
of GTase is believed to playa key role in the Golgi retention 
signal [Aoki et aI., 1992]. In this region the cys29 and HisJ2 
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were found to be critical for the GTase to be retained in the 
Goigi. 
Studies have shown that in liver cells, GTase was present 
in Goigi membranes [Schachter et al., 1970; Fraser and 
Mookerjea, 1977; Taatjes et al., 1987]. In HeLa cells GTase 
was found in the trans Goigi network (Taatjes et al., 1987]. 
Other studies have shown that the distribution of GTase in 
Golgi membranes was similar in HeLa and CaC02 cells and that 
GTase was found throughout the trans Golgi membranes (Watzele 
et al., 1991]. The function of the Golgi GTase is primarily to 
catalyse the reactions involved in the synthesis of 
glycoproteins. Traditionally GTase is considered to be a 
marker enzyme for the Goigi membranes. 
The localization of GTase on numerous cell-membranes has 
been shown using immunological, cytochemical and biochemical 
techniques (Roseman, 1970; Shur and Roth, 1975: Pierce et al., 
1980; Runyan et al., 1988). GTase has been detected on the 
surface of cell-membranes in absorptive intestinal cells (Roth 
et al., 1985a), human ovarian adenocarcinoma cells [Lopez et 
aI., 1991; Evans et aI., 1993], Swiss tT3 fibroblasts [Evans 
et aI., 1993), HeLa cells [Roth and Berger, 1982] and rat 
phaeochromatocytoma cells [Begovac and Shur, 1990). Roseman in 
1970 put forth the hypothesis that cell surface GTase played 
a key role in cell adhesion and recognition. In view of 
Roseman's hypothesis other authors have since then reviewed 
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the role of cell surface GTase [Shur, 1984; Bayna et al., 
1986; Shur and Roth,1975i Shur, 1991]. Cell surface GTase is 
thought to serve as a receptor in cell-cell interactions 
during murine fertilisation (Miller et al., 1992], neurite 
growth [Begovac et al., 1991], mesenchymal cell migration 
(Hathaway and Shur, 1992], cell adhesion [Shur, 1983) and 
morula compaction [Bayna et al., 1988]. 
A number of GTases have been purified including (31 ..... 4 
GTase from malignant ascitic fluid [Boyle et al., 1988) I (31 ..... 4 
GTase from Ehrich ascites tumour cells (Elices and Goldstein, 
1988], (31 ..... 4 GlcNAc GTase from hUman embryonal carcinoma cells 
[Suganuma et al., 1987], (31 ..... 4 GTase isoenzymes from serum of 
cancer patients [Podolsky and Weiser, 1979), (31 ..... 4 GTase from 
human malignant pleural effusion (Ram and Mungal, 1984: Boyle 
et al., 1988), (31 ..... 4 GTase from rat small intestine (Weiser et 
al., 1987], (31 ..... 4 GTase from rat liver microsomes (Fraser and 
Mookerjea, 1977; Kawano et al., 1992) and (31 ..... 4 GalNAc GTase 
from rat small intestine (Wilson et al., 1987]. 
I. 3.2. GTase in the small intestine 
The distribution of GTase in the small intestine has been 
.-
the focus of many investigations (Weiser 1973 a,b; Lau and 
carlson , 1981; Wilson et al., 1984; Kim et aI., 1975]. Weiser 
[1973 a, b] reported that GTase activity was higher in the 
crypt cells compared to the villi in the small intestine of 
rat. However, in a later study it was reported that the villus 
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cells were rich in GTase and that GTase was largely 
concentrated in the basolateral plasma membranes of villus 
cells [Weiser et al., 1978; Wilson et aI, 1984]. According to 
studies by Kim et al [1975], GTase was equally distributed in 
the crypt and villus cells. These discrepancies are thought 
to be due to the different techniques employed to separate the 
crypt and the villus cells. Using immunocytochemical 
techniques, the localisation of GTase has been studied in 
human small intestinal enterocytes [Pestalozzi et al., 1982; 
Roth et al., 1985a]. GTase was found on the trans Golgi and 
plasma membranes of absorptive cells, being more concentrated 
along the brush border membrane. The lateral plasma membrane 
was also labelled and the intensity of the label decreased 
progressively towards the basal portion of the enterocytes. 
The glycocalyx extending from the microvillus tips was 
intensely labelled whereas the microvillus core showed very 
little label. 
The presence of ecto-GTase or extracellular GTase in 
small intestinal epithelial cells suggests that GTase in 
intestinal cells besides its usual role in glycoprotein 
f 
synthesis, may have additional role in cell-cell 
interaction (Weiser, 1973 a,b; La Mont et al .• 1974; Vegt et 
al., 1981]. 
1.3.3. GTase in other tissues (cells) 
Immunological techniques have been used to study the 
53 
distribution of GTase in rat hepatocytes [Taatjes et aI., 
1987]. In intact liver cells GTase was found to be spread out 
in the trans-Golgi and appeared as a spot like fluorescence. 
In cultured hepatocytes GTase was extensively distributed 
throughout the Golgi tubular network. These studies indicated 
that there was a difference in the Goigi localisation of GTase 
between intact and cultured hepatocytes. GTase has been 
purified from rat liver microsomes [Fraser and Mookerjea, 
1977; Kawano et aI., 1992]. The presence of GTase activity has 
also been demonstrated in bovine liver [Hudgin and Schachter, 
1971b]. In hepatic disease elevated levels of serum GTase have 
been observed (Kim et al., 1972 a,b]. Other researchers have 
reported that in the rat chronic ethanol consumption lead to 
decreased GTase activity in liver and Goigi fractions [Gausch 
et aI., 1992]. In the rat, streptozotocin induced diabetes 
resulted in decreased GTase activity in liver (Tepperman et 
aI., 1983]. 
GTase has also been studied in other tissues and cells. 
In porcine thyroid cells, thyrotropin caused an increase in 
cellular GTase activity [Franc et aI., 1984]. Leukaemic L1210 
, 
cells showed the ability to release soluble GTase activity 
into the medium (Klohs et aI., 1984]. In leukaemia cells 
obtained from patients, GTase in cell membranes was increased 
compared to normal cells [ROSSowski and Srivastava, 1983]. In 
studies with human ovarian adenocarcinoma cells a release of 
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soluble GTase was observed into the culture medium (Sichel et 
a1., 1991). The GTase activity released as well as the cell 
surface GTase dependent cellular adhesion and 
proliferation. It further observed that though 
intracellular GTase was unchanged, both the cell surface and 
the soluble GTase were increased in adhering cells compared to 
non adhering cells. The presence of cell surface GTase 
activity has also been demonstrated in hamster fibroblasts, 
where it was observed that dividing but not resting 
fibroblasts released GTase into the mediUm [LaMont et a1., 
1977) . 
1.3.4. Soluble GTases 
Soluble GTases occur in a wide variety of mammalian 
tissue fluids and have been detected in hUman serum [Kim et 
a1., 1972a,b; Podolsky and Weiser, 1979; Davey et a1., 1984), 
rat serum [Fraser and Mookerjea, 1977), porcine serum (Hudgin 
and schachter, 1971b) and hamster serum [Podolsky et al., 
1977). Other extracellular fluids where GTase activity has 
been detected include human milk [Gerber et a1., 1979; Amano 
et a1., 1991], bovine milk [Babad and Hassilid, 1964; Magee et 
.. 
a1., 1973], pleural effusions [Kim et a1., 1982) and hUman 
ascitic fluid [Gerber et a1., 1979]. 
The human (Masri et a1., 1988; uejima et a1., 1992), 
bovine [Narimatsu et a1., 1986; Shaper et a1., 1986; Masiby 
and Qasba, 1989) and murine [Nakazawa et a1., 1988; Shaper et 
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al., 1988] cDNAs encoding GTase have been cloned and 
sequenced. Recently the properties of the enzyme produced by 
cDNA expression have been studied (Masiby and Qasba, 1989; 
Nakazawa et aI., 1988, 1991). It is believed that the soluble 
forms of GTase in body fluids occur due to proteolytic release 
from the membrane anchor {Paulson and Colley, 1989 J. 
During pathological conditions, especially cancer, 
increases in GTase activity have been observed in serum 
[Podolsky et al., 1977, 1978 and 1981; capel et al., 1982], 
ascitic fluid [Gerber et al., 1979; Boyle et aI., 1988} and 
pleural effusions [Ram and Mungal, 1984]. The possibility of 
serum GTase being a marker enzyme for cancer has been the 
subject of a number of investigations (Capel et aI., 1982; 
chatterjee et aI., 1980, 1985; Davey et aI., 1983; 1984; Ram 
and Mungal, 1985J. Serum GTase activity has been elevated in 
cancer, particularly ovarian [Davey et aI., 1984; 
Chatterjee et al., 1980 and 1985]. However other benign 
diseases can also lead to elevated serum GTase levels [Kim et 
al., 1972a, b; Kessel et al., 1977J. Also there is a broad 
overlap in serum GTase levels between cancer patients and 
i 
normal controls (Kessel et aI., 1977; Chatterjee et aI., 
1980, 1985; Davey et aI., 1984]. Another problem stems from 
the fact that increases in serum GTase activity usually occur 
in the later stages of the disease. Therefore with all these 
factors taken into consideration the measurement of 
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GTase activity is thought to be inadequate as a diagnostic 
test for cancer. 
A cancer associated isoform of GTase (GTase II) in human 
serum was initially reported by Weiser and coworkers [1976] 
and later characterised [Podolsky et aI., 1977, 1978]. GTase 
II was found to be slower moving in non-denatured PAGE 
compared to GTase I (the normal isoform of GTase). The 
presence of GTase II was shown to correlate positively with 
the presence of cancer [ Podolsky et aI., 1978, 1981]. Two 
isoforms of GTase have also been separated from malignant 
ascitic fluid ( Boyle et aI., 1988]. Like serum there was a 
close similarity between the forms in terms of their kinetic 
properties. GTase II had a higher level of sialic acid 
residues. 
Though liver is considered to be the major source of 
soluble GTase activity in blood and other extracellular 
fluids, the presence of GTase in other tissues indicates that 
liver may not be the sole source of soluble GTase activity. 
SECTION ... PROTEASES AND PROTEASE INHIBITORS IN DISEASE STATES 
, 
I .... 1. Prot eases 
I.4.1.A. Serine proteinases 
Serine proteinases are the largest and best studied 
family of proteolytic enzymes. Prot eases _play vital roles in 
physiological processes including digestion, 
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complement activation, blood coagulation, fibrinolysis, 
release of physiologically active peptides and pregnancy 
[Neurath, 1984; Powers and Harper, 1986; Nilsson, 1991; 
Mignati and Rifkin, 1993]. Though the physiological importance 
of proteinases cannot be disputed, the fact remains that 
proteinases can also prove extremely hazardous. 
uncontrolled proteolysis destroy the protein 
component of cells and ultimately lead to cell death, which 
probably accounts for the fact that more than 10% of the 
circulatory blood proteins are protease inhibitors (Powers and 
Harper, 1986]. Proteinases have been implicated in 
pathological processes including tumour invasion, 
inflammation, pancreatitis, renal disease and septicemia 
[Powers and Harper, 1986; Pepper et al., 1990; steven et al., 
1992a,b; Techner et al., 1992; Wada et al., 1993 a,b; Zamir et 
al., 1993 ] . Examples of some serine proteinases and their 
fUnctions in pathophysiology are shown in Table 1.2. 
In a serine proteinase the active site is typically 
made up of two regions which are the catalytic site and the 
substrate binding site(s). Most inhibitors of serine 
.. 
proteinases interact with both of these regions [steitz and 
Shulman, 1982; Powers and Harper, 1986). 
Three major classes of serine proteinases can be 
distinguished based upon their primary substrate specificity. 
These include (1) trypsin-like proteinases, (2) chymotrypsin-
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Table 1.2. Examples of serine proteinaseso Examples of serine 
proteinases and the pathological processes they are involved 
in are shown in the table. [Adapted from Powers and Harper, 
1986] . 
Normal function Representative enzymes 
Blood 
coagulation 
Digestion 
Fibrinolysis 
Phagocytosis 
factor IXa 
factor Xa 
factor Xla 
factor Xlla 
factor VIla 
thrombin 
activated protein C 
plasma kallikrein 
trypsin 
chymotrypsin 
elastase (pancreatic) 
enterokinase 
plasmin 
plasminogen activator 
elastase (granulocyte) 
cathepsin G 
chymases (mast cell) 
tryptases (mast cell) 
vascular clotting, 
cerebral infarction, 
coronary infarction 
pancreatitis 
tumour invasion 
inflammation, 
emphysema, 
adult respiratory 
distress syndrome, 
rheumatoid arthritis 
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like proteinases and (3) elastase-like proteinases. Trypsin 
proteinases will cleave substrates which have positively 
charged amino acid residues such as Arg (arginine) and Lys 
(lysine). chymotrypsin and elastase will preferentially act 
substrates with aromatic large aliphatic and 
smallaliphatic side chains respectively [Powers and Harper, 
1986] . 
I.4.1.B. Plasmin and. plasminogen activators (PAs) 
Plasmin is a broad spectrum proteinase found in mammalian 
blood capable of degrading components of the extracellular 
matrix including laminin, fibronectin and fibrin [Norman, 
1958; Edy and Collen, 1977; Matsuda et aI., 1980]. It has been 
long recognised that plasmin has a high affinity for fibrin 
and fibrinogen, and that blood contains a large excess of 
plasmin inhibitors [Norman, 1958; Christensen and Clemmensen, 
1977, 1978]. Plasmin is a trypsin-like endopeptidase which 
attacks the lysyl-Lys bond in a variety of proteins. The many 
possible substrates for this enzyme include casein, protamine, 
cell-membrane proteins, immunoglobulin, ACTH, glucagon, 
complement components and factors V, VII and XI of the 
( 
clotting system [Edy and Collen, 1977; Moroi and Aoki, 1977). 
Plasminogen activators (PAS) are serine proteinases which 
convert plasminogen to plasmin [Clemmensen et al., 1981: 
Saksela and Rifkin, 1988; sitrin et aI., 1990). In humans the 
process of plasminogen activation is thought to be a critical 
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component of diverse biological systems including the 
complement and clotting systems. .In.........Y.i this reaction is 
catalysed by PAs and results in the conversion of plasminogen 
to plasmin. Plasmin plays an important role in the maintenance 
of vascular potency by converting insoluble fibrin to soluble 
fibrin degradation products [Thorsen et al., 1981; Sakata and 
Aoki, 1982; Blasi et al., 1987; Saksela and Rifkin, 1988; 
sitrin et al., 1990; Vassalli et al., 1991]. Vertebrate PAs 
can be divided into four main groups, circulating PAs found in 
blood, tissue PAs, urinary PAs (urokinase) and tissue culture 
PAs [ Levin and Loskutoff, 1982; Sprenger and Kluft, 1987: 
Janicke et al., 1991]. In plasma the predominant PAs include 
tissue type and urokinase PAs. The molecular weights of the 
circulatory PAs (98000 - 165000 Da) are different from the 
urinary and tissue PAs not in circulation (which have 
molecular weights between 50 000 - 80 000 Da). This difference 
has been attributed to the formation of aggregates in plasma. 
In the maintenance of normal physiological conditions, 
control of the integrity of a cell's environment is an 
important factor. This in turn depends on the control of both 
.. 
anabolic and catabolic mechanisms. Removal of the 
extracellular matrix within a connective tissue is controlled 
by proteinases like collagenase and plasminogen once it has 
been converted into its active form plasmin. It is therefore 
not surprising that plasmin and PA have been implicated in 
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numerous physiological and pathophysiological processes 
including embryogenesis, angiogenesis, ovulation, inflammation 
and tumour metastasis [Busso et aI., 1987; Sugihara et aI., 
1989; Vassal Ii et al., 1991). Dexamethasone caused reduction 
in PA activity in the rat brain tumour cells (Wolf et aI., 
1993]. Highly metastatic cells are known to produce classes of 
degenerative enzymes including PA and release them at higher 
concentrations than normal cells [Liotta et al., 1986). A 
tissue type PA is thought to be an initiator of tumour cell 
invasion during metastasis [Dano et aI., 1985; Jankun et aI., 
1991]. Plasmin and PAs also play vital roles in the 
maintenance of vascular potency by converting fibrin to 
soluble fibrin degradation products [Thorsen et aI., 1981; 
Sakata and Ayoki, 1982; Vassal Ii et aI., 1991; Sane et aI., 
1993] . 
I.4.1.C. Trypsin 
Trypsin is thought to play a key role in the onset and 
development of pancreatitis [Morgan et aI., 1968; Creutzfeldt 
and schmidt, 1970; Steer, 1986; Arais et al., 1993). It is 
believed that in the acute stage of p~.ncreatitis, trypsin 
reactivates itself and other pancreatic enzymes, resulting in 
increased levels of trypsin and decreased levels of trypsin-
inhibitors in plasma. 
Other conditions are also known to affect trypsin levels 
in plasma and/or urine. Alcohol has been shown to affect 
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pancreatic secretions in animals [Singh, 1983; Tsukamoto et 
al., 1986] and man (Varcaigne et al., 1980]. This probably 
accounts for the observed increase in both pancreatic 
trypsinogen and plasma trypsin in rats exposed to alcohol 
(Tsukamoto et al., 1986 ] . Increased trypsin activity in plasma 
has been reported in patients with uraemia [Shannon et al., 
1985]. Recent studies by See and Smith (1992] suggest that 
urinary trypsin levels/ activity playa significant role on 
the physiologic processes involved in haemostasis and 
susceptibility towards urinary tract infections. The active 
urinary trypsin was shown to promote fibrinolysis .in....Y.lll:2 and 
bacterial adherence to urothelial surface in vivo. Trypsin 
also plays a role in the pathophysiology of lung tissue. In 
the rat, trypsin injection caused emphysema and decreased 
trypsin inhibitory activity in plasma [Reichart et al., 1991, 
1992 ) . 
Very little is otherwise known regarding the role of 
trypsin in inflammatory processes and cancer. Two tumour-
associated trypsins (TATS) have been isolated from mucinous 
ovarian cyst fluid [Koivunen et al., 19.89 ) . TAT is thought to , 
account for the proteolytic activity of a number of human 
tumour cell lines [Koivunen et al., 1990, 1991a,b]. 
1 . ".2. Protease inhibitors 
I.".2.A. Serpins 
The serpins are a superfamily of serine proteinase 
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inhibitors present in plasma [Carrell and Travis, 1985, 
Carrell and Boswell, 1986]. This family includes a large group 
of homologous proteins, including Cl I antitrypsin (also known 
Ct l proteinase inhibitor {A1PI}), Ct2 antiplasmin, 
antithrombin III, heparin cofactor II, rat angiotensin, Cl-
inhibitor and ovalbumin [Peterson et al., 1979; Carrell et 
aI., 1979, 1982]. A number of factors complicate the 
discussion and understanding of this family of inhibitors. 
Firstly, Cl l antitrypsin is not primarily an inhibitor of 
trypsin. Its main target is leucocyte elastase, although it 
can also inhibit other proteinases such as trypsin, plasmin, 
chymotrypsin and kallikrein. These factors have resulted in a l 
antitrypsin being renamed AlP!. Also murine Cl I chymotrypsin is 
inhibitor of trypsin-like proteinases rather than 
chymotrypsin. Yet another anomaly is the fact that 
members of this family such as egg white ovalbumin show no 
inhibitory activity [Hunt and Dayhoff, 1980]. 
The shared characteristics of this group of proteins 
include their common 
proteinase inhibitor, 
derivation from an ancestral serine 
as well as similarities in their 
I 
tertiary structure and reactive centres. Serpins are generally 
small glycoproteins (with molecular weights between 40 000 and 
80 000 Da) containing a single polypeptide chain and a 
variable number of oligosaccharide side chains: four in 
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antithrombin, three in A1PI and one in ovalbumin [Carrell et 
al., 1982; Carrell and Travis, 1985 ]. The serpins show 
sequence similarities indicative of common tertiary 
structure. 
I.".2 • B. Q 2 Antiplasm.in 
Two main types of plasmin inhibitors are known to exist 
in mammalian blood, those which inhibit plasmin (also known as 
antiplasmins) and those which inhibit the activation of 
plasminogen (also known as antiactivators) ( Norman 1958]. 
Blood contains at least five proteins other than ():2antiplasmin 
and PA-inhibitors which have the ability to inhibit plasmin. 
These include A1PI, inter trypsin inhibitor, 02 
macroglobulin, antithrombin III heparin complexes and C1 
inhibitor. 
The major plasmin inhibitor in human plasma is oJ 
antiplasmin which has a molecular weight of approximately 70 
000 Oa and was independently identified by four groups (Bagge 
et al., 1976; Collen, 1976; Moroi and Aoki, 1976; Mullertz and 
Clemmenson, 1976 ] . Wiman and coworkers (1979) demonstrated 
that different plasminogen fragments 1 0ntaining Lys binding 
sites were able to compete with plasmin for interaction with 
():2 antiplasmin ( Wiman and Collen, 1978 a,b; Wiman et al., 
1978; 1979; Wiman, 1981 ] . It was also found that a high-
affinity binding site in the first three triple-loop 
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structures of plasminogen is mainly responsible for this 
interaction [Wiman 1981; Lijnen et al., 1983] . Several 
researchers have shown that cr:2 antiplasmin inhibits the 
binding of plasminogen to fibrin (Moroi and Aoki, 1977; Aoki 
and Sakata, 1980; Suenson and Thorsen, 1981). It has also been 
demonstrated that the binding ability towards fibrin of an 
isolated plasminogen fragment containing the high affinity 
lysine-binding site is decreased by a1antiplasmin (Aoki and 
Sakatai, 1980: Suenson and Thorsen, 1981]. Later studies 
revealed that human serum contains one form of antiplasmin 
which binds to plasminogen and another form that does not bind 
(40% of total antiplasmin) (Christensen and Clemmensen, 1978; 
Wiman, 1981). The non-plasminogen-binding form lacks a 26 
residue peptide from the C terminus (Sasaki et al., 1983). 
In purified systems cr:2 antiplasmin has been shown to 
react with trypsin (Wiman, 1981). It reacts slowly with 
urokinase {Holmberg et al., 1980; Sarnama et al., 1980], 
kallikrein, Factor Xa, thrombin (saito et al., 1979) and 
tissue-type plasminogen (KOringer and Collen, 1981]. In normal 
plasma a1 antiplasmin is able to bind plasmin and to a lesser 
I 
extent trypsin. However, cr:2 antiplasmin does not bind to 
thrombin, chymotrypsin, tissue type PA [Edy and Collen, 1977] 
or papain [Moroi and Aoki, 1976, 1977). Therefore it appears 
that a 2 antiplasmin behaves differently in purified systems 
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compared to blood. Q 2 Antiplasmin c an exert an inhibitory 
effect on fibrinolysis at three levels, (1 ) rapid inactivation 
of plasmin, (2) interference with the adsorption of 
plasminogen to fibrin and (3) by cross-linking to fibrin 
[Weitz et al., 1993] . 
When blood is clotted in the presence of calcium ions, Q 2 
antiplasmin is cross-linked to the fibrin [Collen, 1976; Wiman 
and Collen, 1978 a, b; Sakata and Aoki, 1982). When fibrin is 
formed, tissue type PA and plasminogen adsorb to the clot in 
a sequential and well ordered manner . The affinity of tissue-
type PA for plasminogen is high [Hoylaerts et al., 1982]. The 
plasmin formed on the fibrin surface has both its Lys binding 
sites and its active site occupied and is only slowly 
inactivated by Q 2 antiplasmin. In normal plasma, significant 
activation of plasminogen by tissue-type PA is negligible and 
Q 2 antiplasmin will rapidly bind any free plasmin, thereby 
preventing proteolysis of other plasma proteins such as 
fibrinogen (Ohlsson and Collen, 1977 J. 
Proteases and their inhibitors are involved in a number 
of disease processes. Cf2 Antiplasmi ~ is an acute phase 
reactant whose concentration in blood is increased during the 
acute phase response [Matsuda et al., 1980J. Increased Q 2 
antiplasmin levels have been observed in patients with 
thrombosis (Teger-Nilsson., et al 1978, Samana et al., 1980]. 
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Major surgery has been associated with significant decreases 
in plasma levels of plasminogen and cz2 antiplasmin 
[Frisch,1980; Buller et al., 1981 ]. In cardiac disorders 
plasma concentrations of cz2 antiplasmin were decreased [Aoki et 
al., 1977; Frisch, 1980]. Some studies have found that cz2 
antiplasmin levels in blood decreased in the 
microembolism syndrome in man and rat [Bagge et al., 1976]. In 
patients with septic shock there was an increase in serum 
plasminogen and cz2 antiplasmin which was related to mortality 
[Gallimore et al., 1980 ]. In hepatic disease, particularly 
c irrhosis, increased fibrinolysis is a well known fact and is 
often accompanied by decreased levels of circulating cz2 
antiplasmin [Aoki and Yamanaka, 1978; Teger-Nilsson et al., 
1978 ] . 
I.4.2.C. Plasminogen-activator inhibitors (PAIs) 
The actions of plasmin and PAs are regulated to a great 
extent by their protease inhibitors. Four kinds of plasmin 
activator inhibitors (PAIS) are present in mammals, namely 
endothelial PAl-I, placental/macrophage PAI-2, urinary PAI-3 
or protein-C-inhibitor and protease ne7in [Ericksson et al., 
1985; Blasi et al., 1987; Loskutoff et al., 1989; Seebacher et 
aI., 1992] . 
The primary inhibitor of PA is PAI-1 which is also the 
most researched PAl and is a serpin [Loskutoff et al., 1989]. 
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PAI-1 is present in blood, platelets, tissues and can rapidly 
form inactive 1:1 inhibitor-protease c omplexes ( Ericksson et 
al., 1985; Sawdley and Loskutoff, 1991 ] . Also PAI-1 has been 
implicated in a number of pathological conditions. High plasma 
levels of PAI-1 have been associated with higher rates of 
mortality in patients suffering from septicemia and septic 
shock [Kruithof et al., 1993 ) . Phorbol myristate ester caused 
increased production and release of PAI-1 in rabbit 
fibroblasts [ Murphy et al., 1993 ) . Tumour necrosis factor 
caused an increased release of PA and PAI in granulocytes 
[ Logan et al., 1992 ) . 
I. "'.2. D. Q 1 Proteinase inhibitor (A1PI) 
AIPI is the most researched proteinase inhibitor in human 
blood [Travis and salvesen, 1983; Heidtmann and Travis, 1986). 
The principle reason for this is the prevalence of the 
genetically caused deficiency of AIPI [LaUrell and Ericksson, 
1963; Martin et al., 1973) . The clinical manifestation of A1PI 
deficiency appears in the form of liver disease and/ 
emphysema in deficient patients. The emphysema is caused by 
alterations in the balance of proteinase:-proteinase inhibitor 
t 
activity which results in increased elastase activity. The 
major target of A1PI is leucocyte elastase and therefore 
decreases in A1PI generally result in tissue damage [Ericksson 
1984 ]. 
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Human AlP! makes up the major portion of the a band in 
serum or plasma following gel electrophoresis. The protein is 
produced mainly in the liver parenchymal cells, secreted into 
blood and distributed to other parts of the body. The mature 
protein (molecular weight - 52 000 Da) consists of a single 
polypeptide chain of 394 amino acid residues, containing one 
free cysteine residue, no disulphide bridges and three 
carbohydrate side chains [Carrell et al., 1982]. 
AlP! contains a single reactive site, concentrated around 
a Met-Ser sequence of 36 amino acid residues from the C 
terminus [Johnson and Travis, 1978; Boswell et aI., 1983]. 
Proteinases are inhibited by a 1: 1 complex formation, which is 
thought to involve cleavage of the reactive site peptide bond 
of the inhibitor. These complexes are reported to be very 
stable and cannot be dissociated by treatment with denaturing 
agents. Evidence for this comes from the crystallographic 
studies done with cleaved AlP!, which indicated that AlP! was 
a globular protein with an ordered structure, 3D%: of the 
molecule being in the helical form and 40%: in f3 sheets 
[Lobermann et al., 1984]. 
t 
The occurrence of multiple variants of AlP! has been well 
documented [Fagerhol and Laurell, 1970; Martin et al., 1973; 
Dietz et aI., 1974; Brewerton., 1984; Hinney et aI., 1992} . 
The genetic variants of the inhibitor generally exhibit slight 
differences in their isoelectric points [Pierce et aI., 1976; 
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Lorier and Hawes, 1984). At least 20 different forms of AlP! 
have been separated on the basis of their isoelectric points. 
The genes for the isoforms are assigned a letter according to 
the pi (Proteinase inhibitor) system eg PiM [Fagerhol and 
Laurell, 1970; Heidtman and Travis, 1986]. The phenotype 
present in plasma reflects the equal expression of paternal 
and maternal alleles, such as piMZ . The most common allele is 
PiM and the protein has intermediate electrophoretic mobility, 
whereas piz has the highest isoelectric point of all the 
known variants. 
Microheterogeneity between isoforms of AlP! is common and 
is due largely to the differences in the glycan side chains 
[Vaughan et aI., 1982 ] . Human AlP! contains three glycan side 
chains, all at Asn residues attached to the polypeptide chain 
{Hodges et aI., 1979; Mega et aI., 1980]. Major isoforms of 
PiM have been isolated and found to contain different 
combinations of the two possible chains with variable amounts 
of the terminal NeuAc residues . 
The most researched pi type is the ZZ variant which is 
always associated with def icienc::y of plasma AlP! . 
t 
Heterozygous piMZ individuals have serum AlP! levels about 50\ 
of normal and homogenous individuals (PiZZ) have AlP! levels 
of less than 15% of normal. An extensive clinical study 
carried out by Bruce et al. (1984), revealed that the PiMZ 
genotype often leads to an early onset of emphysema. The basic 
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defect in AlP! deficiency appears to be in the secretion of 
the molecule since in liver tissue inclusion bodies containing 
AlP! were present [Liebermann et al., 1972; Bathurst et al., 
1984]. Active AlP! can be extracted from these globules 
suggesting that in pizz individuals, A1PI is synthesised but 
not properly secreted into blood. Analysis of serum A1PI from 
PiM and piz patients revealed that the carbohydrate content of 
these variants was similar (Hercz, 1984]. The A1PI present in 
hepatic globules however had a higher Man content compared to 
serum A1PI [Bathurst et al., 1984]. It was determined that the 
impaired secretion of A1PI, in piz individuals is caused by 
intrinsic errors in the post-translational oligosaccharide 
modification due to incomplete glucose trimming in secretory 
proteins [Gross et al., 1983]. 
The first function attributed to AlP! was its ability to 
inhibit trypsin which lead to the protein being named oJ 
antitrypsin (Schultze et al., 1962]. However since then a 
large number of serine proteinases have been shown to have the 
ability to form complexes with A1PI. These proteinases include 
neutrophil and pancreatic elastases, <;:hymotrypsin, plasmin, , 
thrombin, acrosin [Panell et al., 1974; Heidtman and Travis, 
1986] and tissue kallikreins [Hirano et al., 1984). The main 
target of the human A1PI is neutrophil elastase [Ericksson, 
1984; Savolainen and Berode, 1988]. 
72 
A variety of pathophysiological conditions are associated 
with alterations in either the levels or functional ability of 
circulating AlP!. Inherited deficiency of A1PI is associated 
with predisposition towards the early onset of a variety of 
diseases in children and adults (Laurell and Ericksson, 1963; 
Martin et al., 1973: Ericksson., 1984; propst et al., 1992). 
These include pulmonary emphysema, chronic pancreatitis, liver 
disease and viral infections. 
Exposure to cigarette smoke has been shown to lead to 
decreased proteinase inhibitory activity in serum [Janoff et 
al., 1980; Dooley and Pryor I 1982; Evans and Pryor, 1992: 
Silverman et al., 1992]. The decreased inhibitory activity can 
be attributed to lowered elastase inhibitory activity of A1PI 
in blood. This imbalance between proteases and protease 
inhibitors is thought to increase the risk of pulmonary 
emphysema in smokers compared to non smokers. Dogs treated 
with chloramine showed impaired function in serum A1PI 
[Abrahms et al., 1981). 
Increased serum levels of A1PI have been observed in 
hepatic carcinoma (Lee et al., 1992] and chronic liver disease 
I 
[Trischitta et al., 1991]. Serum AlP! is an acute phase 
reactant and increased serum levels of AlP! have been observed 
in inflammation (Travis and Salvesen, 1983; Heidtman and 
Travis, 1986; Trischitta., et al 1991]. The role of A1PI is 
thought to be inhibition of the proteolytic enzymes which are 
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particularly active during the acute phase response. 
l.IIV) .2.E. Antithrombin III (AT) 
Antithrombin III (AT) is a serum glycoprotein, with a 
molecular weight of approximately 58 000 Da which plays a 
major role in controlling serine proteases in the intrinsic 
coagulation system [Abilgaard, 1969,1981 ) . Though thrombin is 
the main target of AT, it also inhibits other serine 
proteinases including plasmin, trypsin and kallikrein. The 
mechanism of inhibition involves the formation of 
equimolar, stable complex between the inhibitor and enzyme 
such that the active site of the protease is not accessible to 
substrates. The inhibitory effect of AT towards thrombin is 
enhanced by heparin [Abilgaard., 1969; Rosenberg and Damus, 
1973]. The major role of AT is in the regulation of blood 
clotting. Individuals with a congenital deficiency of AT have 
reduced plasma levels of the inhibitor and run an increased 
risk of developing deep vein thrombosis [Abildgaard, 1981] . 
1.4.2. F. Acid stable trypsin inhibitors (ASTIs) 
Muller in 1908, followed by Bauer and Reich in 1909 
originally reported the presence of a ( trypsin inhibitor in 
human urine. since then acid stable trypsin inhibitors (ASTls) 
have been detected and purified from human plasma and urine 
[Shulman, 1955; Sumi et aI., 1987). A number of ASTIs have 
been detected in other body fluids including bile [Yamamoto et 
aI., 1986 ] . bronchial mucous (Hochstrasser et aI., 1973], 
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ascites of malignancy and tumour effusions [Akazawa et aL, 
1983J. The ASTls purified have molecular weights ranging from 
between 23 000 to 86 000 Oa [Akazawa et aL, 1983, Maruyama et 
al, 1984; Okumichi et al., 1984: Yamamoto et al., 1986). 
These proteins also share similar antigenicity and 
chemical properties. ASTIs exhibit a broad spectrum of 
inhibition towards a number of proteases, including trypsin, 
plasmin and leucocyte elastase [Sumi et al., 1987]. Proksch et 
al (1973) purified an ASTI from urine and reported that it was 
antigenically similar to inter a trypsin inhibitor, and that 
the latter may serve as a precursor for ASTI. However Clavey 
and coworkers [1979) purified an ASTI from urine which did not 
share any antigenicity with inter 0: trypsin inhibitor. 
Therefore some controversy exists as to whether inter 0: 
trypsin inhibitor serves as a precursor for ASTI. 
Increased levels of ASTI (s) in urine and plasma have been 
reported in kidney disorders [Toki and sumi, 1982; Maruyama et 
aL, 1984, 19911. ASTI is present in kidney tissue and it is 
believed that ASTI is produced by the kidneys and excreted 
into urine by the proximal tubules [Maruyama et al., 1984, 
( 
1991). Increased production of ASTI by the kidney was observed 
during inflammation in the rat, which lead to subsequent 
increases in serum and urinary levels of ASTI (sugiki et aL, 
1991). Other researchers have also reported increased serum 
levels of ASTI during inflammation and ASTI is thought to be 
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an acute phase marker [Jonsson et al., 1982]. The kidney is 
thought to be one of the main sources of ASTI in urine and 
plasma. An ASTI has also been detected in liver [Odum et al., 
1987) and human hepatoma cells have been shown to release 
endothelial cell growth factor similar to ASTI [McKeehan et 
aL, 1986]. The presence of ASTI(s) has been demonstrated in 
tumours of the kidney, stomach, colon, cerebrum (Yoshida et 
al., 1989] and lung (Okumichi et al., 1984). Increased levels 
of ASTI in urine have been detected in patients with malignant 
tumours (Onitsuka et al., 1985). 
I.4.2.G. Tumour associated trypsin inhibitor (TATI) or 
pancreatic secretory trypsin inhibitor (PSTI> 
The acinar cells in the pancreas produce and secrete a 
trypsin inhibitor referred to as pancreatic secretory trypsin 
inhibitor (PSTI) or Kazal inhibitor (Kazal et al., 1948). It 
is a small peptide with a molecular weight of 6 000 Da. 
Tumour associated trypsin inhibitor (TATI) was detected 
initially in the urine of patients suffering from ovarian 
cancer [Stenman et al., 1982]. Since then the sequencing of 
this peptide has revealed it to be identical to PST I . Tomita , 
et al (1987) have shown that PSTI and ASTI are encoded by the 
same gene, confirming the fact that they are indeed identical. 
TATIjPSTI is a protease inhibitor and its expression in 
malignancy is thought to be indicative of protease activity in 
tumour tissue. 
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TATI/PSTI is produced by the pancreas and very high 
concentrations are present in pancreatic fluid [Kazal et aL, 
1948; Sheving, 1983]. Very 10 ..... levels of TATI/PSTI are 
normally detected in plasma and urine [Kitahara et al., 1980]. 
Increased levels of TATI/PSTI have been observed in tumour 
fluid [Halila et aI., 1985; Tomita et aI., 1987] and 
production of TATI/PSTI has been demonstrated in many tumour 
cell lines [ogata, 1988; Koivunen et aL, 1991a,b]. Increased 
serum levels of TATI/PSTI have been observed in tumours of the 
pancreas, ovary, oesophagus and bladder [Ueda et al., 1989; 
Taccone et aL, 1991], malignant gastric disease [Higashiyama 
et aL, 1990 a,b; 1992; Gion et aI., 1991; Toricaguena et aL, 
1991] and colorectal cancer [Tomita et aI., 1990; catarino and 
Conde, 1991]. Pancreatitis and pancreatic 
associated ..... ith increased concentrations of TATI/PSTI in serum 
(Aroasio and Piantino, 1991]. 
TATI/PSTI has been detected in the mucosa of the 
gastrointestinal tract and is secreted into the gastric juice 
(Bohe et aL, 1986a; Freeman et aI., 1990a, b; Shibata et aI., 
1986). Severe infections and trauma cant lead to elevated serum 
levels of TATI/PSTI [Kitahara et aI., 1980; Matsuda et aI., 
1985; oga ..... a et aL, 1985) and it has been hypothesised that 
TATI/PSTI behaves as an acute phase marker [Oga ..... a, 1988). In 
pancreatic diseases such acute pancreatitis, the 
preactivation of zymogen prot eases particularly trypsin is 
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believed to playa vital role in the development of disease 
[Creutzfeldt and Schmidt, 1970; Steer, 1986). The 
physiological role of TATI/PSTI is thought to be the 
prevention of activation of trypsinogen in the pancreatic duct 
[ Funukoshi et a1., 1992). TATI is able to inhibit trypsin 
[ Huhta1a et a1., 1982; 1983) and acrosin [Huhtala, 1984J which 
are the main targets of the inhibitor in physiology. TATI/PSTI 
shows weak inhibition towards other serine proteinases such as 
plasmin and PAs (Turpeinen et al., 1988]. 
I.4.2.H. Role ot trypsin and plasmin inhibitors in 
pathophysiology of small intestine 
Trypsin and plasmin inhibitors have been implicated in a 
number of pathophysiological processes associated with the 
intestine. Though liver and blood cells are considered to be 
the main sites of production of AlP! the protein has also been 
detected in other tissues, including the epithelial lining of 
the small and large intestine [Geboes et a1., 1982; Bohe et 
a1., 1986 a,b, 1987, 1988; Rijsinghani et a1., 1993]. The 
presence of A1PI has also been demonstrated in intestinal 
carcinomas (Kitas et a1., 1982; Damajnoi et a1., 1983; Katoaka 
et a1., 1989]. It is believed that A1PI is synthesised in 
neoplastic tissues such as human intestinal epithelium during 
intestinal carcinoma as a result of expression of the A1PI 
gene [Kitas et al . , 1982 ] . TATI/PSTI have been found in small 
intestinal mucosa in Paneth and goblet cells [Bohe et a1., 
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1986a,b, 1987, 1988; Fukayama et a1., 1986; Freeman et a1., 
1990a, b). There is some evidence suggesting that the presence 
and/ or expression of trypsin inhibitors such as A1PI and TATI 
is related to the progression of gastrointestinal cancer 
(catarino and Conde, 1991; Gion et a1., 1991; Piatino and 
Aroasio, 1991]. 
Protease inhibitors particularly A1PI are believed to 
play important roles in intestinal diseases including 
inflammatory disease, Crohn's disease and protein-losing 
enteropathy. During inflammatory bowel disease regions of the 
intestine particularly the intestinal wall are affected by the 
inflammatory processes (Beck, 1987]. Though the serum levels 
of most acute phase proteins are increased, the serum levels 
of proteinase inhibitors are either unchanged or decreased 
(Bohe et a1., 1986a,b; Strygler et aI., 1990]. It is thought 
that the severe inflammatory processes in the intestine are 
accompanied by pronounced tissue destruction where proteases 
are involved which in turn leads to decreased circulatory 
levels of inhibitors. Protein losses are a common event in 
inflammatory intestinal disease and Crohn' s disease. The 
.. 
faecal clearance of plasma AIPI is used as a measure of 
protein leakage into the intestinal tract [Mizon et a1., 1988; 
Strygler et e1., 1990]. Other studies have shown that the A1PI 
excreted in the faeces of patients with inflammatory disease 
had different molecular forms compared to normal individuals 
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[Mizon et aL, 1991; E1 Yamini et aL, 1992]. The A1PI in 
faeces of patients with intestinal disease had molecular 
weights of 51 000 and 45 000 Oa respectively compared to a 
molecular weight of 38 000 Oa found in normal subjects. 
SECTION. 5. PURPOSE OF PRESENT RESEARCH 
Previously it was reported that heat-inactivated 
when added to incubations of intestinal slices caused a 
release of soluble STase into the incubation medium [Ratnam et 
aL, 1987]. According to these authors in order for the 
release of STase to occur there was an absolute requirement 
for heat-inactivated serum in the incubation medium. other 
studies have shown that colchicine treatment in the rat 
resulted in increased STase activity in intestine, intestinal 
lymph and serum [ Fraser et aL, 1980; Ratnam et aL, 1980 and 
1981 ) . Thermal injury in the rat also resulted in increased 
STase activity in small intestine [Chu et al., 1988]. These 
researchers have hypothesised that the intestine could serve 
as a source of STase activity in body fluids. However, very 
little is known regarding the release of STase from intestine 
t 
and the factors which affect this process. 
The pr imary purpose of the present research was to study 
the release of soluble STase from jejunal slices and to 
determine the role played by heat-inactivated serum in the 
release process. Initial studies during the course of this 
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thesis revealed that the STase was being released into the 
incubation medium even in the absence of serum supplements, 
but the enzyme released was subject to proteolysis. It 
determined that the heparin-binding fraction (HBF) was the 
serum component which was antiproteolytic and was required to 
measure STase activity. The additional objectives of this 
research were 
(1) to characterize the protease inhibitory activity of HBF, 
(2) to investigate the relationship between protease-
inhibitory/ protease activity and STase activity and 
(3) to determine whether GTase activity was also influenced by 
the levels of protease-inhibitory/ protease activity . 
. ,
CHAPTER II. MATERIALS AND METHODS 
11.1. Materials 
IL1.i. Rats 
Male Sprague-Dawley rats (body weight 150-350 g) were 
obtained from Charles River Canada Inc., La Prairie, Quebec. 
Unless stated otherwise rats were fasted for 18 hours and had 
free access to drinking water prior to the experiments. 
11.1.2. Chemicals and reagents 
Unless specified otherwise, the chemicals/ reagents used 
were of commercial origin and of the highest grade available. 
Adenosine-S'-diphosphate (ADP), alcohol dehydrogenase 
({ADH}, equine liver, 1-2 units/ mg), antipain, bovine AGP, 
bovine fetuin, bovine pancreatic trypsin inhibitor (bpti), 
bovine serum albumin (BSA), Na-benzoyl-L-arginine-ethyl ester 
(BAEE), a-benzoyl-DL- arginine-p-nitroanilide (BAPNA), a-
casein, chymotrypsin (type II, bovine pancreas, 40-60 units/mg 
protein), glutaminase (grade V was from E. coli; 50-200 
units/ mg protein), glutamate dehydrogenase (type IV bovine 
liver; 40 units per mg protein); GTase (Gal ,61 ..... 4 GlcNAc, 
bovine milk, 5-15 units /mg protein), elastase (human plasma, 
50 units/ mg protein), heparin (porcine intestinal mucosa low 
molecular mass, Na salt 4-6 kDa), heparin agarose (contained 
410 }jg heparin/ ml packed gel), AIPI (human plasma), a2 
antiplasmin (human plasma), kallikrein (human plasma, 5-15 
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unitsl mg protein), leupeptin, nicotamide-adenine-dinucleotide 
(NAD), orcein-elastase, papain (papaya latex, 50 units I mg 
protein), plasmin (human plasma, 3-6 unitsl mg protein), N-
succinyl-l-phenylalanine-p-nitroanilide (SUPHEPA), trypsin 
(type XI, bovine pancreas, 6000-9000 BAEE units/mg protein) 
and trypsin-agarose (was in the form of insoluble enzyme 
attached to cross linked beaded agarose, 50-100 unitsl ml 
packed gel) were purchased from sigma (st. Louis, MO, USA). 
Horse serum and Waymouth's MB 752/1 medium (IX) 
from Gibco Diagnostics (Burlington, ontario, Canada). 
Sialyllactosamine isomers [(a2-3) and (a2-6») were from 
Oxford Glycosystems (Rosedale, N. Y., USA). 
Pure STase a2-6[N) (E.C . 2 .4.99.1., from rat liver) and 
STase a2-3[O) (E.C.2.4.99.4., from porcine liver) 
purchased from Boehringer Manheim (Laval, Quebec, Canada). 
11.1.3. Radioisotopes 
CMP[14C )NeuAc (1.8mCi/mmol), UDP[ 14C]Gal (300mCi/mmol), 
[14C]glucosamine hydrochloride (54.2 mCi/mmol) and e4C)leucine 
(52mCi/mmol) were purchased from New England Nuclear (Lachine, 
Quebec, Canada). 
II 1. 4 Buffer. and .olution. 
Acetate butter- (0.5 M; pH 5 0), CH3COONa.3H20 (6 89) was 
dissolved in 100 ml distilled water (Solution 1). Glacial 
acetic acid (2.9 ml) was diluted with deionised water 
(Solution 2). 67.8 ml of solution (1) was mixed with 32.2 ml 
of solution (2). 
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Glycine NaQH byffer" (pH 9) NaCl (100 roM) and glycine (100 mM) 
were mixed 1: 1 and 885 ml of the resulting solution was 
diluted to 1000 ml with 100 mmol/l of NaOH. 
Hanks' byffer- (pH 7.4) NaCl (0 137 M), NaHC03 (26 mM), 
Na2HPO .. (0.34 mM), KH2P04 (0.44mM), EGTA (0.5 mM), 0 8 mM 
MgS04.7H20, KCl (5.4 mM) . 
Kreb's-bicarPonate byffer· (pH 7.4) NaCl (0.154 M), KCl (0.154 
M), CaCI2 (0.11 M), KH2PO.. (0.154 M), MgS047H20 (0.15 M), 
NaHC03 (0.15 M) . 
Kreb's-bicarbonateIBSA" (pH 7.4) NaCI (118 mM), KCI (4.8 mM), 
CaCl 2 (2.9 mM), KH2P04 (0.95 rnM), M3S04 .7H20 (1.2 mM), NaHC03 
(23.8 mM), 0.25\ BSA. 
Lysine-phosphate byfter' (pH 7.4) I-lysine (0.15 M), 
KH2 P04 (0 . 1M) . 
Waymouths MediumlBSA' (pH 7.4) Waymouth' s MB 752/1 medium 
plus 0.2\ (w/v) BSA. 
2- (n-morpholino) ethane sulfonic acid fMES)' (pH 6.8) MES 
1.25M. 
Phosphate buffer; (pH 7.6) K2HP04 (0.1 M). 
Triethanolamine buffer (TAA)· (pH 7.8) f TRA (0.2M), CaC1 2 
(20 mM). 
Tris buffer' (pH 7.4) 5 mM Tris-HCI. 
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II. 2. Analytical Procedures 
II.2.1. Electrophoresis 
The Phastsystem electrophoresis unit (Pharmacia) was used 
to analyze samples by SDS-PAGE. Typically samples of HHS, HRS, 
HBF and TBP at concentrations ranging from between 0.5- 5 
mg/ml were analyzed. Gels were run as per the instructions of 
the manufacturer. The electrophoresed samples were stained 
with Coomassie Blue R 250 dye (Pharmacia Blue R) with the aid 
of the development unit of the Phastsystem. The molecular 
weights of the SDS-denatured proteins were determined by 
comparison with low-molecular-mass-standards (Pharmacia). 
II.2.2. High performance liquid chromatography (HPLC) 
The purity of TBP was determined by HPLC on a Perkin-
Elmer series 4 HPLC system using a TSK-250 gel filtration 
column (7. 5x300mm; Bio-Rad). Protein samples were filtered 
through 0.45 I-'m filters to remove particulate matter. 
Typically 20-30 I-'g of protein was injected into the column, 
which had been equilibrated with 10 bed volumes of 0.05 M 
Na2so4 , 0.02 M NaH2 P04 buffer (pH 6.8) at a flow rate of 1.0 
ml/min. The eluent from the column was continuously monitored 
f 
at 280 nm using a LC-95 uv/visible spectrophotometer detector 
(Perkin-Elmer). The area under the absorbance peak was 
determined using a LCI-100 Laboratory Computing Integrator 
(Perkin-Elmer) and the area % used as an indicator of protein 
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purity_ 
HPLC was also used to analyze the product (sialyl-
lactosamine isomers) of assays for STase when lactosamine was 
used as an acceptor _ The procedure followed was similar to a 
previously published method [Ratnam et al., 1987]. The residue 
obtained from assays (section II.7.1.B.) was dissolved in 50~l 
water containing approximately 50% a2-3' and 50% a2-6' 
sialyllactosamine (50~g) and the solution filtered through 
0.45 ~M filters to remove particulate matter. Aliqouts (10-20 
~l) of this mixture were chromatographed on a Perkin Elmer 
series 4 HPLC system using a Lichrosorb NH2 column (4 x 250 
mmi particle size, 5 ~m) _ The column was equilibrated 
isocratically with a 18:7 (v/v) mixture of acetonitrile and 15 
roM KH2 P04 (pH 5.2) at a flow rate of 2ml/min. Absorbance of 
the eluent was measured at 195 nm. The volume of the eluent 
corresponding to the areas under the absorbance peaks 
collected and fractions counted for radioactivity. 
11.2.3. Affinity chromatography 
II. 2.3 .A. Isolation of the heparin-binding fraction (HBF) from 
heat inactivated serum 
Heparin-agarose was packed into a column (20 x 2 cm) and 
the column equilibrated with at least 10 bed volumes of Tris 
buffer (5roMi pH 7.4) a t a flow rate of 30ml per hour. HRS or 
HHS was passed through the column (lml serum per 2ml packed 
86 
gel) and fractions of the eluent collected. The unbound 
fractions resulting after each application of serum were 
pooled and concentrated by ultrafiltration to the original 
volume of serum applied. Absorbance was monitored at 280 nm 
using an LKB Unicord S Detector. The column was washed 
thoroughly with 5mM Tris buffer until the absorbance of the 
eluent was less than 0.05 at 280 nm. The heparin-bound 
fraction (HBF) was eluted with 1M NaCI and the eluent fraction 
containing the protein peak collected. HBF was dialysed 
exhaustively against deionised water (thrice). HBF was 
lyophilised and stored at _200 C dissolved in either KRB or 
Tris-buffer, until use. The absorbance was monitored at 280nm. 
HHS was also applied to a Sepharose column using the 
above procedure. The unbound fractions were pooled and 
concentrated by ultrafiltration. 
Protein measurements were carried out according to the 
procedure of Lowry et al., (1951). 
II.2.3.B. Isolation of trypsin-binding protein (TBP) 
Trypsin-agarose (4 x 50 units) was mixed with 20 ml 
agarose, packed into a column (20 x 2 ( cm) and equilibrated 
with approximately 10 bed volumes of 5 roM Tris buffer (pH 
7.4), at a flow rate of 30ml per hour. HBF (40mg dissolved in 
2 ml 5mM Tris-HCI) was applied to the column. The unbound-
trypsin fraction was collected, concentrated to half its 
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volume by ultrafiltration, dialysed against deionised water 
(thrice) and lyophilised. The column was washed intensively 
with SmM Tris buffer until the absorbance was less than 0.05 
at 280 nm. The bound fraction was eluted with 20 mM HCI, the 
volume under the protein peak was collected, dialysed against 
deionised water (thrice), lyophilised, dissolved in Tris-HCI 
or KRB and stored at -20°C. 
II.2.3.C. Concanavalin A (Con-A) affinity chromatography 
Con-A agarose was packed into a column (10 x 2 cm) and 
the column equilibrated with at least 10 bed volumes of O.SM 
Tris/ 1 roM MgCI2/ 1mM caCl2 (pH B) . Chromatography was carried 
out according to the procedures described by Koj et aI, (1982) 
and Pas et aI, (1989). TBP (500 JJ.g) dissolved in 5mM Tris-
buffer was passed through the column which was washed 
thoroughly with the equilibrating buffer until the absorbance 
of the effluent was less than 0.05 at 280 nm . The bound 
protein was eluted with 100 roM methyl mannoside and the 
fraction under the protein peak collected, dialysed against 
deionised water (thrice), lyophilised and stored at -20°C 
dissolved in Tris-buffer. 
11.2. •• Assay Condi tiona 
Assay conditions for all enzyme assays, in particular the 
concentrations of substrates, protein concentrations, 
incubation times and optimal pH for all enzyme assays were 
88 
established prior to experiments. Protein concentrations and 
incubation times were determined so that the rate of formation 
of product was directly proportional. Substrate concentrations 
used were not a limiting factor in product formation. All 
assays were done in duplicate. 
11.3. preparation ot serum samples 
11.3.1. Control rat serum 
Rats were exsanguinated under light ether anaesthesia by 
wi thdrawing blood from the abdominal aorta. Serum was 
recovered from clotted blood by centrifugation at 1240 x g for 
5 minutes. 
11.3.2. Serum trom turpentine treated rats 
For some experiments rats were injected with commercial 
grade turpentine (0.5 mIl 100 g body weight), subcutaneously 
in the thigh region (Fraser et al., 1984]. Control rats 
received a similar volume of 0.9 % NaCL Thirty h following 
injection, rats were exsanguinated under light anaesthesia and 
serum obtained from clotted blood as described above. 
11.3.3 . preparation ot heat-inactivated serum 
Serum (either rat or horse) was heated by incubating in , 
a water bath at 56°C for 30 min. This resulted in the 
inactivation of STase and GTase activities. 
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11. ... preparation of desialylated and degalactosylated protein 
AGP and fetuin were used as the protein acceptors for 
glycosyltransferase assays. Both proteins (1 g) 
desialylated and degalactosylated according to the method of 
Spiro (1964). Briefly, desialylation was carried out by acid 
hydrolysis where the protein was incubated at ao °c with 200 
mls of O.OSM J4S04 for 60 minutes, after which the protein 
solution was neutralised with approximately 1.5 - 2ml of NaOH. 
The solution was dialysed against O.lM NaCl (once), and 
against de ionised water (twice) before it was lyophilised. 
In order to obtain the degalactosylated protein the 
dialysate after dialysis with water, was treated with 10 ml of 
0.2M sodium metaperiodate plus 10 ml 1M sodium acetate for 8 
hours at 22 °C. Following this 10 ml of ethylene glycol was 
added and the solution stirred for 1 hour at 4°C. The solution 
was then treated with 25 ml of 0.1 M BaH4 (pH a) and left for 
a hours at 4°C, after which the pH was adjusted to 5 with 
acetic acid. The resulting solution was dialysed against O.lM 
NaCl (twice), followed by deionised ( water (thrice). The 
solution was treated with 0.7 ml concentrated "2S04' pH 
adjusted to 7 with 2 ml O.lN NaOH, dialysed initially against 
0.1 M NaCl (twice), followed by deionised water (thrice) 
before it was lyophilised. 
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11.5. Jejunal slices and medium. 
11.5.1. Preparation of jejunal medium. 
Rats were exsanguinated under light ether anaesthesia and 
blood drawn for serum samples as described (section 11.3.1.). 
The small intestine was removed, the first 10 cm from the 
pyloric end of the stomach (duodenum) was discarded, the next 
30 cm taken as the jejunum and used in experiments. The 
jejunal tissue was rinsed gently with ice cold 0.9% NaCI and 
then cut into 0.5 cm slices. Jejunal slices (10-15 slices; 
-0.5 g of tissue) were incubated in oxygenated (mixture of 95% 
oxygen and 5% carbon dioxide) 25 ml stoppered Erlenmeyer 
flasks containing 2 ml KRB buffer with 25 roM glutamine. unless 
stated otherwise, the flasks were incubated at 37°C in a water 
bath. The buffer used was KRB or KRB supplemented with either 
20% (v/v) heat inactivated serum or 30 mg albumin or 20% (v/v) 
glycerol in a final volume of 2m!. At specified time intervals 
between 0 to 6 h, the clear medium obtained by decanting the 
incubation mixture was centrifuged at 12 000 x g for 10 min . 
and the supernatant assayed for STase and GTase activities. 
In some experiments heparin was added to KRB and KRB-, 
enriched incubations at concentrations between 0 and 200 p,g/ 
2m!. 
In studies carried out to examine the effect of serum 
(HHS HRS) and its fractions on the release of STase and 
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GTase, jejunal slices were incubated as above in KRB or KRB 
containing either HBF, TBP, unbound-heparin fraction or 
unbound-trypsin fraction. In some experiments jejunal slices 
were incubated as above in KRB or KRB containing 200-400 JJ.g of 
antiprotease (leupeptin, antipain, bovine pancreatic trypsin 
inhibitor, 02 antiplasmin or AlPI). 
II.S.2. studies on the viability of jejunal slices 
II.S.2 . A. Measurement of incorporation of glucosamine and 
The rates of protein and glycoprotein synthesis by 
jejunal slices during incubation were determined by measuring 
the incorporation of either [14C] -leucine or [14C] -glucosamine 
into TCA/PTA precipitable cellular proteins. Jejunal slices 
incubated in oxygenated KRB or KRB containing 20% (v/v) 
HHS as described earlier. [14C] Glucosamine-hydrochloride (0.5 
.umol, 20.ul, 0.5 JJ. ci/mmol) or (14C]leucine (0.5 JJ.mol, 20JJ.l, 0.5 
.uCi/mmol) was added to each set of five flasks at 0,2,3 and 4 
hours. In each flask, the incorporation of radioactivity into 
jejunal proteins was monitored at 0, 10, 20, 60 and 120 min 
according to the method of Forstner (19?0). After incubation, 
the jejunal slices were removed and washed with KRB containing 
a 10 fold excess of unlabelled leucine or glucosamine. The 
washed slices were homogenised in 2 ml KRB using a Polytron 
homogeniser (setting 7 for 2x10s). Protein was precipitated by 
92 
leaving the homogenates overnight at 4°C in a mixture of 10\ 
TCA and U PTA (1:1; v/v). The mixture was centrifuged and the 
supernatant removed. The pellet was resuspended in TCA/ PTA 
and centr ifuged for 10 minutes (12 000 g ; X3). The 
supernatant was removed and the pellet suspended in 2 ml 
chloroform/ methanol (3:1; v/v) and centrifuged for 10 minutes 
(12 000 g; x3). The pellet was dried under nitrogen, suspended 
in 1 M KOH and aliquots used for the measurement of 
radioactivity and protein. 
II.S.2.B. Measurement of glutamine + glutamate 
Jejunal slices were incubated in KRB or KRB supplemented 
with 20% (v/v) HHS for time intervals ranging from a to 4 
hours (RRS contained 25 roM glutamine). Medium samples 
prepared as described (section 11.5.1). Perchloric acid 
extracts were prepared as described (section 11.11.1) and the 
supernatant was then used in the assays. Glutamine + glutamate 
in the medium was measured using glutaminase and glutamate 
dehydrogenase, according to the procedures described by Lund 
( 1974 ) . The principle of the method is outlined in reactions 
(1) and (2). Reaction (1) was allowed to. proceed and a portion , 
of the reaction mixture was taken for the glutamate assay. 
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glutaminase 
(1) L-glutamine + Hp ----------------.... L-glutamate + NHJ 
glutaminase 
(2) L-glut&mll.te + Hp + NAO+ --------.... 2-oxoglutarate + NADH + NH. 
Briefly, the assay mixtures contained 0.4 ml of sample, 
0.5 ml acetate buffer (0.5 M), 0.1 ml of glutaminase (0.005 
units! ml acetate buffer) and 0.4 ml deionised wa ter. Standard 
incubations were carried out similarly except that 0.5 ml 
deionised water I 0.1 ml glutaminase and 0.5 ml I-glutamine (10 
roM) were used. The glutamine free blank contained 0.5 ml 
buffer, 0.1 ml glutaminase and 0.4 ml deionised water. The 
reaction mixture was incubated at 37 °c for 1 h and the 
reaction stopped by cooling the tubes ice. In the next 
stage, incubations contained 1 ml of the reaction mixture, 2 
ml glycine-NaOH buffer (pH 9) I 0.1 ml ADP (33.5 roM) and 0.2 
ml NAD (27 roM). The contents of the tubes were mixed and the 
absorbance of the solution was measured at 340 nm. Glutamate 
dehydrogenase 0.05 ml (5mg!ml) was added, tubes were allowed 
to stand at room temperature for 45 minutes after which the 
absorbance was measured at 340 nm. Ttfe differences in the 
respective absorbance values were taken as a measure of 
glutamine + glutamate concentration. 
II . 6 . preparation of hepatocytes 
Rat hepatocytes were prepared according to a 
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modification of the collagenase perfusion procedure previously 
described by Seglen (1973). Rats .... ere anaesthetized .... ith ether 
and the abdominal cavity exposed. The liver .... as perfused 
through the portal vein .... ith calcium-free Hank's buffer at 37 
"c excised free of other tissue and placed in a reservoir. The 
perfusion solution .... as changed to Hank's buffer (120 ml 
containing 25 mg of collagenase, 35 mg of caCl 2 .2H20) and this 
solution was re-circulated through the liver at a flo .... rate of 
30 ml/min at 37°C for 15 min. The perfusion solution .... as 
oxygenated continuously .... ith 95%: oxygen and 5%: carbon 
dioxide. After perfusion .... ith the collagenase solution, the 
liver was placed in a 100 m.m. Petri dish on ice, rinsed .... ith 
Waymouths medium/BSA and then squeezed in order to release the 
cells. The cell suspension .... as kept on ice for 10 min to lower 
the temperature to bet .... een 0-4°C and filtered through 8 layers 
of cheesecloth to remove aggregates. The filtrate was .... ashed 
three times by centrifuging at 50 x g for 5 min. The final 
cell pellet .... as re-suspended in ice-cold Waymouths medium /BSA 
and used immediately. Cell viability .... hich .... as assessed by 
0.02%: trypan blUe exclusion, .... as found to be bet .... een 82-85 %: . 
.. 
The concentrations of hepatocytes .... as determined by microscopy 
using a counting chamber (1/400 mm2 x 1/10 mm deep) from 
Hausser Scientific. Hepatocytes (1 x 106 cells) were suspended 
in 2 ml Waymouths medium containing 25 roM glucose in 
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Erlenmeyer flasks. Some incubations were supplemented with 
either 20% (v/v) heat-inactivated serum, 250 jJ.g TBP or 500 jJ.g 
HBF. Flasks were oxygenated (95t oxygen and 5% carbon dioxide) 
and incubated at 37°C for up to 4 h. At time intervals 
between 0 and 4 h flasks were removed from incubation, the 
contents decanted out and centrifuged at 10 000 x g for 10 
minutes. The clear medium was removed and used in assays. 
11.7. Glycosyltransterase assays 
11.7.1. Assays tor STase activity 
II.7.l.A. Assays with desialylated protein acceptors 
STase was assayed using DS-alAGP or DS-fetuin according 
to the method described by Ratnam et al (1987). Briefly, the 
assay mixture contained 20 jJ.I jejunal or hepatocyte medium 
(80-120 jJ.g protein), 5 jJ.I CMP e4 ]C NeuAc (5.6 nmol; 27000 
d.p.m.), 5 jJ.l DS-AGP (250 J,tg), 5 jJ.I MES buffer (pH 6.8),15 jJ.I 
de ionised water, in a total volume of 50 jJ.I. Assays were 
incubated at 37°C for 3 h (in the case of jejunal medium) or 
1 h (in the case of hepatocyte medium), after which the 
reaction stopped by the addition of 1 ml of an ice-cold 
mixture of 5% trichloroacetic acid (TeA) and It 
,. 
phosphotungstic acid [(PTA); 1: 1, v/v]. The precipitate formed 
was filtered under suction through 2.4 cm diameter glass fibre 
filters (Whatman 934 AH), which were dried and counted for 
radioactivity using Ready Safe scintillation fluid in a Wallac 
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1209 Rackbeta Liquid scintillation Counter. Control 
incubations were carried out without any exogenous acceptor. 
Assays for serum STase were similar to that described for 
jejunal medium except that 10 1"1 sample was used and the 
reaction mixtures incubated for 30 min. In assays with the 
pure STases, the assay mixture contained 101"1 sample (enzyme 
mixtures were prepared as described in section 11.10) I 10 1"1 
CMP e4 ]C NeUAc (11.2 n mol; 55000 d.p.m.); 101"1 DS-AGP (for 
a:2 - 6 STase; 500 .ug) or 10 1"1 DS-fetuin (for a:2-3 STase; 500 
.ug), 5 /.ll Triton X-110 (0.5%) and 15 1"1 deionised water in a 
total volume of 50 1"1. Assays were incubated at 37QC for 30 
min . 
11.7.1.8. Assays with lactosamine as acceptor 
In order to determine the specific linkage (NeuAc a:2-3 
Gal or NeuAc a:2 .... 6 Gal) STase was assayed using lactosamine as 
an acceptor. The a2-3 and a2-6 sialyllactosamine isomers 
formed were separated by HPLC, the volume under the 
sialyllactosamine peaks collected and aliquots counted for 
radioactivity as described (section 11.2.2). Assays were 
carried out according to a previou,sly published method 
( Dall'Olio et al., 1990]. Briefly, the assay mixture contained 
30 1"1 of medium sample, 10 1"1 of sodium cacodylate buffer (80 
roM, pH 6.5), 10 MnCl2 (10 roM), 201"1 lactosamine (250 /.lg), 20 
1"1 CMP e4 C]-NeUAC (80 pmol; 385714 d.p.m.), 10 1"1 deionised 
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water in a total volume of 100 ~l. Assays were incubated at 
37°C for 3 hours and the reaction terminated by the addition 
of chloroform/methanol (1: 1), the protein precipitate was 
removed by centrifugation at 12 000 x g for 5 min in an 
Eppendorf microcentrifuge. The protein pellet was washed twice 
with chloroform/methanol (3ml totally). The combined 
supernatants were dried under nitrogen, the residue dissolved 
in sialyllactosamine and samples processed by HPLC as 
described (section 11.2.2). 
II.7.2. Assays tor GTasa activity 
Assays for GTase were carried out according to the method 
previously described by Fraser and Mookerjea, (1977). Briefly 
the assays contained 20 ~l of jejunal or hepatocyte medium, 
5 J.lI UDpe4C)Gal (3nmol; 17800 d.p.m.), 5 J.lI DSG-Q1AGP or DGS-
fetuin (250~g), 5 J.lI ATP (100 nmol), 5 J.lI MnCl2 (625 nmol), 5 
~l MES buffer, 5 J.lI deionised water in a total volume of 50 
~l. Incubations were carried out at 37°C for 3 h (in the case 
of jejunal medium) or 1 h (in the case of hepatocyte medium), 
after which the reaction was stopped by the addition of 1 ml 
ice-cold TCA/PTA as described for So:rase. The precipitate 
formed filtered under suction and counted for 
radioactivity as described for STase (section 11.7.1.). 
Control incubations were carried out in the absence of 
exogenous acceptor. 
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Assays for serum GTase were similar except that 10 j.ll 
sample was used and the reaction mixture incubated for 30 min. 
In assays with pure GTase, the assay mixture contained 10 j.ll 
sample (enzyme mixture was prepared as described in section 
11.10), 10 /oil DSG-AGP or DSG-fetuin (500 j.lg), 10 /oil UDP( '4C]Gal 
(6 nmol, 36 000 d.p.m.), 5 /oil MES buffer, 5 j.ll Triton X-100 
(0.5%) and 15 /oil deionised water in a total volume of 50 j.ll. 
Assays were incubated at 37 0 C for 30 min. 
1I.8. Sialidase and eMP-sialic acid hydrolase activities 
11.8.1. Assays for sialidase activity 
Sialidase activity was measured in 2 and 4 h jejunal 
medium samples obtained from incubations in KRB and KRB 
supplemented with 20% (v/v) HHS. The method used was similar 
to that described by Fraser et al., (1980]. The purpose of 
these experiments was to determine whether there was 
significant sialidase activity in the medium samples, which 
could cause in liberation of sialic acid from the sialylated 
protein acceptor (AGP) and thereby interfere with STase 
assays. 
Rats were injected intraperitonealry with colchicine (0.5 
mgt 100 g of body weight). Colchicine was made up just before 
use by dissolving 5 mg in 1 ml of 0.9% NaCI. Rats were 
exsanguinated 18 h after injection under ether anaesthesia, 
jejunal tissue removed and washed thoroughly with 0.9% NaCl. 
99 
Mucosal cells obtained by scraping the surface with a 
glass slide. The cells were washed twice with KRB by 
centrifugation at 12 000 g for 10 min after which the cells 
were resuspended in KRB, filtered through one layer of 
cheesecloth and homogenized using a Polytron homogenizer. 
The homogenised cell fraction (2ml, 1.8 mg protein) was 
incubated at 37°C with 1 ml eMP [He] NeuAc (1.2 Ilmol, 2IlCi), 
2 ml rat serum, 2 ml MES buffer in a total volume of 10 mI. 
After 3 h of incubation the reaction mixture was centrifuged 
for 10 min at 12 000 x g and washed with Tris-Hel (50mM 
containing 0.25 M sucrose) to remove soluble proteins and 
labelled nucleotide sugar. 
The insoluble labelled pellet (201l1, 18-20 Ilg protein) 
was used as substrate in an assay consisting of 20 lil jejunal 
medium, 10 III of MES buffer (pH 6.8) in a total volume of 50 
iiI. Reactions were stopped at zero time and after a 3 h 
incubation at 37°C with 1ml TCA/PTA (5%/1%). Precipitates were 
filtered, washed and radioactivity measured as described 
(section 11.7.1.). Release of labelled sialic acid from the 
pellet was used as a measure of sialid1se activity. 
11.8.2. Assays for CMP-NeUAc hydrolase activity 
CMP-NeuAc acid hydrolase activity was measured in samples 
of jejunal medium obtained from incubations in either KRB or 
KRB plus HHS according to the method of Fraser and coworkers 
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(1980). The purpose of these experiments was to determine 
whether there CMP-NeUAc hydrolase activity in medium 
samples which causing hydrolysis of CMP-NeuAc thereby 
limiting its availability during STase assays. 
Medium samples obtained from 2 and 4 h jejunal 
incubations in KRB and KRB containing HHS respectively 
(section 11.5.1.). Samples in a volume of 1 ml were incubated 
with CMP 14C NeuAc (120 nmol, 100 ",1, 0.2 ",Ci) for 4 h at 37 0 
C. At 1-h time intervals aliquots of 200 ",1 were removed, the 
reaction stopped with an equal volume of cold 95% ethanol, the 
tubes were allowed to stand on ice for 30 min and the 
supernatants were removed. The respective supernatants were 
pooled, dried under nitrogen and dissolved in distilled water 
containing 50 ",g of a mixture of CMP-NeuAc and NeuAc (1: 1). An 
aliquot of the supernatant was injected into an Lichrosorb 
amine column connected to a Perkin Elmer HPLC system. HPLC was 
performed as described for the separation of sialyllactosamine 
isomers (section 11.2.2.). Peaks corresponding to CMP-NeuAc 
and NeuAc collected and fractions counted for 
radioactivity. Zero time samples and st'~lOdard radioactive CMP-
NeuAc samples were also chromatographed and in these 
there was no evidence of hydrolysis of CMP-NeuAc. 
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J1.9. stability of STase and GTase in sera from control and 
turpentine treated rats 
Serum samples (200 - 500 1'1) obtained from either control 
turpentine treated rats were incubated for up to 4 h at 
37"C, without TBP or supplemented with TBP (250 p.g/ 2ml). At 
time intervals of 0, 1, 2 and 4 h samples were removed and 
stored at -20"C until assayed. 
J1.10 . Experiments with pure STase and GTase 
Pure STase (0:2 ..... 6 or 0:2 ..... 3; 0.4 mU/iO /-'1) and pure GTase 
(0.4 mU/iO /-'1) were mixed 1:1 (v/v). Plasmin or trypsin (0 to 
0.012 mg) were added to the glycosyltransferase mixture and 
samples incubated at 37 "c for 10 minutes, after which samples 
were removed from incubation and assayed for STase and GTase 
activities. In some experiments TBP (0.0 to 0.03 mg) was added 
in increasing amounts to the glycosyltransferase mixture along 
with 0.01 mg protease. Samples were incubated at 37 "c for 10 
min and assayed for glycosyltransferase assays as described 
(sections 11.7.1. and 11.7.2). 
11.11. Measurement of protease inhibitory and protease 
activities 
11.11.1. sample preparation 
Perchloric acid extracts were prepared from serum and HBF 
according to the procedure described by Fritz et al (1974). 
HRS was mixed with an equal volume of 6% (w/v) perchloric acid 
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and the precipitated protein removed by centrifugation (1200 
x g for 15 min.). The supernatant was treated by the drop wise 
addition of 5M ~C03 until the pH was between 6 and 7. The 
precipitate was removed by centrifugation and the supernatant 
used in assays. Unless otherwise stated AlP!, 85A, HBF and TBP 
were used at concentrations of 30 Jlg! ml. 
11.11.2. Assays tor trypsin inhibitory activity 
11.11.2.A. Assays with BAPNA 
Trypsin inhibitory activity was assayed using the peptide 
BAPNA, as described by Fritz et al., 1974. As shown in the 
reaction, BAPNA i s converted to N-benzoylarginine and p 
nitroanilide. The p-nitroanilide formed is coloured and can be 
monitored by measuring the absorbance at 405 nm. 
T~YPSIN (OH)" 
.-benaoylarg1.niDe-p-aitroaailida 
(BAPIfA) 
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Briefly, the assay mixture contained 0.2 ml trypsin (50 
JJg/ ml in O. ODIN HCl), 1. 7 ml TRA buff er, 0.1 ml inhibitor 
sample. Control assays were done with 0.2 ml trypsin (50 I1g/ 
ml in O.OOlN HCl) and 1.8 ml of TRA. The reactants were 
incubated at 25 °C for 5 minutes after which I ml BAPNA (2.2 
roM) was added. The solutions were incubated for 30 minutes at 
25 °C, the reaction was stopped by cool ing the tubes on ice 
and the absorbance of the solutions was measured at 405 
The differences in the absorbance values between trypsin 
assays and trypsin plus inhibitor assays were taken as a 
measure of trypsin inhibitory activity. Concentrations of 
unbound-heparin fraction and unbound-trypsin fraction for up 
to 5 mg/ml did not show trypsin inhibitory activity. 
When trypsin activity was measured, assays were similar 
and contained 1.0 ml of medium, 1 ml of TRA buffer and lml of 
BAPNA. Solutions were incubated for 30 minutes at 25°C, after 
which the reaction was stopped and absorbance measured as 
described above. 
II-I102.B. Assays with a casein 
Trypsin inhibitory activity using . a casein as substrate , 
assayed according to the method of Fritz et al., (1974). 
The enzymatic breakdown of azocasein yields TCA-soluble 
hydrolysis products, the formation of which can be monitored 
by an increase in absorbance at 366 nm. A typical reaction 
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mixture contained 0.2ml of trypsin (50 ~gl ml), 0.7 ml of 
phosphate buffer, 0.1 ml of the inhibitor sample and 2 ml of 
a casein (2%). Control assays with trypsin were similar except 
that the incubations contained 0.2 ml trypsin, 0.8 ml 
phosphate buffer and 2 ml of casein. Reactants were mixed and 
incubated at room temperature for 10 minutes and 3 ml of TCA 
(5%:) added. The contents of the tubes were mixed and the tubes 
allowed to stand for 30 minutes at room temperature. The tubes 
were centrifuged at 12 000 x g for 5 minutes, supernatants 
separated and absorbance measured at 405 nm. The differences 
in the absorbance values between trypsin assays and trypsin 
plus inhibitor assays were indicative of inhibitory activity 
towards trypsin. 
Concentrations of unbound-heparin fraction and unbound-
trypsin fraction for up to 5 mg/ml did not show inhibitory 
activity towards trypsin. 
11.11.3. Assays tor plasmin inhibitory activity 
11.11.3.A. Assays with BAEE 
Plasmin inhibitory activity using the peptide, BAEE, was 
measured according to the method described by Fritz et al., 
.. 
(1974). Hydrolysis of BAEE results in the liberation of 
ethanol which is measured enzymatically (reactions 1 and 2). 
(1) Benzoyl-L-arginine ethyl ester -----... benzoyl-L-arginine + ethanol 
(2) Ethanol + NAD+ -------... acetaldehyde + NADH + H" 
The assay mixture contained 2.3 ml of glycine-NaOH 
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buffer, 0.2 ml of plasmin (50 ~gjml), 0 . 1 ml of inhibitor, 0.1 
ml of NAO + (60 mgjml), 0.02 ml of AOH (30 mgjml) and 0.5 ml of 
BAEE (6 roM). Control incubations with plasmin contained 0.2 ml 
plasmin, 2.4 ml buffer, 0.1 ml of NAD +, 0 . 12 ml ADH and 0.5 
ml BAEE. The contents of the tubes were mixed and tubes were 
incubated for 20 min at 25°C. The reaction was stopped by 
cool ing the tubes on ice after which the absorbance was 
measured at 364 nm. The differences in the absorbance values 
between plasmin assays and plasmin plus inhibitor assays were 
indicative of inhibitory activity towards plasmin. 
Concentrations of unbound-heparin fraction and unbound-trypsin 
fraction for up to 5 mgjml did not show plasmin inhibitory 
activity. 
When plasmin activity was measured assays were similar 
and contained 0 . 5 ml BAEE, 0.1 ml NAD+, 0.02 ml ADH and 2.6 ml 
buffer . 
II-li. 3 .D. Assays with a casein 
Plasmin inhibitory activity using a casein as substrate 
assayed as described for the measurement of trypsin-
inhibitory activity (section 11.11. 2. [8]) except that plasmin , 
(50 ~gjml) was used instead of trypsin and that the buffer 
used was lysine phosphate. Concentrations of unbound-heparin 
fraction and unbound-trypsin fraction for up to 5 mgjml did 
not show plasmin inhibitory activity. 
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II-11.". Assays for thrombin inhibitory activity 
The procedure was similar to that used for the 
determination of plasmin inhibitory activity with BAEE as the 
substrate (section 11.11.3 [A]) except that thrombin (50 
Ilg/ml) was used instead of plasmin. Concentrations of HBF and 
TBP for up to 5 mgjml did not show thrombin inhibitory 
activity. 
11.11.5. Assays for kallikrein inhibitory activity 
The method used was similar to that described for 
measurement of plasmin-inhibitory activity with BAEE (section 
11.11.3. [A» except that kallikrein (50 J'g/ml) was used. 
Concentrations of HBF and TBP for upto 5 mg/ml did not show 
kallikrein inhibitory activity. 
11.11.6. Assays for chymotrypsin inhibitory activity 
Chymotrypsin inhibitory activity was assayed using the 
peptide SUPHEPA as described by Fritz et al., (1974). 
Hydrolysis of SUPHEPA by chymotrypsin results in the formation 
of N-3-(Carboxypropionyl) -L-phenylalanine and p-nitroanilide. 
The liberation of p-nitroanilide is measured. The substrate N-
succinyl-L-phenylalanine-p-nitoanilide . (SUPHEPA) is also known , 
as N-3- (Carboxypropionyl) -L-phenylalanine-p-ni troanil ide. 
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Briefly the assay mixture contained 0.2 ml of 
chymotrypsin (0. 1 mg Iml), 0.2 ml of inhibitor, 1.6 rol of TRA 
buffer (0.2 M). The reactants were mixed and incubated for 5 
minutes at 25 "c after which 1 rol of SUPHECA (12.8 mM) was 
added and reactants were incubated for a further 20 minutes. 
control incubations with chymotrypsin were similar and 
contained 0.2 ml of protease, 1.8 rol TRA and 1ml of SUPHECA. 
The reaction was stopped by cooling the tubes ice and 
absorbance of the solution was measpred at 405 The 
differences in the absorbance observed between protease and 
protease plus inhibitor assays were indicative of inhibitory 
activity_ Concentrations of HBF and TBP for upto 5 rng/rnl did 
not show chymotrypsin inhibitory activity_ 
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11.11.7. Assays for elastase inhibitory activity 
Elastase inhibitory activity ...... as assayed using orcein-
elastin as the substrate according to the method of Appel 
(1974). The mucoprotein fraction of orcein-elastin is degraded 
by elastase giving soluble hydrolysis products. The amount of 
dye liberated is a measure of enzymatic activity. 
orcein-elastin ------+ orcein + hydrolysis products. 
Briefly the assay mixture contained 0.2 ml of elastase 
(50 jjgjml), 0.1 ml of inhibitor, 2.2 ml of phosphate buffer, 
0.05 ml of orcein-elastin (5 roM). Control incubations with 
elastase were similar and contained 0 . 2 ml elastase, 2.3 ml of 
buffer and 0.5 ml of substrate. The reactants were mixed and 
incubated for 30 minutes at 37 "c after which the reaction was 
stopped by cooling the tubes ice. The tubes were 
centrifuged at 12 000 x g for 15 minutes, supernatants 
separated and absorbance measured at 578 nm. The difference in 
absorbance bet ...... een elastase assays and elastase plus inhibitor 
assays were indicative of inhibitory activity. Concentrations 
of HBF and TBP for upto 5 mgj ml did not show chymotrypsin 
inhibitory activity. 
11.11.8. Assays for papain inhibitory activity 
Assays were similar to those described in section 
IL1l.l. (A) except that papain (50 jjgjml) ...... as used instead of 
trypsin. Concentrations of HBF and TBP for upto 5 mgjml did 
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not show papain inhibitory activity. 
11.12. Data presentation and statistical analysis 
The computer program SigmaPlot 5 (Jandel Scientific) 
used to plot figures. Data are reported as mean ± S.D. 
(standard deviation). Differences between means were tested 
for statistical significance by analysis of variance CANOVA) 
and the Bonferroni method, with the aid of the computer 
program GraphPAD InStat. P values of 0.05 or less were taken 
to indicate a significant difference between means. 
110 
CHAPTER Ill. ROLE OF HEAT-INACTIVATED HORSE SERUM 
(HHS) ON THE SIALYLTRANSFERASE (STASE) RELEASED FROM 
JEJUNAL SLICES 
111.1. IntrodUction 
In the cell STases occur bound to the GoIgi, ER and cell 
membranes [Roth et aI., 1986; Taatjes et al., 1988]. STases 
also occur in the soluble form in body fluids, such as human 
and rat serum [Hudgin and Schachter., 1972; Mookerjea et al., 
1972] and rat intestinal lymph (Ratnam et al., 1981). Liver is 
generally considered to be the main source of soluble STase 
activity in serum and other body fluids. It has been proposed 
that other tissues such as intestine could also contribute to 
soluble STase activity and evidence to support this theory is 
present in the literature. For example colchicine treatment in 
the rat resulted in increased STase activity in intestinal 
lymph and serum (Fraser et al., 1980; Ratnam et al., 1981). 
Also, thermal injury in the rat caused elevations in STase 
activity in small intestine and serum (Chu et al., 1988). 
Considering these factors it is important to understand the 
release of STase from intestine. 
Previous studies have revealed that the incubation of rat 
jejunal slices resulted in the release of soluble STase into 
the incubation medium (Ratnam et al., 1987). In these studies 
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there was an absolute requirement for HHS in the incubation 
medium, in order to observe the release of STase from jejunal 
slices. Though it is clear that STases can occur in tissue 
fluids and incubation media due to the release of the 
membrane-bound enzymes from cell membranes, the factors which 
control the levels of soluble STase activity have not been 
clearly defined. 
The purposes of the present study were therefore 
(1) to study the release of STase from rat jejunal slices and 
(2) to define the role of HHS in the release of STase. 
111 . 2. Results 
111.2.1. Effect of RHS on STase release from jejunal slices 
Figure 3.1 shows the release of STase during the 
inCUbation of rat jejunal slices. When the incubation buffer 
KRB, was supplemented with 20% (v/v) HHS the STase activity 
in the medium increased with time for up to 6 h. However, when 
the jejunal slices were incubated in KRB alone or in KRB 
supplemented with either 20% glycerol or 30 mg BSA only trace 
amounts of STase were detected in the medium [Figure 3.11. The 
concentration of BSA used (30 mgt 2ml) corresponded to the , 
amount of protein present in 20% (v/v) HHS. The levels of 
STase activity detected in medium samples obtained from 1, 2, 
4 and 6 h inCUbation of jejunal slices in KRB + 20% (v/v) HHS, 
were increased compared to samples from jejunal incubations in 
KRB (P < 0.001 for the 1, 2 and 4 h time points). The 
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Figure 3.1. Effect of the presence of HHS in the incubation 
medium on STase release from jejunal slices 
Figure 3.1. Effect of the presence of HHa in the incubation 
medium on aTase release from ieiunal slices. Jejunal slices 
were incubated in KRB ( 0 ) I or in KRB supplemented with 
either 20% (v/v) HHS ( 6 ), 30 mg BSA (0 ) or 20% (v/v) 
glycerol ( 0 ). At the indicated times, incubations were 
stopped, and the medium was decanted, centrifuged and assayed 
for STase activity as described in Materials and Methods 
(sections 11.5.1 and 11.7.1) . STase activity is expressed as 
pmol of NeuAc transferred to DS-AGP/h per ml of incubation 
medium. Results represent means ± S.D. from four experiments. 
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progressive increase in the STase activity released into the 
medium, observed during incubations supplemented with HHS, 
was dependent on the concentration of HHS used, for up to 20% 
(v/v) of HHS [Figure 3.2 ) . 
The addition of 0.3% (v/v) Triton X-lOa to the assays for 
STase in the medium obtained from KR8 + 20% (v/v) HHS 
incubations, did not result in significant increases in the 
STase activity measured (Figure 3.3; P> 0.05 indicating that 
the means for the 1, 2, 4 and 6 h time points, were not 
significantly different). This indicated that the STase 
released into the medium was soluble in nature. 
When the jejunal incubations were carried out in KRB + 
20% (v/v) HHS at 37" C, the levels of STase activity detected 
in the medium ranged from between 800 to 2300 units for the 2, 
4 and 6 h time points (Figure 3.4: STase activity is expressed 
as p mol/h per ml medium). However, when the incubations were 
carried out in KRB + 20% (v/v) HHS at 4 "C, the levels of STase 
activity detected in the medium were less than 100 units for 
the 2, 4 and 6 h time points [Figure 3.4]. Likewise trace 
amounts of STase « 100 units) were d;etected in the medium 
when jejunal slices were incubated in KRB at 4 "C. 
Lactosamine was also used as acceptor to assay for 
STase activity in 4 h medium samples obtained from jejunal 
incubations in KRB + HHS. The results showed that the STase 
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Figure 3.2. Effect of the concentration of HHS in the 
incubation medium on STase release from 
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Figure 3.2. Effect of t h e concentration of HHB in the 
incubation medium on STase release from ieiuna l slice •• 
Jejunal slices were incubated in KRB ( 0 ) or in KRB 
supplemented with HHS at concentrations of either 5% [v/V] 
( \l ), 10\ lV/V) (0 ), 1st lV/V) ( <> ), 20\ lv/v) ( & ), 30' 
[v/v] ( . ) or 40% [v/v] ( • ). At the indicated times, 
incubations were stopped, medium samples were prepared and 
assayed for STase activity as described in Figure 3 . 1. STase 
activity is expressed as pmol of NeuAc transferred to DS- AGP/h 
per ml of incubation medium. Results represent means ± S.D. 
from three exper iments. 
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Figure ) .3. Effect of Triton X-IOO on the medium STase 
activity 
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Figure 3.3. Effect ot Triton X-IOO on the medium STasa 
activity. Jejunal slices were incubated in KRB + 20% (vjv) 
HHS and at the indicated times medium samples were prepared as 
described for Figure 3.1. samples were assayed for STase 
activity in the presence ( -.- ) or absence ( .......... ~) of 0.3% 
(vjv) Triton X-100 as described in Materials and Methods 
(section II. 7 .1). STase activity is expressed as pmol of NeuAc 
transferred to DS-AGPjh per ml of incubation medium. Results 
represent means ± S.D. from five experiments. 
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Figure 3.". Effect of temperature on the release of STa se. 
Jejunal slices were incubated in either KRB (( . ) at 4°C; 
( 0) at 37°C), or in KRB + 20\ (v/v) HHS [( .. ) at 4°Ci 
('iJ ) at 3rC], as described in Figure 3.1. Medium samples 
were prepared and assayed for STase activity as described for 
Figure ).1. STase activity is expressed as pmol of NeuAc 
transferred to DS-AGP/ h per ml medium. Results represent 
means from two experiments. 
present in the medium was predominantly that which catalysed 
the a2-6 linkage of NeUAc to the Gal residue of lactosamine, 
indicating that the enzyme was the a2-t6 Gal,81-4 GlcNAc STase 
( Figure 3.5 ) . 
III.2.2. viability of jejunal slices during incubation 
The glutamate + glutamine in the incubation medium 
decreased over the 6 h of incubation [Figure 3.6). There was 
no significant difference between the rates of decrease 
whether the incubations were carried out in KRB or in KRB + 
20 % (v Iv) HHS [P > 0.05 indicating that the means were not 
significantly different]. As a control, flasks containing KRB 
or KRB + 20% (v/v) HHS were incubated without any jejunal 
tissue for up to 6 h and the glutamate + glutamine measured. 
In these flasks the decrease in glutamine + glutamate over the 
6 h of incubation was less than 5%. 
In other experiments jejunal slices were incubated in 
either KRB alone or in KRB + 20% (vjv) HHS for 0, 1, 3 or 4 h, 
at which times labelled glucosamine or leucine were added and 
the incubations further continued . In these incubations the 
rates of incorporation of [ 14C ] -glucosamine (Figures 3.7(a) and 
3.7(b)) and ( 14C)-leucine ( Figures 3.7(c) and 3.7 (d)] into 
acid-insoluble proteins were measured for up to 120 min. The 
maximum incorporation of leucine into acid-insoluble proteins 
occurred within 30 minutes. In the case of glucosamine the 
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isomers 
Figure 3.5. HPLC elution profiles of sialyl-lactosamine 
isomers. Medium samples were prepared by incubating jejunal 
slices in KRB + 20% (v/v) HHS for 4 h as described in Figure 
3 . 1. samples were assayed using lactosamine as the acceptor as 
described in Methods and Materials (section 11.7.1. B). Samples 
were processed and HPLC performed as described (section 
II.2.:2). Fractions under the peaks for a2-3 (al and a2 .... 6 (h) 
sialyl-lactosamine collected and counted for 
radioactivity. STase activity (f'2ZI) is expressed as p mol/h 
per ml medium. Results represent means ± S.D. from three 
experiments. 
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Figure 3. 6 . Glutamine + glutamate in the incubation med i um . 
Jejunal slices incubated in either KRB ( 0 ) or KRB + 
20t (vjv) HHS ( ~ ) as described in Figure 3 . 1. Control 
incubations were carried out in either KRB ( ..• .. ) or KRB + 20t 
(vjv) HHS ( ...• ... ) without jejunal slices . At indicated times 
incubations were stopped, medium samples prepared and assayed 
for glutamine as described in Materials and Methods (section 
II.5.2 . B.) . Results are expressed as %: of g l utamate and 
glutamine left in medium . Results represent means ± S.D . from 
four experiments. 
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Figure 3.7. Incorporation of [14C] glucosamine and [ L4C] 
leucine into proteins by jejunal slices 
Figure.3.'. Incorporation of 114Clglucosamine and [I4Clleucine 
into proteins by jejunal slices. Jejunal slices were incubated 
in KRB (a and c) or in KRB + 20% (vjv) HHS (b and d) 
described in Figure 3-1. [I.C] Glucosamine (a and b) or 
[ 14C)leucine (c and d) were added after 0 h ( 0 ), 2 h ( ... ), 
3 h ( . ) or 4 h ( 0 ) to incubations which were further 
continued for a maximum of 120 min. At the indicated times 
these incubations were stopped, homogenates of the slices 
prepared and the incorporation of radio labelled glucosamine or 
leucine into acid-insoluble proteins was measured as described 
in Materials and Methods (section II.5.2.A.). Results are 
expressed as d.p.m./mg of protein and represent mean values 
from two exper iments . 
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rate of incorporation continued to increase for up to 120 min. 
Also, the overall rates of incorporation for both labelled 
glucosamine and leucine decreased progressively from 0 to 4 h 
of incubation. This suggested that the cells were less 
efficient in synthesising glycoproteins and proteins at 4 than 
at 0 h. The decreasing rates of glycoprotein and protein 
synthesis were similar whether the incubations were carried 
out in KRB alone or in KRB supplemented with HHS. 
III.2.3. Sialidase and CMP-NeUAc hydrolase activities in 
medium 
Sialidase activity was measured in 2 and 4 h medium 
samples obtained from jejunal incubations in either KRB or KRB 
+ HHS respectively. Jejunal mucosal samples from colchicine 
treated rats were incubated with CMP (14 C] -NeuAc in order to 
prepare the labelled substrate for sialidase activity 
described (section 11.8.1). Studies by Fraser et aI., (1980] 
have indicated that intestinal tissue homogenate samples 
prepared from colchicine treated rats are good endogenous 
acceptors for STase. The medium samples were incubated with 
the labelled substrate and the release of radiolabel from the 
substrate taken as a measure of sialidase activity. Release of 
radioactive label was lower in medium samples obtained from 
incubations in KRB compared to samples obtained from KRB + HHS 
incubations (Table 3.1]. 
122 
Tabla 3.1. Sialidase activity in medium samples obtained fro. 
iejunal incubations. Jejunal homogenate samples from 
colchicine treated rats were incubated for 3h with eMP 
ct4C]NeuAc to prepare the labelled substrate for sialidase 
activity as described in the Materials and Methods (section 
II.B.1). The labelled substrate was then incubated for 3h with 
medium samples obtained from jejunal slice incubations in 
either KRB or KRB + 20% (v/v) HHS. The release of [14C]NeuAc 
was monitored and sialidase activity is expressed as pmol of 
NeuAc released. Results represent means from two experiments. 
sialidase activity 
Incubation p mol NeuAc in p mol 
mixture pellet NeUAc 
released 
Oh 3h 
KRB (2h) 731 730 1 
KRB (4h) 763 753 10 
KRB + 20% 641 621 20 
(v/v) HHS 
(2h) 
KRB + 20% 700 681 19 
(v/v) HHS 
(4h) 
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CMP-NeuAc hydrolase activity was measured in 2 and 4 h 
medium samples obtained from incubations in either KRB or KRB 
supplemented with 20% (v/v) HHS [Table 3.2). During these 
experiments the samples were incubated with CMP [ 14C) -NeuAc 
for 3 h after which the radioactivity in the unhydrolysed CMP 
[ 14C)-NeuAC and free NeuAc was measured. The free NeuAc 
released was lower in medium samples obtained from incubations 
in KRB compared to KRB + HHS samples (Table 3.2]. 
III.2.". Function of DB in the release of STasa 
In order to investigate the role of HHS in the release of 
STase during jejunal incubations, (1) 20% (v/v) HHS was added 
to KRB containing the jejunal slices throughout the incubation 
(2) either 20% (v Iv) HHS or 0.9% NaCl was added 
immediately to the decanted KRB medium obtained after 0, I, 2 
and 4 h of incubation respectively and STase activity was 
measured. These results indicated that the immediate addition 
of HHS to KRB partially restored STase acti vi ty (Figure 3. B] . 
In samples where HHS was added immediately to medium obtained 
from jejunal incubations in KRB, STase activity 
significantly higher for the 1, 2 <v1d 4 h time points, , 
compared to samples where 0.9% NaCl was added [P < 0.001 for 
the 1, 2 and 4 h time points). In further experiments where 
HHS was added at different times to KRB medium kept on ice 
there was a gradual loss of STase activity with time compared 
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Table 3.2. eMP NeUAc hydrolase activity in mediwa sample. 
obtained from ieiunal incubations. 2h and 4h medium samples 
from jejunal incubations in either KRB or KRB + 20\ (v/v) HHS 
were incubated with CMP[ 14C] NeuAc for 3h as described in 
Materials and Methods (section 11.8.2 . ) . Reactions were 
stopped by addition of 95\ ethanol, samples centrifuged, 
supernatants separated and dried under nitrogen. The residue 
was dissolved in 50j.ll water containing 50 j.lg of a mixture of 
unlabelled CMP-NeUAc and NeUAc. CMP-NeUAc and NeUAc were 
separated by HPLC as described (section 11.2.2) and the 
fractions under the respective peaks were counted for 
radioactivity. Results represent means from two experiments. 
CMP NeuAc hydrolase activity 
Incubation p mol NeUAc p mol 
mixture acid left NeUAc 
unhydrolyzed released 
KRB 2700 213 
(2h) 
KRB 2644 216 
(4h) 
KRB + 20% 2713 280 
(v/v) HHS 
(2h) 
KRB + 20% 2731 250 
(v/v) HHS 
(4h) 
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Figure 3.8. Effect of immediate addition of HHS to KRB medium 
on STase activity released from jejunal slices 
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Figure 3.B. Effect of immediate addition of BRa to KRB mediwa 
on aTase activity released from jejunal slices. Jejunal slices 
were incubated in KRB ( 0 ) or in KRB + 20% (v jv) HHS ( 6 ) 
as described in Figure 3. L At the indicated time intervals 
the incubations were stopped and the medium was decanted. 20\ 
(v jv) of 0.9% NaCl was added immediately to the decanted 
medium obtained from jejunal incubations in KRB (0 ) or in 
KRB + HHS (6 ). 20% (vjv) HHS was also added to decanted 
medium samples from jejunal incubations in KRB ( 0 ). The 
samples were then assayed for STase activity as described in 
Figure 3.1. STase activity is expressed as pmol of NellAc 
transferredj h to oS-AGP per ml medium. Results represent 
± S.D. from three experiments. 
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to samples where HHS was added immedia tely [Figure 3.9]. 
III.2. 5. Effect of antiproteasesl proteases on STase released 
Antipain, BPTI, leupeptin or pepstatin added to KRB 
during 2 and 4 h incubations resulted in 3 to 5 fold increases 
in STase activity at a 200 ug dose and 3 to 6 fold increases 
at a 400 ug dose, compared to incubations in KRB alone [Table 
3.3]. Similar addition of human AlP! to KRB resulted in 11 to 
20 fold increases for the 2 and 4 h incubations at a 200 ug 
dose and 22 and 33 fold increases for the 400 ug dose [Table 
3 . 3 ]. Q 2 Antiplasmin caused 13 and 19 fold increases for 2 and 
4 h inc ubations at the 200 IJ.g dose, and 20 and 30 fold 
increases at the 400 IJ.g dose, in medium STase activity 
compared to incubations in KRB alone . 
Trypsin activity in the medium was higher when jejunal 
slices were incubated in either KRB alone or KRB containing 30 
mg BSA compared to KRB + HHS incubations [Figure 3 . 10]. 
The addition of increasing concentrations of KRB medium 
obtained after 4 h incubation of jejunal slices inhibited the 
STase activity of the 4 h KRB + HHS medium (Figure 3.11). 
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Figure 3.9. Effect of immediate addition of HHS to KRB medium 
on STase activity released from jejunal slices 
12S·A 
Figur' 3.9. Effect of i_ediate addition ot HBS to ItRB 
medium. on STase activity released from iejunal slices. Jejunal 
slices ..... ere incubated in either KRB ( 0 ) or KRB + 20% (v/v) 
HHS ( 6 ) as described for Figure 3.1. After 2 h of 
incubation the medium samples were decanted into tubes ..... hich 
kept on ice. At the indicated times 20% (v/v) of 0.9% 
NaCl was added to the decanted medium samples obtained from 
KRB ( 0 ) and KRB + HHS incubations ( 6 ). To another set of 
decanted samples from KRB incubations, 20% (v/v) HHS was added 
( <> ). STase activity measured as described in Figure 
3 . 1. STase activity is expressed pmol of NeuAc 
transferred/h to DS-AGP per ml incubation medium. Results 
represent means ± S.D. from four experiments. 
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Tabl. 3.3. Effect of antiproteas.s on the STas. activity 
released during jejunal incubations. Jejunal slices were 
incubated in KRB or in KRB containing either 20% (vjv) HHS or 
antiprotease [200 (Table Ja and Table Jb) or 400 ~g of 
antipain, BPTI, leupeptin, pepstatin, Q-2 antiplasmin or 
A1PI). Medium samples were prepared from 2 hand 4 h 
incubations and STase activity measured as described in 
Materials and Methods (sections 11.5.1. and 11.7.1.). STase 
activity is expressed as pmol of NeUAc transferred/h to DSG-
AGP per ml of medium. Results represent means ± S.D. from 
experiments. 
Incubation mixture 
Antiprotease 
(pg/2ml 
no antiprotease 
STase activity 
(p mol/h per ml medium) 
2h 4h 
62.3 + 26 10.4 + 23.1 
antipain (200) 256.8 + 30.1 222.9 + 187.3 
antipain (400) 220.8 + 156.1 239.0 + 116 
BPTI (200) 223.9 + 87.4 239.0 + 117.1 
BPTI (400) 316.2.! 59.9 355.3 + 59.9 
leupeptin (200) 347.0 + 136.5 222.9 ± 187.3 
leupeptin 400 328.4 + 102.2 464.2 + 68.9 
I peps tat in 200 287.5 + 103.4 385.4 + 123.2 
I pepstatin (400) 309.6 + 87.5 385.4 + 78.4 
A1PI (200) 142.0 + 124.0 1438.3 + 95.6 
AIPI 400 1378.9 + 526.0 2332.6 + 193.7 
a2 antiplasmin (200) 812.9 + 22.5 1272.3 + 131.2 
a 2antiplaemin (400) 1272.6 .! 321.8 2147.8.! 118.3 
HHS 20'\ (v/v) 1444.9 + 42.5 2479.5 + 123.2 
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Figure 3.10. Trypsin activity in the medium 
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Figure 3.10. Trypsin activity in the medium. Jejunal slices 
were incubated in KRB ( . ) or in KRB supplemented with either 
20% (v/v) HHS ( • ) or 30 mg BSA ( • ) as described for 
Figure 3.1. At the indicated times, incubations were stopped, 
the medium was decanted, centrifuged and assayed for trypsin 
activity as described in Materials and Methods (section 
11.11.2. [AJ). Trypsin activity is expressed as nmol of 
substrate hydrolysed /min per ml medium. Results represent 
means from two exper iments. 
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Figure 3.11. Effect of addition of 4b ItRB medium on STase 
activity. Jejunal slices were incubated for 4 h in KRB or in 
KRB supplemented with 20\ (vjv) HHS as described for Figure 
3.1 and medium samples were prepared. Increasing volumes of 4 
h KRB medium was added to 4 h KRB + HHS medium and STase 
activity measured described in Figure 3.1. STase activity 
is expressed as pmol of NeuAc transferred to DS-AGP jh per ml 
medium. Results represent means ± S.D. from four experiments. 
111.2.'. Ef"fect of the heparin and the heparin-l:dnding 
fraction (RBF) of DS on the STase activity released during 
jejunal incu))ations 
Heparin when added to jejunal slice incubations at a 
concentration of 100 ugj 2ml, decreased the activity of STase 
released in the presence of HHS {Figure 3.12; P < 0.001 for 
the 1, 2, 4 and 6 h time points]. Also, heparin in a dose 
dependent manner decreased the activity of STase released 
during jejunal incubations supplemented with HHS [Figure 
3.13]. The addition of heparin (100 ugj2ml] to incubations 
resulted in 70 and 55% decreases in STase activity for the 4 
and 2 h jejunal medium samples respectively. An increase in 
the heparin concentration to 200 jJ.gj ml further decreased 
STase activity by 79 and 76% respectively in the 4 and 2 h 
jejunal medium samples. Heparin when added directly to the 
assays at concentrations of 100 and 200 ug/ 2ml caused 
decreases in STase activity of 10, 20 and 25, 39 % for the 4 
and 2 h jejunal medium samples respectively [Figure 3.14). 
This suggested that when heparin was present during the 
incubation of jejunal slices it caused greater inhibition of 
, 
STase activity or that it inhibited the release of STase 
compared to when heparin was added directly to the assays. 
This lead to further studies to determine whether heparin was 
binding to specific antiproteolytic protein(s) in HHS and if 
these protein(s) had an effect on STase activity. 
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Figure 3.12. Effect of heparin on the STase activity released 
from jejunal slices 
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Figure 3.12_ Effect of heparin on the STase activity released 
from jejunal slices. Jejunal slices were incubated in KRB + 
20\ (vjv) HHS as described for Figure 3.1. Heparin (100 I'gjml) 
added at a h to one set of incubations ( 6 ). Control 
incubations were carried out in the absence of heparin ( • ). 
At the specified times, medium samples were prepared and STase 
activity in the medium was measured as described in Figure 
3.1. STase activity is expressed as pmol of NeuAc transferred/ 
h to DS-AGP per ml medium. Results represent means ± S.D. from 
five exper iments. 
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Figure 3.13. Effect of heparin concentrations on the STase 
activity released from jejunal slices 
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Figure 3.13. Effect of heparin concentrations on the STase 
activity released from jejunal slices. Increasing 
concentrations of heparin were added at zero time to jejunal 
incubations supplemented with 20% (v/v) HHS. The incubations 
were stopped at either 2 h • ) or 4 h ( A ) and medium 
samples were analyzed for STase activity as described in 
Figure 3.1. STase activity is expressed as pmol/ h of NeuAc 
transferred to DS-AGP per ml of incubation medium. Results 
represent means ± S.D. from three exper iments. 
134-8 
The unbound-heparin fraction and HBF were separated from 
HHS by affinity chromatography using heparin-agarose [Figure 
3.15] . When the unbound-heparin fraction was used in 
incubations, the activity of STase in the medium was 
significantly decreased compared to incubations wherein 
complete HHS was used [Figure 3.16; P < 0.001 for the 1, 2 and 
4 h time points]. 
In control experiments HHS was applied to an agarose 
column and the unbound-agarose fraction collected. When 20% 
(v jv) of the unbound-agarose fraction was added to incubations 
the activity of STase in the medium was similar to that 
observed when HHS was used [Figure 3.16: P> 0.05 indicating 
that the means were not significantly different for the 1, 2 
and 4 h time points]. When HBF [500 ugj 2ml] was added to 
incubations, STase activity detected in the medium was similar 
to that observed with HHS [Figure 3.16; P > 0.05 indicating 
that the means were not significantly different for the 1, 2 
and 4 h time points]. Addition of increasing concentrations of 
HBF up to 1200 ugj 2ml to the jejunal slice incubations 
resulted in a progressive increase of STase activity in the 
.. 
medium compared to incubations in KRB [Figure 3.17; P < 0.001 
for the 200, 500, 800 and 1200 I1g doses compared to KRB]. 
These results suggested that HBF was the fraction of HHS which 
was required in the incubation medium in order to measure the 
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Figure 3.14. Effect of heparin on the assay for STase. Jejunal 
slices were incubated in KRB + 20% (vjv) HHS. At 2 h ( ... ) and 
4 h ( ~ ) incubations were stopped and medium samples 
processed as descr ibed in Figure ). 1. Samples were then 
assayed for STase activity in the presence of increasing 
concentrations of heparin. STase activity is expressed as pmol 
of NeuAc transferredjh to OS-AGP per ml incubation medium. 
Results represent means ± S.D. from four experiments. 
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Figure 3.15. Affinity chromatography profile of the binding 
of HHS to heparin agarose: separation of the 
heparin-binding fraction (HBF) 
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Figure 3.15. Affinity chromatography profile of the binding of 
HHB to heparin-agarose: separation of the heparin-binding 
fraction (HBP). HHS was applied to a heparin-agarose column 
which had been equilibrated with 5 mM Tris buffer as described 
in Materials and Methods (section II.2.3.A). The column was 
then washed extensively with Tris-buffer until the absorbance 
of the eluent at 280 nm was less than 0.05. The bound fraction 
was eluted with 1 M NaCl in Tris-buffer and processed. This 
graph was regenerated by digitizing the elution profile with 
Sigmaplot 5. O. 
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Figure 3.16. Effect of HBF and heparin-unbound fractions 
fractions of HHS on medium STase activity 
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Figure 3.16. Effect of HBF and heparin-unbound fractions of 
HHS on medium STase activity. Jejunal sections were incubated 
in KRB supplemented with either 20% (vjv) HHS ( 0 ), 20% 
(vjv) unbound-heparin fraction ( A ), 20% (vjv) unbound 
sepharose fraction ( 0 ) or 500 I1g HBF ( <> ) as described in 
Materials and Methods (sections I1.2.3.A. and 11.5.1). At the 
indicated times the medium samples were prepared and assayed 
for STase activity as described in Figure 3.1. STase activity 
is expressed as pmol of NeuAc transferred to DS-AGPjh per ml 
medium . Results represent means ± S. D. from four experiments. 
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Figure 3 .17. Effect of HBF on medium STase activity 
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Figure 3.17. Effect of HBF on medium. STase activity. Jejunal 
sections were incubated in KRB (D). or in KRB supplemented 
with either 20% (v/v) HHS ( _ ) or 200 -1200 Jjg HBF (B ). 
After 4 h of incubation medium samples were prepared and STase 
activity measured as described in Figure 3.1 . STase activity 
is expressed as pmol of NeuAc transferred/h to DS-AGP per ml 
medium. Results represent means ± S.D. from four experiments. 
139- B 
STase activity released during jejunal incubations. HBF when 
added directly to the assays for STase did not increase STase 
activity indicating that HBF was required in the incubations 
in order to exert its protective effect on STase (Figure 
3.18]. HBF was able to inhibit the hydrolysis of BAPNA by 
trypsin, indicating that HBF possessed antiproteolytic 
activity. 
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Figure 3.18. Effect of HBP' on the assay for STase. Jejunal 
slices were incubated in KRB supplemented with 20\ (v/v) HHS. 
At 2 h ( A ) and 4 h ( 6) medium samples were prepared as 
described in Figure 3.1. Increasing concentrations of HBF were 
added to samples which were assayed for STase activity. STase 
activity is expressed as pmol of NellAc transferred/h to DS-AGP 
per ml medium. Results represent means ± S.D. from four 
experiments. 
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Figure 3.19. Trypsin inhibitory activity of HHS and its 
fractions 
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Figure 3. 19. Trypsin inhibitory activity ot RRS and its 
fractions. Inhibition of trypsin activity is compared between 
samples of HHS ( _ ), unbound-heparin fraction (m), HBF 
(m ) and AlPI ( ~ ). Fraction preparation and assays for 
trypsin inhibitory activity were carried out as described in 
Materials and Methods using BAPNA as substrate (sections 
II.2.3.A and II.9.2.A). Trypsin inhibitory activity was 
obtained from the difference between activity in the presence 
and absence of the inhibitor and is expressed as nmol/min per 
ml serum for HHS and the unbound-heparin fraction, and as 
nmol/min per mg protein for HBF and A1PI. Results represent 
means ± S.D. from five experiments. 
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III. 3. Discussion 
The incubation of rat jejunal slices in KRB supplemented 
with 20% (v/v) HHS, lead to a time dependent appearance of 
STase activity in the medium for up to 6 h [Figure 3.1]. When 
the incubations were carried out in KRB alone or in KRB 
supplemented with either 30 mg BSA or 20(V/V) glycerol, only 
trace amounts of STase activity were detected in the medium. 
This indicated that among the different supplements used 
during incubations, HHS was the supplement which was required 
in order to measure STase activity in the incubation medium. 
These results suggested that HHS was exerting an effect either 
on the release process itself or on the STase activity 
released. The STase released soluble in nature as the 
addition of Triton X-lOa to the assays did not result in 
significant increases in activity [Figure 3.3]. These 
observations support those made by Ratnam et aI., (1987] who 
reported that there need for HHS in the incubation 
medium in order to observe the release of STase during the 
incubation of jejunal slices. 
Glutamine is the main fuel for in,testinal cells (Neutra 
and Padykula, 1984], and was the nutrient source used during 
incubations. Therefore, the measurement of glutamine + 
glutamate during jejunal incubations was one of the criteria 
used to assess cell viability during incubations. Glutamine + 
glutamate in the incubation medium decreased with time of 
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incubation from 0 to 6 h [Figure 3.6] . This indicated that 
glutamine was either being utilized or broken down during 
incubations. In control experiments .... ithout jejunal tissue, 
wherein incubations were carried out in either KRB or in KRB 
+ HHS, glutamine + glutamate decreased by approximately 5\: 
over the 6 h of incubation. This suggested that the decrease 
in medium glutamine + glutamate during the 6 h of incubations 
in the presence of jejunal slices was probably the result of 
uptake of glutamine by the jejunal slices. 
Other criteria used to determine the viability of the 
jejunal tissue slices during incubations, included measurement 
of the rates of incorporation of labelled glucosamine and 
leucine into acid-insoluble proteins. The results indicated 
that the cells were more efficient in synthesising proteins/ 
glycoproteins at 0 than at 4 h of incubation, though the cells 
were still synthesising proteins/ glycoproteins at 4 h [Figure 
3.7]. It was also observed that there was no difference 
between the rates of glycoprotein or protein synthesis whether 
the jejunal slices were incubated in KRB alone or in KRB + 
HHS. Both the criteria used to assess viability namely the 
patterns of glutamine uptake and rates of glycoprotein/ 
protein synthesis showed similar results for incubations in 
KRB and KRB + HHS. Therefore the addition of HHS to KRB had no 
beneficial or detrimental effect on the viability of the 
jejunal slices. Also, the differential appearance of STase 
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activity in the presence of HHS could not be attributed to 
differences in viability between HHS-free and HHS-supplemented 
incubations. 
Sialidase and CMP-NeuAc hydrolase activities were not 
higher in KRB incubations compared to incubations supplemented 
with HHS [Tables 3.1 and 3.2]. Therefore the low levels of 
STase activity detected in incubations carried out in KRB 
alone was not due to the increased activities of either CHP-
sialic acid hydrolase and or sialidase. 
According to the results presented in this section HHS or 
antiproteases were required in order for sign ificant amounts 
of STase to be detected in the incubation medium. Among the 
antiproteases used A1PI and 01 antiplasmin were the most 
effective in terms of reproducing the effect of HHS on STase 
activity (Table 3.3]. The medium obtained after jejunal 
incubations in KRB alone showed higher trypsin activity 
compared to medium obtained from HHS supplemented incubations 
[Figure 3.10). This suggested that the higher proteolytic 
activity in KRB medium might be linked to the low levels of 
STase activity observed. 
HHS when added immediately to medium obtained from 
jejunal incubations in KRB alone, caused a restoration of 
STase activity [Figures 3.8 and 3.9]. This indicated that 
STase was being released during incubations even in the 
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absence of RRS, but that RRS was required in order to measure 
STase activity. Also this raises the possibility that the 
proteases were less active in the presence of jejunal slices 
so it was only when the slices were removed that most of the 
proteolysis of STase occurred. Medium obtained from 4 h 
incubation of jejunal slices in KRB alone, when added to 
medium from 4 h RRS-supplemented incubations inhibited STase 
activity ( Figure 3.11]. This suggested that there might be 
protease(s) in the incubation system which were destroying the 
STase activity released. This is supported by the observation 
that HRS, A1PI and Cf2 antiplasmin were able to protect the 
STase. 
The addition of heparin to jejunal incubations containing 
HRS decreased the STase activity released into the medium 
( Figures 3 . 12 and 3.13 ] . Though heparin also had an inhibitory 
effect on STase activity when added to assays for STase, the 
inhibition was greater when heparin was presen t during 
incubations. This led to further investigations for factor(s) 
in HHS which might bind to heparin and which had an effect on 
STase activity. Heparin is known to bind and interact with a 
number of molecules including growth factors (Quinkler et al., 
1989; zarnegar et aI., 1990) and proteins (Raulais et aI., 
1991). using heparin-agarose RSF was separated from RHS 
(Figure 3.15]. HSF, when added to incubations, was able to 
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reproduce the effect of HHS on STase activity [Figures 3.16 
and 3.17]. STase activity detected in the medium was markedly 
lower when the unbound-heparin fraction of HHS was used to 
supplement incubations, compared to incubations containing 
either HHS or HBF. Thus the removal of HBF by heparin resulted 
in the loss of protection of STase activity by HHS [Figure 
3.16]. Furthermore HBF displayed trypsin inhibitory activity 
[ Figure 3.19]. This implied that antiproteolytic serum 
components or proteins such as HBF, A1PI and a-2 antiplasmin 
played a vital role in determining the measurable STase 
activity released into the incubation medium. 
A number of investigations have been directed towards 
studying STase in the small intestine [Kim et aI., 1975; BioI 
et al . , 1987: 1992 ]. Immunocytochemical studies have shown 
that STase was present in ER and Golgi membranes as well as in 
post-Golgi apparatus structures including mucous droplets and 
plasma membranes [Taatjes et al., 1988], indicating that STase 
is widely distributed in the membranes of intestinal cells. In 
these studies the focus has largely been towards defining the 
role of STase in cell renewal, differentiation and cell-cell 
interactions. 
other investigators have measured soluble STase and 
intestinal STase in pathological conditions. For instance, 
thermal injury in the rat resulted in increased STase activity 
in intestine and serum [ Chu et aI., 1988]. Colchicine 
147 
treatment in the rat resulted in increased STase activity in 
intestine, intestinal lymph and serum [Fraser et al., 1980; 
Ratnam et aI., 1981, 1987). These investigators have 
hypothesised that the intestine could contribute to the levels 
of soluble STase in extracellular fluids. 
The factors which are involved in the release process are 
poorly understood. Since STases are membrane bound enzymes 
conversion to the soluble form would have to involve release 
from the membranes. The release of the STase molecule from the 
membrane is believed to occur due to proteolytic cleavage 
[ Lammers and Jamieson, 1988, 1989, 1990; colley et aI., 1989; 
Jamieson et al., 1993: McCaffrey and Jamieson, 1993}. 
Ratnam and coworkers (1987) reported that there was 
absolute requirement for HHS in the incubation medium in order 
to observe the release of STase from rat intestinal slices. 
The results presented in this chapter support this 
observation. However, this effect of HHS on STase activity was 
due most likely to the anti proteolytic properties of HHS. The 
results also indicate that HBF the spec if ic 
antiproteolytic component of HHS which ,governed the levels of 
STase released during jejunal incubations. Though HBF did not 
affect the release process directly, it is evident that the 
STase activity released was labile, HBF was able to protect 
STase and thereby permit the determination of STase levels in 
the incubation medium. The protease responsible for releasing 
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the soluble STase from the membrane is not the same as the 
protease which degrades STase because HHS did not prevent the 
release but only prevented degradation of the enzyme released. 
Also, HHS did not contain this protease because purified 
protease inhibitors (a2 antiplasmin or AlPI) gave the same 
increase in STase as HHS did . 
Among the antiproteases used AlPI and a-2 antiplasmin 
were most effective in reproducing the effect of HHS on STase 
activity [Table 3.3 ) . Trypsin act i vity was higher in medium 
obtained from KRB incubations compared to medium obtained from 
KRB + HHS incubations [ Figure 3 .10) . The addition of medium 
obtained after 4 h incubations of jejunal slices in KRB, to 4 
h medium samples from KRB + HHS incubations caused an 
inhibition in STase activity . These results collectively 
suggest that protease(s) were present in the jejunal 
incubation system which were capable of destroying STase and 
that antiproteases when present were able to prevent 
proteolytic degradation of STase. 
In conclusion the soluble STase activity released into 
the incubation medium during jejunal incubations was easily 
destroyed by proteases and antiproteases such as HBF, AlPI or 
a-2 antiplasmin were required in the incubation medium in 
order to measure the STase activity released. The results also 
imply that during jejunal incubations levels of protease 
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inhibi tors and proteases may play key roles in determining the 
levels of STase activity released. 
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CHAPTER IV. RELATIONSHIP BETWEEN ANTlPROTEOLYTlC 
PROTEINS IN RAT SERUM AND THE GLYCOSYLTRANSFERASE 
ACTIVITIES RELEASED DURING JEJUNAL INCUBATIONS 
IV.l. Introduction 
GTases are enzymes which catalyse the transfer of Gal 
onto suitable glycoprotein or oligosaccharide acceptors 
(Schachter and Roseman., 1980; Beyer et a1., 1981]. Gal 
residues on the glycopeptide chains usually serve as acceptors 
for the reaction catalyzed by STase, as NeuAc is usually 
added onto Gal residues. Increases in soluble GTase activity 
occur during cancer in extracellular fluids including serum 
[Podolsky et a1., 1977,1978; capel et a1., 1982], ascitic 
fluid [Gerber et a1., 1979) and pleural effusions [Ram and 
Mungal, 1984). 
There are some pathophysiological conditions where, 
though increases in STase activity were observed, serum GTase 
activity was unchanged. For instance, during turpentine 
induced inflammation in the rat, increases were observed in 
liver activities of both STase and GTaS~ [Kaplan et al., 1983; 
Fraser et al., 1984]. However in serum, though STase activity 
was increased, GTase remained unchanged. In the rat, following 
colchicine injection, increases in STase activity but not 
GTase activity, were observed in intestine, intestinal lymph 
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and serum ( FraSer et al., 1980; Ratnam et al., 1981; Ratnam et 
al., 1987]. In both these conditions though soluble serum 
STase activity was increased GTase activity remained unchanged 
suggesting that the factors which control the levels of these 
two enzymes are different. 
Results presented in the previous chapter indicated that 
STase released during the incubation of rat jejunal slices was 
labile. Also, antiproteolytic agents such as HHS, HBF isolated 
from HHS, A1PI or 0:-2 antiplasmin were required in the 
incubation medium in order to measure the STase activity 
released. The purposes of the experiments outlined in this 
chapter were 
(1) to determine whether HBF from heat inactivated rat serum 
(HRS) , like HBF from HHS had a role in protecting the STase 
activity released during jejunal incubations, 
(2) to determine whether GTase was released during jejunal 
incubations and if GTase activity was dependant on HBF, 
(3) to further study the relationship between protease 
inhibitory and STase activities and 
(4) to characterise the protease inhibitory activity of HSF. 
IV.2. Results 
IV.2.1. Ef"fect of BRS on the STase and GTase acti vi ties 
released during iejunal incubations 
Figure 4.1 compares the release of STase and GTase from 
jejunal slices into the inCUbation medium, when the 
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Figure 4.1. Effect of HRS in the incubation medium on STase 
and GTase release from jejunal slices 
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Figure ".1. Effect of HR8 in the incubation ma dium on 8T.sa 
and GTasa release from jejunal slices. Jejunal slices were 
incubated in either KRB ( 0, . ) or KRB + 20% (v/v) HRS 
( l:::. , A ). At the indicated times, incubations were stopped, 
the medium decanted, centrifuged and assayed for STase and 
GTase activities as described in Materials and Methods 
(sections 11.5.1.,11.7 . 1. and 11.7.2). STase (--) and 
GTase ( .... _ ... ) activities are expressed as pmol of NeUAc or Gal 
transferred to DS-AGP or DSG-AGP/h per ml medium. Results 
represent means ± S.D. from three experiments. 
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incubations were carried out in either KRB or KRB + 20% (v/v) 
HRS. The activities of STase and GTase in medium, increased 
with time for up to 4 h. Unlike STase, the increment of GTase 
activity was not dependent on the presence of HRS. STase 
activity, detected in the medium was significantly higher in 
samples obtained from KRB + HRS incubations, compared to 
incubations in KRB alone (Figure 4.1; P < 0.001 for the 1, 2 
and 4 h time points]. In the case of GTase, activity remained 
similar in samples obtained from incubations in either KRB or 
KRB + HHS [Figure 4.1; P > 0.05 indicating that the means were 
not significantly different ] . 
tV.2.2. Effect of HBF on ST.se and GTase activities released 
during iejunal incubations 
Heparin when added to the incubations, inhibited the 
activity of the STase released in the presence of HRS [Figure 
4.2; P < 0.01 for the 1, 2 and 4 h time points]. However, 
heparin did not have an effect on the GTase activity released 
into the medium during incubations in KRB or in KRB + 20% 
(v/v) HRS [Figure 4.3; P > 0.05 indicating that there was no 
significant difference between the mean,.]. 
Using heparin-agarose the heparin-unbound fraction and 
HBF were separated from HRS [Figure 4.4]. When the unbound-
heparin fraction (20%, v/v) used to supplement 
incubations, STase activity in the medium was decreased 
compared to incubations supplemented with HRS (20%, v/v) 
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Figure 4.2. Effect of heparin on STase released from jejunal 
slices 
155 ,-A 
Figure ".2. Effect of heparin on STasa released froll jejunal 
slices . Heparin (100 /.lg/2ml) was added at a h to jejunal 
incubations carried out in KRB ( ........ ) or in KRB + 20% (v/v) 
HRS (_ ..... ). Control incubations were carried out in the 
absence of heparin in KRB (~) or KRB + 20% (v/v) HRS 
(--6-). At specified times, the medium samples were processed 
and STase activity measured as described in Figure 4.1. 
Results represent means ± S.D. from six experiments. STase 
activity is expressed as pmol of NeuAc transferred to DS-AGP/h 
per ml incubation medium. 
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Figure 4.3 . Effect of heparin on GTase released from jejunal 
slices 
Figure ".3. Effect of h eparin on GTase released from jeiunal 
slices. Heparin (100 Ilgj2ml) was added at 0 h to incubations 
carried out in KRB ( ... • .. _) or in KRB + 20% (vjv) HRS ( ........ ). 
control incubations were carried out without heparin in KRB 
( ~ ) or in KRB + 20% (vjv) HRS (fr ). At the indicated 
times, the medium samples were processed and GTase activity 
measured as described in Figure 4.1. GTase activity is 
expressed as pmol of Gal transferred to OSG-AGP/h per ml 
medium. Results represent means ± S.D. from six experiments. 
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Figure 4.4. Affinity chromatography profile of the binding 
of HRS to heparin-agarose: separation of the 
heparin-binding fraction (HBF) 
Figure".". Affinity chromatography profile of the binding of 
HRS to heparin-agarose: separation of the heparin-binding 
fraction (HBF). HRS was applied to a heparin-agarose column 
which had been previously equilibrated with 5 roM Tris-buffer 
as described in Materials and Methods (section II.2.3.A). The 
column was then washed extensively with Tris-buffer until the 
absorbance of the eluent at 280 nm was less than 0.05. The 
bound fraction was eluted with 1 M NaCl in Tris-buffer and 
processed. This graph was regenerated by digitizing the 
elution profile with Sigmaplot 5.0. 
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(Figure 4.5; P < 0.01 for the 1, :2 and 4 h time points].When 
HBF (500 ~g) used to supplement KRB during incubations 
STase activity detected in the medium was similar to that 
observed when HRS was used as supplement [Figure 4.5; P > 0.05 
indicating that the means for the 1, :2 and 4 h time points 
were not significantly different]. STase activity in 4 h 
medium was increased when HBF (from 500 - 1:200~g) was used to 
supplement incubations, compared to incubations in KRB (Figure 
4.6; P < 0.001 for incubations supplemented with either 200, 
500, 800 or 1200 ~g HBF compared to incubations without 
supplement] . 
In contrast to STase, GTase activity in the medium 
remained similar whether incubations were carried out in KRB 
or KRB supplemented with either HRS, HBF or unbound-heparin 
fraction [Figure 4.7; P > 0.05 indicating that for the 1, 2 
and 4 h time points, there was no difference between samples 
from KRB incubations compared to samples from incubations 
supplemented with either HRS, HBF or the unbound-heparin 
fraction]. GTase activity was not affected by increasing the 
concentrations of HBF, as activity was similar between 4 h 
medium samples obtained from KRB incubations and incubations 
supplemented with 200 - 1200 JJ.g HBF (Figure 4.8; P > 0.05 
indicating that there was no significant difference between 
samples obtained from incubations in KRB, compared to samples 
obtained from incubations where KRB was supplemented with 
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Figure 4.5. Effect of the HBF and heparin-unbound fraction 
of HRS on the medium STase activity 
159-A 
Figure". 5. Effect of the HBP and heparin-unbound fraction of 
HRS on the medium STase activity. Jejunal sections were 
incubated in KRB (0 ) or in KRB supplemented with either 20% 
(vjv) HRS (6 ), 20% (vjv) unbound-heparin fraction (<» or 
500 I-£g HBF (0 ). At the indicated times medium samples were 
processed and STase activity measured as described in Figure 
4.1. STase activity is expressed as pmol of NeuAc transferred 
to DSG-AGPjh per ml medium. Results represent means ± S.D. 
from four experiments. 
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Figure 4.6. Effect of HBF on the medium STase activity 
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Figure 4.6. Effect of HBF on the medium STase activity. 
Jejunal slices were incubated in KRB D ) or in KRB 
supplemented with either 20% (vjv) HRS ( _ ) or increasing 
concentrations [200 to of 1200] Jjg HBF (~). Medium samples 
were prepared after 4 h of incubation and STase activity was 
measured as described in Figure 4.1. STase activity is 
expressed as pmol of NeUAc transferred to OS-AGPjh per ml 
incubation medium. Results represent means ± S.D . from four 
experiments. 
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Figure 4. 7. Effect of HBF and heparin-unbound fraction of 
HRS on the medium GTase activity 
161-A. 
Figure". 7. Ettect ot the HBF and heparin-unbound tractions ot 
aRB on the .ediWll GTase activity. Jejunal slices were 
incubated in KRB ( 0) or in KRB supplemented with either 20% 
(v/v) HRS ( 8), 500 119 HBF (0) or 20% (v/v) unbound-heparin 
fraction ( 0 ). At the indicated times the incubations were 
stopped, medium samples processed and GTase activity measured 
as described in Figure 4.1. GTase activity is expressed as 
pmol of Gal transferred to DSG-AGP/h per ml medium. Results 
represent means ± S. D. from five experiments. 
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Figure 4.8. Effect of HBF on the medium GTase activity 
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Figure 4.8. Effect of BBF on the medium GTase activity. 
Jejunal slices were incubated in KRB ( c::::J ) or in KRB 
supplemented with either 20% (vjv) HRS ( _ ) or increasing 
concentrations [200 to of 1200] J.l.g HBF (~). Medium samples 
were prepared after 4 h of incubation and GTase activity was 
measured as described in Figure 4.1. GTase activity is 
expressed as pmol of Gal transferred to DSG-AGPjh per ml 
incubation medium. Results represent means ± S . D. from four 
exper iments. 
162-8 
either 200, 500, 800 or 1200 JJ.g HBF]. 
IV.2.3. Protease and protease inhibitory activities in the 
mediwa and their effect on STasa and GTase activities 
Trypsin and plasmin activities in the medium increased 
with time when the jejunal slices were incubated in either KRB 
alone or in KRB supplemented with either 30 mg BSA or 20% 
(v/v) HRS (Figures 4.9 and 4.10]. In incubations where KRB was 
supplemented with 20% (v/v) HRS, both trypsin and plasmin 
activities in the medium remained markedly lower compared to 
medium from incubations in either KRB or KRB + BSA [Figures 
4.9 and 4.10] . For trypsin activity, P < 0.001 for the I, 2 
and 4 h time points for samples incubated in KRB and KRB + BSA 
respectively, compared to KRB + HRS incubations. Likewise, for 
plasmin activity P < 0.001 for the I, 2 and 4 h time points 
for samples incubated in KRB and KRB + BSA respectively I 
compared to KRB + HRS incubations. 
The addition of 500 IJ.g of either A1PI or Q 2 antiplasmin 
to jejunal incubations in either KRB, KRB + BSA or KRB + HRS 
resulted in decreased trypsin and plasmin activities in the 
medium compared to incubations wi thout t IP! or Q 2 antiplasmin . 
For trypsin activity in samples with and without A1PI, P < 
O. 01 for the 1, 2 and 4 h time points I when incubations were 
carried out in KRB + HRS, KRB + BSA and KRB respectively. 
Similarly, for plasmin activity in samples with and without Q 2 
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Figure 4.9. Trypsin act' . ~v~ty in medium 
Figure ".9. Trypsin activity in medium . Jejunal slices were 
incubated in KRB (-0-), or in KRB supplemented with either 30 
mg BSA (-0-) or 20\ (vjv) HRS ( -fr ) as described for Figure 
4.1. Parallel experiments were carried out wherein 500 J.Lg AlP I 
added to jejunal slices incubated in either KRB (.-e-.), 
KRB + 30 mg BSA ( ...• ... ) or KRB + 20% (vjv) HRS ( ... - ). At the 
indicated times incubations were stopped, the medium was 
decanted, centrifuged and assayed for trypsin activity as 
described in Materials and Methods (section 11.11.2. A) . 
Trypsin activity is expressed mol of substrate 
hydrolysedj min per ml medium. Results represent means ± S.D. 
from four experiments . 
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Plasmin activity in medium 
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Figure ".10. Plasmin activity in medium.. Jejunal slices were 
incubated in KRB (-0-) or in KRB supplemented with either 30 
mg BSA (--0--) or 20\ (v/v) HRS (-tr) as described for Figure 
4.1. Parallel experiments were carried out wherein 500 ~g Q 2 
antiplasmin was added to jejunal slices incubated in either 
KRB (-.. --), KRB + 30 mg BSA (-_ ..... ) or KRB + 20% (vjv) HRS (-. -.). 
At the indicated times incubations were stopped , the medium 
was decanted, centrifuged and assayed for plasmin activity as 
described in Materials and Methods (section 2 . 11 . 3. (A]) . 
Plasmin activity is expressed n mol of substrate 
hydrolysedj min per ml medium. Results represent means ± S.D. 
from four experiments . 
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antiplasmin, P < 0.01 for the 1, 2 and 4 h time points, .... hen 
incubations carried out in KRB + HRS, KRB + BSA and 
KRBrespectively. 
STase activity higher in medium obtained from 
incubations .... here KRB .... as supplemented .... ith either A1P1 or Q 1 
antiplasmin, compared to incubations in KRB (Figure 4.11]. P 
< O. 01 for the I, 2 and 4 h time points, .... hen the incubations 
supplemented .... ith Q 2 antiplasmin, A1PI and HRS 
respectively, compared to incubations in KRB . In the case of 
GTase, activity remained similar .... hether the incubations .... ere 
carried out in KRB or in KRB supplemented .... ith either HRS, 
AlP! or Q 2 antiplasmin [Figure 4.12; P > O. 05 indicating that 
the means .... ere not significantly different for the 1, 2 and 4 
h time points ) . 
Addition of 100 I-Ig heparin to jejunal incubations 
containing HRS resulted in increases in trypsin and plasmin 
activities [Figures 4.13 and 4.14]. In the case of trypsin 
activi ty P < O. 001 for the 1, 2 and 4 h time points between 
samples obtained from KRB + HRS incubations compared to KRB 
+ HRS + heparin incubations. Like .... ise, l for plasmin activity P 
< O. 001 for the 1, 2 and 4 h time points bet .... een samples from 
KRB + HRS incubations compared to KRB + HRS + heparin 
incubations. The addition of increasing amounts of KRB medium 
.... hich .... as obtained after 4 h of incubation, to medium obtained 
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Figure 4.11. Effect of addition of AlP! and Q2 antiplasmin 
to jejunal incubations on STase activity 
167 ~A 
Figure •. 11. Effect of addition of A1PI and Q, antiplaslDin to 
jejunal incubations on STase activity. Jejunal slices 
incubated in either KRB ( CJ ) or in KRB supplemented .... ith 
either 20% (vjv) HRS ( t:::.. ), 500 ~g A1PI (<» or 500 ~g Ql 
antiplasmin ( 0 ). Medium samples were prepared and STase 
activity measured as described in Figure 4.1 . STase activity 
is expressed as pmol of NeuAc transferred to DS-AGPjh per ml 
medium. Results represent means ± S.D. from four experiments. 
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Figure 4.12. Effect of addition of AlP! and 02 antiplasmin 
to jejunal incubations on GTase activity 
168 -A 
Figure 4.12. Effect of addition of A1PI and Q-2 antiplaslI.in to 
jejunal incubations on GTase activity. Jejunal slices 
incubated in either KRB ( • ) or in KRB supplemented with 
either 20% (v/v) HRS ( .. ), 500 ~g A1PI ( • ) or 500 JJg Q 2 
antiplasmin ( • ). Medium samples were prepared and GTase 
acti vi ty measured described in Figure 4.1. GTase is 
expressed as pmol of Gal transferred to DS-AGP/h per ml 
medium. Results represent means ± S.D. from four experiments. 
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Effect of heparin on trypsin act' . l.~lty 
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Figure 4.13. Effect of heparin on trypsin activity. Jejunal 
slices incubated in KRB ( 
with either 20% (v/v) HRS ( 6 
o ) or in KRB supplemented 
) or 20% (v/v) HRS + 100 ~g 
heparin (0 ). At indicated times medium samples were 
prepared and assayed for trypsin activity as described in 
Figure 4.9. Trypsin activity is expressed as nmol of 
substrate hydrolysed/ min per ml incubation medium. Results 
represent means ± S . D. from four experiments . 
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Figure 4 . 14. Effect of heparin on plasmin acti vi ty 
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Figure 4.14. Effect of heparin on plasmin activity. Jejunal 
slices were incubated in KRB ( 0 ) or in KRB supplemented 
with either 20t (v!v) HRS ( 6 ) or 20t (v!v) HRS + 100 /Jg 
heparin ( 0 ). At indicated times medium samples were 
prepared and assayed for plasmin activity as described for 
Figure 4.10. Plasmin activity is expressed as nmol of 
substrate hydrolysed! min per ml incubation medium. Results 
represent means ± S. D. from four exper iments. 
17(}o8 
from 4 h incubations in KRB + 20% (vjv) HRS, resulted in 
inhibition of STase activity [Figure 4.15]. Similar inhibition 
was not observed for GTase where the addition of 4 h KRB 
medium caused increase in GTase activity in 4 h medium 
samples from KRB + HRS incubations [Figure 4.15]. This 
increase in GTase activity was due to the fact that GTase 
acti vi ty was present in the 4h KRB medium being added. 
Heat-inactivated serum from turpentine treated rats had 
higher trypsin and plasmin inhibitory activities compared to 
heat inactivated serum from control rats (Figure 4.16; P < 
0.001 for trypsin and plasmin inhibitory activities 
respectively, between heat inactivated sera from turpentine 
and control rats]. When heat-inactivated serum from turpentine 
treated rats was used to supplement incubations, trypsin 
activity in the 2 and 4 h medium was decreased compared to 
incubations where heat- inactivated serum from control rats 
was used (Figure 4.17; P < 0.001 for the 2 and 4 h time 
points]. Likewise the addition of heat-inactivated serum from 
turpentine treated rats resulted in decreased plasmin activity 
in medium compared to incubations containing heat-inactivated , 
control serum (Figure 4.18 i P < 0.01 for the 2 and 4 h time 
points] . 
When heat-inactivated control used in 
incubations trypsin and plasmin activities were decreased in 
the 2 and 4 h medium samples compared to incubations where KRB 
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Figure 4.15. Effect of addition of 4 h KRB medium on STase 
and GTase activities 
172-A 
Figure 4.15. Effect of addition of .. hUB medium on STaa. and 
GTase aetivities. Jejunal slices were incubated for 4h in KRB 
alone or in KRB supplemented with 20\ (v/v) HRS as described 
in Figure 4.1 and medium samples prepared. STase ( 6 ) and 
GTase ( .A activities were measured in HRS supplemented 
medium in the presence of increasing volumes of 4 h KRB medium 
as described. Glycosyltransferase activities are expressed as 
pmol of NeUAc or Gal transferred/h to DS-AGP and DSG-AGP 
respectively per ml of incubation medium. Results represent 
± S.D. from five exper iments. 
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Figure 4.16. Trypsin and plasmin inhibitory activities in 
heat inactivated sera from turpentine treated 
and control rats 
Figure 4.16. Trypsin and pIall.in inhibitory activities in heat 
inactivated lIera froID. turpentine treated and control rats. 
Serum was obtained from turpentine treated rats (~) and 
control rats ([[]), trypsin and plasmin inhibitory activities 
were measured as described in Materials and Methods (sections 
I1.J.1, 11.3.2, I1.1l.2.A. and I1.1l.3.A. Trypsin (panel B) 
and plasmin (panel A) inhibitory activities were obtained from 
the differences between activities in the presence and absence 
of inhibitor as nmoll min per ml serum. BAPNA and BAEE were 
the substrates used for trypsin and plasmin respectively. 
Results represent means ± S. D. from six experiments. 
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Figure 4.17. Trypsin activity in medium supplemented with 
heat-inactivated serum from turpentine 
treated rats 
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Figure .... 17. Trypsin activity in medium supplemented witb 
beat-inactivated serum from turpentine treated rats. Jejunal 
slices were incubated in KRB (D) or in KRB supplemented with 
20% (v/v) heat-inactivated serum from either turpentine 
treated rats (0 ) or control rats ( 6. ) and medium samples 
prepared as described in Figure 4.1. Trypsin activity 
assayed using BAPNA as substrate as described for Figure 4.9 
and is expressed as n mol of substrate hydrolysed/ min per ml 
of incubation medium. Results represent means ± S.D. from six 
exper iments . 
174·8 
2S 
c 
5 20 / .; >- ~ .... E :; E ;:: 1 S u ~ < ~ 
Z '" /~ i c CI) E :s /' 10 0.. "0 E S ~~ 
2 3 
INCUBATION TIME (h) 
Figure 4.18. Plasmin activity in mediuITI supplemented with 
heat-inactivated serum from turpentine 
treated rats 
Figure ... 18. Plasmin activity in medium supplemented with 
heat-inactivated serum trom turpentine treated rats. Jejunal 
slices .... ere incubated in KRB ( 0) or in KRB supplemented with 
20% (vjv) heat-inactivated serum from either turpentine 
treated rats ( 6.) or control rats ( 0) and medium samples 
prepared as described in Figure 4 . 1. Plasmin activity .... as 
assayed using BAEE as substrate as described in Figure 4.10 
and is expressed as n mol of substrate hydrolysedj min per tnl 
of incubation medium. Results represent means ± S.D. from six 
experiments. 
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was used [ Figures 4.17 and 4.18; P < 0.001 for trypsin and 
plasmin respectively for the 2 and 4 h time points]. 
Heat-inactivated serum from turpentine treated rats when 
used to supplement incubations, resulted in increased STase 
activity for the 2 and 4 h medium samples compared to 
incubations carried out in heat-inactivated control rat serum 
[Figure 4.19; P < 0.001 for the 2 and 4 h time points]. GTase 
activity however remained similar whether the incubations were 
carried o ut in KRB alone or in KRB supplemented with heat-
inactivated serum from turpentine treated or control rats 
[ Figure 4.19; P > 0 . 05 for the 2 and 4 h time points, 
indicating that the means were not significantly different]. 
IV. 2 . ... Protease inhibitory acti vi ty of HBF 
The protease-inhibitory activity of HBF towards various 
proteases was examined. HBF was able to inhibit: (1) 
hydrolysis of BAPNA and a-casein by trypsin [Table 4-1] and 
(2) hydrolysis of BAEE and a-casein by plasmin [Table 4.2]. In 
these experiments human AIPI and BSA were used as controls 
A1PI is a broad spectrum protease inhibitor known to inhibit 
trypsin, elastase, thrombin, plasmin, 
( 
chymotrypsin and 
kallikrein [Travis and Salvesen, 1983]. HBF did not show any 
inhibitory activity towards elastase, thrombin, kallikrein, 
chymotrypsin and papain (Table 4 . 3]. 
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Figure 4.19 . Effect of heat-inactivated serum from turpentine 
treated rats on the STase and GTase activ ities 
released duri ng jejunal incubations 
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Figure 4.19. Ettect ot heat-inactivated serum trom turpentine 
treated rats on the STase and GTase activities released during 
jejunal incubations. Jejunal slices were incubated in KRB 
( ~ , .. ) or in KRB supplemented with 20% (vjv) of heat-
inactivated serum from either turpentine treated rats (0 , 
. ) or control rats ( 0 , • ). Medium samples were prepared 
at indicated times and STase and GTase activities measured as 
described for Figure 4 . 1. STase (~, 0 , 0) and GTase ( .. , 
. ' • ) activities expressed as pmol of NeuAc or Gal 
transferred onto DS- or DSG-AGPjh per ml medium. Results 
represent means ± S.D . from six exper iments . 
177'8 
Table .... 1. Trypsin inhibitory activity of HBF and TBP. Trypsin 
inhibitory activity of HBF, A1PI, BSA, TBP and the unbound-
trypsin fraction was measured using either BAPNA or casein as 
substrates. Assays were carried out as described in Materials 
and Methods (sections II.2.3.A., II.11.2.A. and II.11.2.B. 
Trypsin inhibitory activity is expressed as the difference 
between activity in the presence and absence of the inhibitor 
as n mol/min per mg protein or % inhibition. Results represent 
means ± S.D. from five experiments. 
trypsin inhibitory activity 
substrate:BAPNA substrare casein 
nmol/min per mg % inhibition 
protein 
HBF 10.14 ± 0.9 44.40 ± 1.6 
A1PI 9.12 ± 0.6 41. 42 ± 5.4 
BSA no inhibition no inhibition 
TBP 35.45 ± 0.7 60.40 ± 6.7 
unbound-trypsin no inhibition no inhibition 
fraction 
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Table 4.2. Plasmin inhibitory aeti vi ty of HBF and TBP. Plasmin 
inhibitory activity of HBF, A1PI, BSA , TBP and the unbound-
trypsin fraction was measured using either BAEE or casein as 
substrates. Assays were carried out as described in Materials 
and Methods (sections 11.2.3.A. and II.11.3 . A. and 11.11.3.B. 
Plasmin inhibitory activity is expressed as the difference 
between activity in the presence and absence of the inhibitor 
as n mol/min per mg protein or % inhibition. Results represent 
means ± S . D. from five experiments . 
HBF 
A1PI 
BSA 
TBP 
unbound-trypsin 
fraction 
plasmin inhibitory activity 
substrate: BAEE 
nmol/min per mg 
protein 
6 . 03 ± 0 . 9 
16.70 ± 0.1 
no inhibition 
15 . 50 ± 1.4 
no inhibition 
substrate: casein 
% inhibition 
2 0.30 ± 0 . 8 
15.60 ± 2 . 7 
no inhibition 
26.32 ± 1.8 
no inhibition 
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Table ,,« 3 « Inhi!;)i tory acti vi ty of HBF and TBP towards 
chymotrypsin. elastase. kallikrein. papain and thrombin. 
Inhibitory activity of HBF and TBP towards chymotrypsin, 
elastase, kallikrein, papain and thrombin was measured as 
described in Materials and Methods (sections II .11. 4. to 
II.l1.8). Inhibitory activity is expressed as the difference 
between activity in the presence and absence of the inhibitor 
and is expressed as n mol/min per mg protein and results 
represent means ± S.D. from four experiments. 
Table 4.3 
Protease 
HBF 
chymotrypsin 0 
elastase 0 
kallikrein 0 
papain 0 
thrombin 0 
Protease inhibitory activity 
(n moll min per mg protein) 
Inhibitor 
A1PI BSA TBP 
7.2 ± 0.9 0 0 
40.2 ± 0.7 0 0 
4.3 ± 0.7 0 0 
1.6 ± 0.4 0 0 
4.1 ± 0.8 0 0 
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IV.2. 5. Isolation of a trypsin-binding protein (TBP) from HBF 
Using trypsin-agarose affinity chr omatography a trypsin-
binding protein [TBP J was separated from HBF [Figure 4.20J. 
TBP on SDS-PAGE showed a major ba nd with an apparent 
molecular mass of 67 000 Da [Figure 4.21J. The gel filtration 
profile of TBP revealed a single peak and the purity of the 
sample was 98% as judged by the area under the HPLC profile 
[Figure 4. 22J. TBP was able to bind to Con-A indicating it was 
a glycoprote i n [ Figure 4.23) . Human albumin which is not a 
glycoprote i n and was used as a control did not exhibit binding 
to Con-A [ Figure 4.23 ) . TBP showed inhibitory activity towards 
plasmin and trypsin [Tables 4 . 1 and 4.2]. However TBP did not 
show inhibitory activity towards either chymotrypsin, 
elastase, kallikrein, papain or thrombin [Table 4.3]. The 
unbound-trypsin fraction of HBF did not inhibit trypsin or 
plasmin (Tables 4.1 and 4.2 ] . 
IV.2.6. Effect of TBP on the STase and GTase activities 
released during jejunal incubations 
TBP when added to KRB during jejunal incubations, had a 
similar effect as HBF on the STase activity released [Figure 
.. 
4 . 24: P < O. 001 for the 1, 2 and 4 h time points, when samples 
from incubations containing HBF and TBP respectively were 
compared to samples from KRB incubations]. Thus, TBP like HBF 
was able to protect the STase activity released into the 
medium. STase activity in the medium was similar when the 
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Figure 4.20. Affinity chromatography profile of the binding of 
HBF to trypsin-agarose: separation of TBP 
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Figure 4.20. Affinity chromatography profile of the binding of 
HBP to trypsin-agarose: separation of TBP. HBF was applied to 
trypsin-agarose column which had been previously 
equilibrated with 5mM Tris-buffer described in Materials 
and Methods (section 11.2.3). The column washed 
extensively with Tris-buffer until the absorbance of the 
eluent at 280 nm was less that 0.05. The bound fraction 
eluted with 20 mM Hel and processed as described. This graph 
was regenerated by digitizing the elution profile with 
sigmaplot 5. O. 
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Figure 4 . 21. 50S-PAGE profiles of HRS, HSF and TBP 
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Figure ".21. SDS-PAGE profiles of HRS. HBP and TBP. 
Electrophoretic profiles are shown of low-molecular-mass-
standard mixture (lanes 1 and 5), HBF (lane 4), HRS (lane 3) 
and TBP (lane 2). Samples were processed for SOS-PAGE 
described in Materials and Methods (section 11.2.1.). The 
standard mixture contained phosphorylase b(94 kOa), BSA (67 
kOa), ovalbumin (43 kOa), carbonic anhydrase (30 kDa), soybean 
trypsin inhibitor (20 kOa) and a lactalbumin (14.4 kOa). 
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Figure -4 . 22. Gel filtration HPLC profile of TBP 
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Figure 4.22. Gel filtration HPLC profile of TBP. Gel 
filtration HPLC profile of TBP (panel B) is compared to that 
of molecular-mass-standard-mixture (panel A). The standard 
contained thyroglobulin (670 kDa), bovine globulin (158 kDa) I 
chicken ovalbumin (44 kDa), bovine myoglobulin (17 kDa) and 
cyanocobalamin BIl (1.35 kDa). HPLC was carried out as 
described in Materials and Methods (section 11.2.2). 
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Figure 4.23. Affinity chromatography profiles of the binding 
of albumin and TBP to Con-A 
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Figure 4.23. Affinity chromatography profiles of the binding 
of albuain and TBP to Con-A . Human albumin (A ) and TBP 
(B) were applied to a Con-A affinity column equilibrated with 
Tris buffer as described in Materials and Methods (section 
II.2.3.C). This graph was regenerated by digitizing the 
elution profile with Sigmaplot 5. 
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Figure 4.24. Effect of TBP on the STase and GTase activities 
released during jejunal incubations 
Figure 4.24. Ettect ot TBP on the BTase and GTase activities 
released during jejunal incubations. Jejunal slices were 
incubated in KRB (0 , . ) or in KRB supplemented with either 
500 p.g HBF ( 0 ' . >, 250 p.g TBP ( V , .. > or 500 p.g 
unbound- trypsin fraction (0 , + ), medium samples prepared 
and glycosyltransferase activities measured as described for 
Figure 4.1. STase (0, a,yo,o> and GTase (0, a ,\J, 0) 
activities are expressed as pmol of NeuAc or Gal transferred 
to OS- or OSG-AGPjh per ml incubation medium. Results 
represent means ± S.D. from five experiments . 
unbound-trypsin fraction (500 I-'g) was used to supplement KRB 
during incubations, compared to incubations in KRB (Figure 
4.24]. The optimum concentration of TBP required to have an 
effect on STase was 250 I-'g per 2 ml medium (Figure 4.25: P < 
0.001 for incubations containing 125, 250, 500 and 600 I-'g TBP 
compared to incubations in KRB]. To achieve a similar effect 
on STase activity 500 ug of HBF per 2 ml medium was required 
and in the case of HRS 20\ (v/v) corresponding to about 30 mg 
serum protein was required. 
TBP did not have any effect on GTase activity, which 
remained similar whether incubations were carried out in KRB 
alone or in KRB + TBP (Figure 4.26; P > o. as indicating that 
the means were not significantly different]. 
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Figure 4.25. Effect of varying concentrations of TBP on 
STase activity 
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Figure 4.25. Effect of varying concentrations of TBP on 
STase activity. Jejunal slices were incubated in KRB {c:::J 
or KRB containing either 500 ~g HSF ( ~ ), 20% (vjv) HRS 
(~) or 125 to 600 /Jog TBP (eBB) and medium samples 
prepared at 4 hand STase activity measured as described in 
Figure 4.1. STase activity is expressed as pmol of NeuAc 
transferred to DS-AGPjh per ml incubation medium. Results 
represent means ± S.D. from five experiments. 
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Figure 4 . 26. Effect of varying concentrations of TBP on 
GTase activity 
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Figure 4.26 . Effect of varying concentrations of TBP on GTas. 
activity. Jejunal slices were incubated in KRB ( c=J) or in 
KRB supplemented with either 500 I-'g HBF (~), 20% (v/v) HRS 
( ~) or 100 to 600 I-'g TBP cm:!!8} medium samples prepared at 
4h and GTase activity measured as described in Figure 4.1. 
GTase activity is expressed as pmol of Gal transferred to OSG-
AGP/h per ml incubation medium. Results represent means ± S.D. 
from five experiments. 
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IV.3. Discussion 
The relationship between trypsin and plasmin inhibitory 
activities in the medium and the STase activity released 
during jejunal slice incubations was studied in the 
experiments described in this chapter. The effect of HRS and 
its heparin-binding antiproteolytic proteins, on the levels of 
STase and GTase activity released during the incubation of 
jejunal slices was also examined. 
It was observed that only trace amounts of STase activity 
were detected in the medium when incubations were carried out 
in KRB alone [Figure 4.1). In order to detect measurable STase 
activity there was a requirement for either HRS itself or HBF 
isolated from HRS in the incubation medium. This finding was 
similar to that observed for HHS in Chapter III. Therefore 
both HHS and HRS as well as their HBFs were exerting a similar 
effect on the STase activity released into the medium. 
GTase activity, which was also released during the 
incubation of rat jejunal slices, however was not affected 
by HBF or HRS (Figures 4.1. and 4.7.). Unlike STase, there 
was no difference in the GTase activity (detected in the medium 
when the incubations were carried out in KRB or KRB + HRS. 
This indicated that the GTase activity released was 
independent of HRS. The results presented in this chapter 
indicate that the measurable STase activity released during 
jejunal incubations was a function of the protease inhibitor/ 
1 •• 
protease composition of the incubation medium. In all the 
cases cited above an increase in trypsin and plasmin 
inhibitory activities was associated with increased STase 
activity in the incubation medium. GTase activity unlike STase 
not influenced by protease activity in the medium. 
A number of proteinase inhibitors in blood have been 
known to bind to heparin including antithrombin, heparin 
cofactor and protein C inhibitors [Pratt et al., 1992]. 
Heparin also accelerates the activation of plasminogen by 
tissue type plasminogen activator (t-PA) [Sprenger and Kluft, 
1987; Sane et al., 1993]. While heparin enhanced the 
inhibitory activities of these proteins, it is also known to 
decrease inhibition by other proteinase inhibitors. For 
example heparin has been shown to decrease the rate of 
inhibition of elastase by AIPI [Frommherz et al., 1991). In 
the studies with the jejunal incubations described in this 
thesis, addition of heparin resulted in inactivation of the 
proteinase inhibitor(s) responsible for protecting the STase 
released. This conclusion is based on the fact that TBP a 
trypsin and plasmin inhibitor, which was effective in , 
protecting STase, was isolated from HBF (Figure 4.24). Also, 
the addition of heparin resulted in increased trypsin and 
plasmin activities in the inCUbation medium along with a 
decrease in STase activity [Figures 4.9, 4.10 and 4.2]. 
Glycosyltransferases are membrane bound enzymes which 
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also occur in the soluble form in tissue fluids. During 
pathological conditions especially cancer, alterations in 
levels of STase and GTase have been observed in body fluids. 
In cancer, elevations in GTase activity have been reported in 
serum [Podolsky et al., 1977 and 1978], ascitic fluid (Gerber 
et al., 1979] and pleural effusions (Ram and Mungal, 1984]. 
Increased serum STase activities have been reported in cancer 
including in multiple myeloma (Weiser et al., 1982; Baker et 
al., 1985; 1987; Frithz et al., 1985]. Recent studies have 
shown that proteolytic enzymes and their inhibitors play a 
role in malignant conditions [Steven et al., 1992a,b; Wad a et 
al., 1993a,b]. Therefore, it is feasible that the levels of 
protease inhibitors/ proteases in pathophysiological 
conditions could affect the levels of enzymes such as STase in 
tissue fluids. 
Protease inhibitors in serum and faeces are used as 
markers for a number of disease conditions associated with the 
intestine. Protease inhibitor/ protease complexes are believed 
to play a role in gastrointestinal disorders such as 
inflammation and Crohn's disease [Florent et al., 1981; Mizon 
.. 
et al., 1988,1991]. In intestine, severe inflammation is 
accompanied by marked tissue destruction wherein proteinases 
and their inhibitors are involved. Serum levels of protease-
inhibitors such A1PI are altered in gastrointestinal 
disease (Bohe et al., 1986a,b]. Faecal A1PI is considered to 
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be a marker for intestinal disease and an increase in a 
glycosylated form of AlPI is considered indicative of the 
severi ty of intestinal inflammation (Mizon et al., 1988, 
1991]. Therefore in this context, the findings that protease 
inhibitors might influence STase activity in the 
gastrointestinal system is interesting. 
In the rat, increases in serum STase activity have been 
observed following colchicine treatment (Ratnam et al., 1981 
and 1987}, thermal injury [Chu et al., 1988] and turpentine 
induced inflammation [Kaplan et al., 1983 i Fraser et al., 
1984]. In all these conditions though serum STase was 
increased, serum GTase activity remained unchanged. It is 
therefore apparent that in some conditions GTase and STase 
activities are regulated differently. However the factors 
involved in the regulation of these enzymes have not been 
clearly defined. 
In the experiments described in this thesis in which 
heat-inactivated serum from turpentine treated rats was used 
to supplement jejunal incubations, there was a marked increase 
in medium STase activity compared to incubations where heat-
.. 
inactivated control rat serum was used to supplement 
incubations (Figure 4.19). Heat-inactivated from 
turpentine treated rats had higher trypsin and plasmin 
inhibitory activities compared to heat-inactivated control 
serum (Figure 4.16]. These results further suggest that the 
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measurable STase activity released during jejunal incubations 
is dependent on the concentrations of protease inhibitors in 
the incubation medium. 
During inflammation there is an increase in the levels of 
certain serum proteins known as the acute phase reactants 
(Koj, 1974; Kushner and Feldman, 1978]. Protease inhibitors 
such as A1P1 (Travis and Salvesen, 1983; Heidtman and Travis, 
1986], 0:-2 antiplasmin (Matsuda et al., 1980] and TAT! (Ogawa, 
1988] are also acute phase proteins whose concentrations in 
are increased during inflammation. Therefore it is 
feasible that the levels of proteinase inhibitors in 
extracellular fluids in pathological conditions such 
inflammation may govern the levels of enzymes such as STase. 
Other studies have shown that turpentine induced inflammation 
in the rat resulted in increased STase and GTase activities in 
liver (Kaplan et al., 1983; Fraser et al., 1984]. However, in 
serum, STase activity alone was increased. This increase in 
serum STase was suggested to be due to the increased activity 
of a cathepsin-D like proteinase which is thought to 
selectively cleave the membrane-bound STase {Lammers 
.. 
and 
Jamieson, 1988,1990]. However, observations from the present 
work suggest that decreased proteolysis of the soluble STase 
could also contribute to its increased activity. 
The observations in this thesis indicate that during 
intestinal incubations, the enzyme was released even when 
1 •• 
incubations were carried out in KRB alone. However, due to 
proteases present in the incubation system which destroyed 
STase, very little activity was detectable in the medium. When 
tryps in and/ or plasmin inhibitors were pre~ent in the 
incubation medium they inactivated the protease and therefore 
permitted the measurement of STase activity. A proposed 
mechanism regarding the role of protease inhibitors and 
proteases on the STase released during jejunal incubations is 
outlined in Figure 4.27. 
Very little is known regarding the factors which govern 
the levels and activities of STases in tissue fluids. The 
resul ts presented in this thesis so far suggest that the 
levels of trypsin and plasmin inhibitors in the incubation 
medium were important in determining the levels of soluble 
STase released during jejunal incubations. Increases in medium 
STase activity were associated with increases in trypsin and 
plasmin inhibitory activities. GTase, which was also released 
in the soluble form during jejunal incubations did not exhibit 
a dependence on trypsin and plasmin inhibitory activity. 
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Figure .fo. 27. proposed mechanism showing the effect of trypsin 
and plasmin inhibitors on STase released during jejunal 
incubations. The figure shows the proposed mechanism whereby 
the membrane-bound enzyme is released from its membrane anchor 
by proteolytic cleavage. The soluble enzyme is a target for 
trypsin and plasmin. Trypsin and plasmin inhibitor (s) prevent 
proteases from destroying STase. 
CHAPTER V. THE RELATIONSHIP BETWEEN STASE ACTIVITY 
AND PROTEASE INHIBITORY ACTIVITIES 
V.1. Introduction 
The results presented in chapters III and IV showed that 
the incubation of jejunal slices resulted in the release of 
soluble STase and GTase into the incubation medium. The STase 
activity released CQuid only be measured if antiproteases such 
as HBF, TBP, AlP! or 0: 2 antiplasmin were present in the 
incubation medium. This dependence on trypsin and/or plasmin 
inhibitory activities was specific for STase, as GTase 
activity was not affected by antiproteases. 
The purpose of the following studies was therefore to 
further investigate the relationship between STase activity 
and trypsin and plasmin inhibitory activities. This was done 
by examining 
(la) the effect of trypsin or plasmin on a mixture of 
commercially available pure STase(s) and GTase, 
(Ib) the inhibition of these proteases by TBP, 
(2) the effect of protease inhibitory activity on serum STase 
.. 
and GTase activities in control and turpentine treated 
rats and 
(3) the effect of protease inhibitory activity of the 
incubation medium on the STase and GTase activities 
released during the incubation of hepatocytes. 
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V.2. Results 
V.2.1. Effect of trypsin and plasmin on pure STase and GTase 
When either trypsin or plasmin was added in increasing 
concentrations (0 to 0.0125 mg) to a mixture of pure STase 
[ 0:2-6 (N) ] and GTaSe, it was observed that STase activity was 
preferentially inhibited compared to GTase activity [Figure 
5.1]. TBP when added in increasing concentrations (0 to 0.03 
mg) was able to prevent the inhibitory effects of plasmin and 
trypsin on STase activity, in the presence of 0.01 mg of 
protease [ Figure 5 . 2]. 
Similar experiments were carried out using a mixture of 
pure 0:2-3 [0] STase and GTase. It was again observed that 
STase was more prone to proteolytic degradation by either 
trypsin or plasmin compared to GTase [ Figure 5.3]. TBP was 
able to protect STase activity against the inhibitory effects 
of plasmin and trypsin [ Figure 5.4 ]. 
V.2.2. Effect of serum protease inhibitors on STase and GTase 
activities in serum 
The incubation of serum obtained from either control or 
turpentine treated rats at 37°C resu~t.ed in a progressive 
decrease in its ability to inhibit trypsin or plasmin activity 
respectively [Figure 5 . 5 ] . Both trypsin and plasmin inhibitory 
activities were higher in serum obtained from turpentine 
treated rats compared to serum obtained from control rats and 
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Figure 5.1. Effect of trypsin and plasmin on (a:2-6(N)] 
STase and GTase 
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Figure 5.1. Effect of trypsin and plasmin on [a2 .... ' (N) 1 STase 
and GTase. Trypsin (-fr , ~) or plasmin ( ....... , ...•... ) were 
added to a mixture of pure STase ( 0 '. ) and GTase ( 0 , 
.). Samples were processed and assayed for STase and GTase 
activities as described in Materials and Methods (sections 
11.10,11.7.1. and 11.7.2.). STase and GTase activities are 
expressed as prool of NeuAc or Gal transferred per mU enzyme to 
OS- or DSG-AGP. Results represent means ± S.D. from four 
exper iments. 
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Figure 5.2. Effect of TBP on counteracting the effect of 
proteases on ra2~6(N)1 STase. 0.01 mg of trypsin HJ-,-O-) 
plasmin ( ...... ,-e-) were added to a mixture of pure STase 
( 0 ' • ) and GTase ( 0 ,. ), along with increasing 
concentrations of TBP. Samples were processed and assayed for 
STase and GTase activities as described in Figure 5.1. STase 
and GTase activities are expressed as pmol of NeUAc or Gal 
transferred per mU enzyme to 05- or DSG-AGP respectively. 
Results represent means ± S.D. from four experiments. 
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Figure 5.3. Effect of trypsin and plasmin on [a2-3 (0) 1 STase 
and GTase. Trypsin (~ , -cr ) or plasmin ( ........ , ...• ) were 
added to a mixture of pure STase ( 0 , • ) and GTase (0,.). 
Samples were processed and assayed for STase and GTase 
activities described in Figure 5.1. STase and GTase 
activities are expressed as pmol of NeuAc or Gal transferred 
per mU enzyme to DS- or DSG-fetuin respectively. Results 
represent means ± S.D. from four experiments. 
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proteases on [a2 ..... 3 (0)] STase 
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Figure 5.... Errect or TBP on counteracting the errect or 
proteases on [a2-3{Q) 1 STase. 0.01 mg of trypsin (-0- ,;:r ) 
or plasmin ( ...•. , ..•. ) were added to a mixture of pure STase 
( 0 , • ) and GTase (0 ,. ) , a long with increasing 
concentrations of TBP . samples were processed and assayed for 
STase and GTase activity as described in Figure 5.1. STase and 
GTase activities are expressed as pmol of NeUAc or Gal 
transferred per mU enzyme to DS- or DSG-fetuin respectively . 
Results represent means ± S . D. from four experiments. 
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Figure 5.5. Effect of incubation time on trypsin and plasmin 
inhibitory activities in serum 
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Figure 5.5. Effect of incubation time on trypsin and plasmin 
inhibitory activities in serum. Serum samples from turpentine 
treated ( . , . ) and control ( 0 , 0 ) rats were incubated 
at 37 "C. At indicated times samples were removed and plasmin 
( • , 0 ) and trypsin ( • ' 0 ) inhibitory activities 
measured as described in Materials and Methods (sections 11.9. 
a nd II.l1.2.A. and II.ll.3.A). Plasmin and trypsin inhibitory 
activities obtained from the differences between 
activities in the presence and absence of inhibitor and are 
expressed as nmol\min per ml serum. Results represent means 
± s. D. from five exper iments. 
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this difference was maintained throughout the 4 h of 
incubation [Figure 5.5; P < 0.01 for the 0, 1, 2 and 4 h time 
points between serum from control and turpentine treated 
rats]. Serum STase activity also remained higher in the 
turpentine treated rats throughout the 4 hours of incubation 
[Figure 5.6; P < 0.01 for the 0, 1, 2 and 4 h time points 
between serum samples from control and turpentine treated 
rats). In both groups STase activity decreased with incubation 
time. TBP when added to serum from either turpentine-treated 
and control rats was able to halt the time dependent decrease 
in serum STase activity [Figure 5.6]. In the case of STase in 
serum from turpentine treated rats, P < 0.01 for the 1, 2 and 
4 h time points between samples incubated with TBP compared to 
samples without TBP. Likewise, for STase in serum from 
control rats P < 0.01 for the 1, 2 and 4 h time points 
between samples incubated with TBP compared to samples without 
TBP. These results indicated that STase activity in serum was 
unstable and that it could be protected by protease inhibitors 
such as TBP. In contrast, GTase activity in serum from both 
control and turpentine treated rats remained similar 
.. 
indicating it was not subject to proteolysis (Figure 5.7; P > 
0.05 indicating that the means were not significantly 
different] . 
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Figure. 5.6. Effect of TBP on STase activity in sera of 
control or turpentine treated rats. Serum from control ( 0 ) 
or turpentine treated ( 6. ) rats was incubated at 37 °C. In 
parallel incubations TBP [125 p,qlml] was added to 
samples from control ( • ) or turpentine treated rats ( • ) 
and samples were incubated. At indicated times samples were 
removed and assayed for STase as described in Materials and 
Methods (sections 11.9. and 11.7.1.). STase activity is 
expressed as p mol of NeUAc transferred to DS-AGP/h per ml 
serum. Results represent means ± S.D. from five experiments. 
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Figure 5.7. Effect of incubation time on GTase activity in 
sera of control an turpentine treated rats 
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Figure 5.7. Effect of incubation time on GTase activity in 
sera of control and turpentine treated rats. Serum from 
control ( • ) or turpentine treated ( • ) rats was incubated 
at 37 °C. At indicated times samples were removed and assayed 
for GTase as described in Materials and Methods (sections 
11.9 . and 11.7.2.). GTase activity is expressed as p mol of 
Gal transferred to DSG-AGP/h per ml serum. Results represent 
means ± S.D. from five experiments. 
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V.2. 3. Effect of the balance between protease and protease 
inhibitory activities in the incubation medium on the STase 
and GTase released during the incubation of hepatocytes 
Liver is the most likely of 
glycosyltransferases . Therefore the effect of trypsin and 
plasmin inhibitors in the incubation medium the 
glycosyltransferase activities released during the incubation 
of hepatocytes was studied . The viability of hepatocytes which 
was assessed using trypan blue exclusion, indicated that at 0 
and 4h, 85% and 75% of the cells were viable. 
Trypsin activity was measured in the incubation medium in 
the absence and presence of protease inhibitors {Figure 5.8] . 
Trypsin activity was decreased in medium obtained from 
incubations supplemented with either 500 ~g HBF, 250 ~g TBP or 
20% (v/v) heat-inactivated serum from control rats, compared 
to incubations without supplement. P < 0.01 for the 2 and 4h 
time points for incubations supplemented with HBF, TBP and 
heat-inactivated control compared to incubations without 
antiprotease. Trypsin activity in the medium was lower when 
heat-inactivated serum from turpentine treated rats was used 
to supplement hepatocyte incubations compared to similar 
incubations supplemented with heat-inactivated control serum 
( P < 0 . 01 for the 2 and 4 h time points ] . 
Simi l arly plasmin activity was decreased in medium 
obtained from incubations supplemented with either 500 ~g HBF, 
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Figure 5.8 Trypsin activity in the medium during the 
incubation of hepatocytes 
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Figure 5.8. Tryps in activity in the incubation medium during 
the incubation of hepatocytes. Hepatocytes were incubated 
without antiprotease ( • ), 20\ (vjv) heat-inactivated serum 
from control rats ( ... ), 20\ (vjv) heat-inactivated serum 
from turpentine treated rats ( A ), 500 jJ.g HBF ( • ) or 250 
jJ.g TBP ( . ) and at indicated times medium samples were 
prepared and trypsin activity measured as described in 
Materials and Methods (sections 11.6. and 1I.l1.2.A). Trypsin 
activity is expressed as n mol of substrate hydrolysedj min 
per 101 medium. Results represent means ± S.D. from five 
experiments . 
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250 I-'g TBP or 20% (vjv) heat inactivated serum compared to 
incubations without antiproteases [Figure 5.9). P < 0.01 for 
the 2 and 4h time points for incubations supplemented with 
HBF, TBP heat-inactivated control serum compared to 
incubations in buffer without antiprotease. Plasmin activity 
in the medium was lower when heat-inactivated serum from 
turpentine treated rats was used to supplement hepatocyte 
incubations compared to incubations containing heat-
inacti va ted control serum [P < 0.01 for the 2 and 4h time 
points) . 
When HBF (500 I-'g), TBP (250 I-'g) and heat-inactivated 
serum (20%, vjv) from either control or turpentine treated 
rats, were used to supplement incubations STase activity in the 
medium increased compared to incubations without 
anti protease [Figure 5.10). P < 0.01 for the 2 and 4 h time 
points, when incubations were supplemented with either HBF, or 
TBP, or heat-inactivated serum from control rats, compared to 
incubations without antiprotease. STase activity in the medium 
was increased when heat-inactivated serum from turpentine 
treated rats was used to supplement incubations, compared to 
incubations supplemented with heat-inactivated serum from 
control rats [Figure 5.10; P < 0.01 for the 2 and 4 h time 
points] . 
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Figure 5.9. Plasmin activity in the medium during the 
incubation of hepatocytes 
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Figure 5.9. Plasmin activity in the incubation medium during 
the incubation of hepatocytes. Hepatocytes were incubated 
without antiprotease ( • ), 20% (v/v) heat-inactivated serum 
from control rats ( ... ), 20% (v/v) heat-inactivated serum 
from turpentine treated rats ( A ), 500 Jlg HBF ( • ) or 250 
Jlg TBP ( • ) and at indicated times medium samples prepared 
as described in Figure 5.8. Plasmin activity was measured as 
described in Materials and Methods (section 2 . 11.2. (8]) and is 
expressed as n mol of substrate hydrolysed/ min per ml medium. 
Results represent means ± S.D. from five experiments. 
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Figure 5.10. Effect of protease inhibitors in the incubation 
medium on the STase released during the 
incubation of hepatocytes 
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Figure 5.10. Effect of protease inhibitors in the incubation 
medium on the aTase released during the incubation of 
hepatocytes. Hepatocytes were incubated without antiprotease 
), 20% heat-inactivated serum from control rats ( • ), 
20% (v/v) heat-inactivated serum from turpentine treated rats 
( A ). 500 ~g HBF ( • ) or 250 ~g TBP ( • ) and at 
indicated times medium samples were prepared as described in 
Figure 5.8. STase activity was measured as described in 
Materials and Methods (section II. 7.1.). STase activity is 
expressed as p mol of NeuAc transferred/h per ml medium. 
Results represent means ± S.D. from five experiments . 
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When lactosamine was used as an acceptor to assay for 
STase activity in 4 h medium obtained from hepatocyte 
incubations in buffer, the results showed that STase was 
predominantly that which catalysed the a2-+6 linkage of NeuAc 
to Gal indicating the enzyme to be a2-6 NeUAc ,Bl-+4Gal,B ..... 4 
GlcNAc (Figure 5.11]. 
In the of GTase, activity remained similar 
regardless of the supplements used (Figure 5.12; means were 
not significantly different for the 2 and 4 h time points]. 
GTase was similar whether incubations were carried out in KRB 
alone or KRB supplemented with either heat-inactivated control 
rat serum, HBF, TBP or heat inactivated serum from turpentine 
treated rats. 
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Figure 5.11. HPLC elution profiles of sialyl-lactosalDine 
isomers. Medium samples were prepared by incubating 
hepatocytes in buffer for 4 h as described in Figure 5-10. 
Samples were assayed for STase using lactosamine as described 
in Materials and Methods (section 11 . 7 . 1.8 . ). Samples were 
processed and HPLC carried out as described (section 11.2 . 2). 
Fractions under the peaks for the a2 ..... 3 (a) and a2 ..... 6 (b) 
sialyl-Iactosamine collected and counted for 
radioactivity. STase activity (rrn ) is expressed as p moll 
min per 106 cells . Results represent ± S.D . from three 
exper iments. 
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Figure 5.12. Effect of protease inhibitors in the incubation 
medium on the GTase released dur ing the 
incubation of hepatocytes 
Figure 5.12. Effect of protease inhibitors in the incubation 
medium on the GTase released during the incubation of 
hepatocytes. Hepatocytes were incubated without antiprotease 
( • ), 20% (v/v) heat-inactivated control serum ( • ), 20% 
(v/v) heat-inactivated turpentine treated serum ( . ), 500 IJ-g 
HBF ( . ) or 250 IJ-g TBP ( 0 ) and at indicated times medium 
samples were prepared as described in Materials and Methods 
(section 2.7.2.). GTase activity is expressed as p mol of Gal 
transferred/h per ml medium. Results represent means ± S.D . 
from five experiments. 
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V. 3. Discussion 
In this chapter the relationship between the balance 
between proteases /protease inhibitory activity and STase 
activity was studied in systems other than the jejunal 
incubations covered in Chapters III and IV. Specifically 
glycosyltransferases from a commercial source, from serum and 
from hepatocyte cultures were studied. The results indicate 
that STase was susceptible to proteolytic inactivation whereas 
GTase was relatively stable. Protease inhibitors form very 
tight or even covalent complexes with their target proteases, 
resulting in inactivation of both the inhibitor and the 
protease [Travis and Salvesen, 1983]. When a mixture of pure 
STase(s) or GTase was treated with either trypsin or plasmin 
it was observed that STase (a2 ..... 6[N] or a2-3{O]) was very 
susceptible to proteolytic inactivation compared to GTase 
[Figures 5.1 and 5.3]. TBP was able to protect STase from 
proteolytic inactivation [Figures 5.2 and 5.4]. Thus from 
these results it can be concluded that STase was 
susceptible to the action of trypsin and plasmin than GTase 
and TBP a protease inhibitor 
proteolytic inactivation. 
able to prevent this 
Turpentine induced inflammation in rat is used as a model 
of the acute phase response. This condition is characterised 
by an increase in serum STase (a2 ..... 6 Gal,Bl ..... 4 GlCNAC) and it has 
been suggested that the enzyme is an acute phase marker 
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[Kaplan et aI., 1983; Lammers and Jamieson, 1987]. The 
increase in STase activity in serum is thought to be due to 
the increased activity of a cathepsin-D like protease in liver 
which cleaves STase from its membrane-anchor [Lammers and 
Jamieson, 1988, 1990; Mccaffrey and Jamieson, 1993]. 
The mechanism of release of STase has been elucidated 
[Weinstein et al., 1987; Paulson and Colley, 1989; Colley et 
al., 1989; 1992]. The sequence of the enzyme determined from 
the cDNA showed that the molecule consists of three 
polypeptide domains [weinstein et aI., 1987; Paulson and 
colley 1989) . The protein contained 403 amino acid residues, 
with the major portion consisting of the catalytic domain 
[Figure 1.12, page 33]. The catalytic domain was attached to 
the intralumenal region of the Golgi via a stem region made up 
of 35 amino acids and this was attached to the membrane domain 
containing the N-terminus consisting of a nine amino acid 
cytoplasmic tail and a 17 amino acid signal anchor region 
[Weinstein et al., 1987; colley et al., 1989; 1992]. It has 
been determined that the anchor domain is extremely important 
for the retention of STase in the Golgi membrane [Colley et 
aI., 1992; Wen et al., 1992]. Therefore, the catalytic unit is 
oriented inside the Golgi to attach the NeuAc to secretable 
glycoproteins that are en route through the Golgi network. 
During the acute phase response it is thought that there is an 
alteration in the trafficking of lysosomal cathepsin-D, so 
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that this protease comes in contact with the STase, resulting 
in proteolytic cleavage of the membrane-bound enzyme which is 
then released into the medium with other secreted proteins 
[Lammers and Jamieson, 1988, 1990; McCaffrey and Jamieson, 
1993; Jamieson et al., 1993]. 
Though the mechanism of release of STase from membranes 
is well worked out, very little is known regarding the factors 
which control the levels of STase in extracellular fluids. In 
humans and experimental animals inflammation can arise due to 
a number of factors including infection, neoplastic disease 
and chemical agents. Inflammation results in characteristic 
biochemical and physiological changes known as the acute phase 
response [Koj, 1974; Kushner and Feldman, 1978; Kaplan et aI., 
1983]. Among these changes is an increase in the level of 
serum glycoproteins known as the acute phase reactants. Serum 
protease inhibitors such A1PI, TATI, ASTI and 0:-2 
antiplasmin are included in this group of acute phase 
reactants. The results presented in this thesis with (1) STase 
released from jejunal slices, (2) pure STases (0:2 .... 6 and 0:2 .... 3), 
(3) serum STase and (4) STase released from hepatocytes have 
.. 
shown that STase activity is related to the balance between 
protease inhibitory and protease activities. Protease 
inhibitors including HBF, TBP, AlPI or 0:-2 antiplasmin when 
added to the incubation medium in both jejunal and hepatocyte 
incubations resulted in higher STase activity being detectable 
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in the medium. It is therefore probable that serum protease-
inhibitors play a role in determining the serum levels of 
STase in pathological conditions. 
other evidence which supports the hypothesis that soluble 
STase activity is dependent on trypsin inhibitory activity 
from the work of Kuhlenschmidt and coworkers [1975J. 
This study involved six paediatric patients with a genetic 
deficiency of A1PI and associated hepatic cirrhosis. In these 
patients serum trypsin-inhibitory and STase activities were 
decreased compared to paediatric controls [Table 5.1]. The 
authors were unable to explain the significantly lower levels 
of STase activity observed in these patients. In contrast, 
serum GTase activity remained similar in patients and 
controls. Other serum enzymes assayed such as alkaline 
phosphatase, .B-galactosidase, alanine transaminase, aspartate 
transaminase were either elevated or within the control range. 
This study provides evidence which supports the hypothesis 
that STase activity is dependent on protease inhibitory 
activity. It should be noted that among all the enzymes 
studied, STase was the only serum enzyme whose activity in 
serum was decreased. 
The release of STase from hepatocytes and liver slices 
has been studied extensively since liver is considered to be 
the major source of serum STase [Kaplan et al., 1983; Van Dijk 
et al., 1986; Woloski et al., 1986). It was observed that in 
21. 
Table 5.1. Serum STase and GTase activities in patients with 
a deficiency of A1PI. Serum STase and GTase activities are 
shown in individuals with AlP! deficiency and controls. 
[Adapted from Kuhlenschmidt et al., 1975]. 
glycosyltransferase activity (I..nnol/ h per ml serum [x 10.1 ) 
GTas8 
accentor ds-fetuin ds-cerulonlasmin ds-AlPI ovalbumin 
I patient I 2.77 1.16 0.70 0.396 
I patient II 2.39 0.96 0.64 0.334 
I patient III 1.02 0.64 0.472 
I oatient IV 2.14 1.08 0.404 
I natient V 2.12 1.05 0.69 0.414 
I patient VI 2.63 1.05 0.67 0.404 
mean (I-VI) 2.30 1.05 0.67 0.404 
Controls 
range 4.04 - 1.68 - 1.24 - 0.26 -
6.64 2.09 1. 66 0.59 
6.06 1.88 1.38 0.40 
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the presence of dexamethasone an increased release of STase 
into the incubation medium was observed during experiments 
with rat hepatocytes [van Dijk et al., 1986]. The soluble 
STase activity released into the medium was higher when the 
incubation medium was supplemented with heat-inactivated serum 
compared to incubations without the serum supplement. The 
results presented in this thesis show that the STase activity 
released into the medium during hepatocyte incubations was 
higher when the medium was supplemented with antiprotease, 
(either HBF, TBP, AIPI, Q 2 antiplasmin or heat-inactivated 
serum), compared to incubations without antiprotease. This 
increase was attributable to the fact that the STase activity 
released was susceptible to proteolytic degradation and that 
the protease inhibitors were able to halt this process. 
When serum from either turpentine treated or control rats 
incubated at 37° C, it was observed that trypsin and 
plasmin inhibitory activities decreased over the 0 to 4 hours 
of incubation [Figure 5.5]. Protease inhibitory activity 
remained higher in turpentine treated serum compared to 
control serum throughout the 4 hours of incubation {Figure 
5.5}. STase activity followed the same pattern as protease 
inhibitory activity and was higher in serum from turpentine 
treated rats compared to serum from control rats {Figure 5.6] . 
Thus higher STase activity was paralleled by higher trypsin 
22. 
and plasmin inhibitory activities. TBP when added to serum 
slowed down the decrease in serum STase activity observed 
during incubation [Figure 5.6]. Serum GTase activity was 
similar in turpentine treated and control rats, indicating 
that GTase, unlike STase was not affected by the protease and 
protease inhibitory activities (Figure 5.7]. 
Very little is known regarding the factors which 
control the levels of soluble STase activity in serum and 
other tissue fluids, as well as the STase released during 
tissue culture experiments. STase activity in serum is 
increased in disease conditions including cancer, such as in 
multiple myeloma [Frithz et al., 1985]. The levels of plasma 
protease inhibitors are increased during cancer and may 
influence plasma STase activities {Yoshida et al., 1989; 
Taccone et al., 1991; Lee et al., 1992]. 
The function of STase in extracellular fluids is unclear. 
The levels of CMP-NeUAc in circulation are low, even during 
the inflammatory response and it is therefore unlikely that 
the function of STase in serum is to sialylate proteins 
{Kaplan et al., 1984]. Since serum STase is thought to playa 
role in inflammation it has been hypothesised that STase is 
utilized in glycosylation reactions at the site of injury 
(Jamieson et al., 1993]. However there is no evidence to 
support this theory at the present time. 
STases are key enzymes in the glycosylation of proteins. 
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NeuAc is usually the terminal sugar on glycan chains and also 
gives a negative charge to macromolecules, which is thought to 
be important for the function of the molecule. For example, 
NeuAc is believed to play 
recognition molecules such 
important role in cellular 
the sialyl-Lex present on 
monocyte, neutrophil and tumour cell surfaces. Sialyl-Lex acts 
as a ligand for recognition between the family of selectin 
adhesion receptors on endothelial cells and lymphocytes 
[Polley et al., 1991; Berg et al., 1992; Majuiri et al., 
1992]. The NeuAc in sialyl-Lex is not present in 02 ..... 6 
linkage, but in an 02-3 linkage. However the role of serum 
STase which is the 02-6 enzyme in not well defined and more 
work is required in order to clearly define the role of STase 
in 
Proteases and their inhibitors are widely distributed in 
tissues including intestine and liver. Trypsin and plasmin 
are present in intestine [Boyd et a1., 1988; Wakabayasi and 
Kawaguchi, 1992] and liver [Tanaka et a1., 1986; Kitada et 
al., 1993; Tamanoue et al., 1993]. Trypsin is secreted into 
the intestine from the pancreas whereas liver synthesizes 
plasmin and secretes it. The presence of trypsin and/or 
plasmin inhibitors in intestine [Geboes et a1., 1982: Bohe et 
a1., 1986 b, 1987] and liver [LaUrell and Ericksson, 1963; 
Liebermann et al., 1972; Bathurst et al., 1984] have been well 
documented. Protease inhibitors are synthesised in liver and 
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secreted into the circulation. Proteases and their inhibitors 
are thought to play important roles in disease processes 
including cancer (Goldfarb and Liotta, 1986; Duffy, 1987; 
Zucker, 1988] and inflammatory diseases (Bohe et al., 1986a,b; 
Strygler et al., 1990]. Plasma levels of protease-inhibitors 
and proteinases are altered in diseases such as emphysema 
(Laurell and Ericksson, 1963; Martin et al., 1973], 
pancreatitis (Martin et al., 1973; Aroasio and Piantino, 1991; 
Taccone et al., 1991], inflammation [Matsuda et al., 1980; 
Jonsson et al., 1982; Travis and salvesen, 1983; Heidtman and 
Travis, 1986] and liver diseases [Aoki and Yamanaka, 1978, 
Trischitta et al., 1991]. Therefore in similar conditions the 
levels of protease-inhibitors in tissue fluids could affect 
STase activity. 
In conclusion STase activity was related to protease-
inhibitory activity in experiments with (1) a mixture of pure 
STase and GTase, (2) STase in serum from turpentine-treated 
and control rats and (3) STase activity released during the 
incubation of hepatocytes. Increased protease inhibitory 
activity was associated with increased STase activity. This 
relationship with protease inhibitory activity was not 
observed in the case of GTase. These studies indicated that 
soluble STase is more sensitive to proteolytic inactivation by 
trypsin or plasmin than is soluble GTase. 
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CHAPTER VI. SUMMARY, GENERAL DISCUSSION AND FUTURE 
PERSPECTIVES 
VI. 1. summary 
(1) . The incubation of jejunal slices resulted in the 
release of soluble STase into the incubation medium. However 
the STase released was susceptible to proteolysis and in order 
to measure activity there was a requirement for either heat-
inactivated serum, AIPI or Q 2 antiplasmin in the incubation 
medium . 
(2). The addition of heparin to HHS or HRS supplemented 
incubations resulted in a decrease in medium STase activity 
compared to similar incubations without heparin . 
(3). HBF isolated from HRS and HHS was determined to be 
the serum component which was exerting the protective effect 
on STase. HSF displayed inhibitory activity towards trypsin 
and plasmin. TBP which also displayed trypsin and plasmin 
inhibitory activity .... as isolated from HBF and able to 
protect the STase activity released from jejunal slices. 
(4). Heat-inactivated serum from turpentine treated rats 
had higher trypsin and plasmin inhibitory activities than did 
heat-inactivated from control rats. When heat-
inactivated serum from turpentine treated rats .... as used to 
supplement jejunal and hepatocyte incubations, STase activity 
released into the medium .... as increased compared to incubations 
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supplemented .... ith heat-inactivated control serum. 
(5). Trypsin and plasmin ..... hen added to a mixture of pure 
STase and GTase, preferentially degraded STase activity. TBP 
.... as able to prevent the decrease in STase activity caused by 
proteases. 
(6). Serum from turpentine treated rats showed higher 
STase as .... ell as trypsin and plasmin inhibitory activities 
compared to control serum. Incubation of sera from control or 
turpentine treated rats at 37° C lead to a decrease in STase 
and protease inhibitory activities. TBP was able to protect 
STase from the action of trypsin and plasmin. 
(7) STase activity released into the medium during the 
incubation of hepatocytes was higher when the incubations were 
supplemented .... ith either heat-inactivated serum from control 
rats, HBF or TBP compared to incubations in buffer alone. When 
the incubations were supplemented with heat-inactivated serum 
from turpentine treated rats STase activity was increased 
compared to incubations where heat-inactivated control serum 
was used. 
VI. 2. General discussion 
VI.2.1. Trypsin and plasmin and their inhibitors 
Trypsin and plasmin have been implicated in a number of 
disease processes. For example, plasmin is thought to playa 
role in angiogenesis, inflammation and tumour metastasis 
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[Vassalli et aI., 1991 J. Trypsin has a function in the onset 
and development of pancreatitis [Creutzfeldt and Schmidt, 
1970; steer, 1986; Arais et aI., 1993]. During pancreatitis 
trypsin and other pancreatic enzymes are activated within the 
pancreas causing tissue damage as well as increased levels of 
trypsin and decreased levels of trypsin inhibitors in plasma. 
Tumour associated trypsins (TATs) have been isolated from 
mucinous ovarian cyst fluid and showed some similarities with 
pancreatic trypsin [Emi et al., 1986; Koivunen et al., 1989, 
1990). TATs are produced by many tumour cell lines of 
different origins [Ikonen et aI., 1990]. 
In the pancreas the role of trypsin inhibitors such as 
TATI/PSTI (tumour associated trypsin inhibitor/ pancreatic 
secretory trypsin inhibitor) is thought to be protection of 
the gland against destruction by premature activation of 
trypsin [Pubols et al., 1974]. The main target of AIPI, which 
is the major protease inhibitor in serum is leucocyte elastase 
and decreases in serum AlPI are associated with pulmonary and 
hepatic damage [Erickson, 1984]. Trypsin inhibitors in the 
intestine are thought to provide the intestinal tissue 
protection against pancreatic trypsin [Freeman et aI., 1990b]. 
Serum and tissue levels of trypsin inhibitors are increased in 
malignant conditions and inflammation [Stenman, 1990, 1991; 
Taccone et aI., 1991]. It is believed that these inhibitors 
protect the tissues frQm being destroyed by proteases. Severe 
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infections and tissue destruction also cause increases in 
serum and urinary levels of trypsin-inhibitors (Lasson et al., 
1986 ; ogawa et al., 1987, Ogawa, 1988; Stenman et al., 1991]. 
Trypsin inhibitors including A1PI (a l proteinase 
inhibitor) , PSTI/TATI (pancreatic secretory trypsin inhibitor/ 
tumour associated trypsin inhibitor) and ASTI (acid stable 
trypsin inhibitor) also inhibit plasmin (panell et al., 1974; 
Heidtman and Travis, 1986; Sumi et al., 1987; TUrpeinen e t 
al., 1988). At least three mechanisms have been described 
which can increase the concentration of trypsin inhibitors in 
circulation. These include leakage due to tissue damage such 
as that seen during pancreatitis, increased production and 
secretion by cells or tumours cells and impaired renal 
function (stenman, 1990; Lasson et al., 1986]. 
It is therefore evident that a number of pathological 
conditions are associated with alterations in the circulatory 
levels of trypsin and plasmin inhibitors. The circulatory 
levels of these inhibitors may in turn affect the levels of 
circulatory proteins such as STase. 
VI . 2 .2. STas. releas ed during i ejunal slice inCUbations 
The soluble STase activity released during jejunal 
incubations was susceptible to proteolytic degradation. 
Therefore in order to measure STase activity released there 
was a requirement for either HHS, HRS, TBP , A1PI or a 2 
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antiplasmin in the incubation medium. All these protease 
inhibitors inhibited trypsin and plasmin. These observations 
support the findings of other researchers who reported that 
HHS when present in the incubation medium caused a release of 
STase from jejunal slices [Ratnam et al., 1987]. The results 
in this thesis indicate that the STase was released even in 
the absence of heat-inactivated serum . However, the STase 
released was labile and the role of heat-inactivated serum in 
the release of STase was to prevent the STase released from 
being destroyed by proteases. Other researchers have also 
reported that the activity of STase released into the 
incubation medium was increased when intestinal incubation s 
were supplemented with heat-inactivated fetal calf serum 
[ Kolinska et al., 1990; Hamr et al., 1993]. Therefore the 
results in this thesis provide an explanation regarding the 
role of heat-inactivated serum in the release of STase during 
intestinal incubations. The STase released into the medium was 
the Gal,B1 .... 4GlcNAC STase ( Chapter III, this thesis] which 
supports the observations made by Hamr et al., (1993] . 
According to the findings in this thesis protease 
inhibitors had a part in determining the levels of STase in 
the incubation medium. The implications arising from this 
observation are that inhibitors of trypsin and lor plasmin in 
inCUbation media or body fluids influence the levels of 
soluble STase. The results indicated that TBP isolated from 
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HBF was the serum component required i n the incubation medium 
in order to measure the STase released. Other inhibitors of 
trypsin and plasmin such as AlP! and 0 2 antiplasmin were 
equally effective. Therefore these results imply that rather 
than one specific inhibitor such as TBP, other inhibitors of 
trypsin and plasmin in general were also effective in 
protecting STase . 
The intestine is rich in proteases with a number of them 
originating from the pancreas [Tsukamoto et al . , 1986]. 
Intestinal secretions are also rich in proteases [Geboes et 
al., 1982 ] . Therefore the presence of proteinases in the 
jejunal slice incubations is not surprising. Protease-
inhibitors/ proteases are thought to play important roles in 
the pathophysiology of the intestine. AIPI, ASTI and TAT! are 
produced by the intestinal cells [Geboes et al., 1982; Bohe et 
al . , 1986 a, b). As discussed in the previous chapter serum 
levels of proteinase inhibitors including AlP! and TAT! are 
altered during pathological conditions, and the altered 
balance between proteinase inhibitors/ proteinases may also 
affect STase . 
Trypsin and plasmin inhibitors in serum are increased 
during the acute phase response [Travis and Salvesen, 1983]. 
For example thermal injury in the rat was also associated with 
increased STase activity in intestine and serum [Chu et al., 
22' 
1988). Therefore in this and similar conditions protease 
inhibitors could influence soluble STase activity in plasma. 
VI.i.3. ST_s. r.le.sed during hepatocyte incubations 
The liver is thought to be the major source of 
STase, as a result of which the release of STase from liver 
slices and hepatocytes has been extensively studied [Kaplan et 
al., 1983; VanDijk et al., 1986; Lammers and Jamieson, 1988]. 
In cultures with hepatocytes and liver slices it has been 
demonstrated that during incubation STase was released into 
the incubation medium [Kaplan et al., 1983; VanDijk et al., 
1986; Lammers and Jamieson, 1988; Harder et al 1990]. The 
enzyme released from rat liver has been well characterized and 
it has been shown to be GaI61 ..... 4GlcNAca2 ..... 6 STase, which is 
similar to the soluble serum enzyme [ Kaplan et al., 1983; 
Lammers and Jamieson, 1988; Harder et al., 1990; this thesis 
Chapter 5]. It has been shown in experiments with hepatocytes 
and hepatoma cell lines that glucocorticoids and cytokines 
caused increased release of STase measured by increased STase 
activity in the medium [VanDijk et al., 1986; Harder et al., 
1990]. This effect of glucocorticoids and cytokines is thought 
.. 
by Wang to be due to increased expression of mRNA for STase 
[wang et al., 1989; 1990a]. 
Serum STase is increased during inflammation in the rat, 
mouse and guinea pig and the enzyme is considered to be an 
acute-phase reactant [Lombart et al., 1980; Lammers and 
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Jamieson, 1986, 1988, 1989, 1990]. This increase in serum 
STase has been attributed to an increase in the activity of a 
cathepsin 0 like protease which cleaves the STase from the 
membrane. But very little information is available regarding 
the factors that control the levels of the STase released. 
Unlike the jejunal incubations where only trace amounts 
of STase activity were detected in the medium when the 
incubations were carried out in KRB alone, appreciable amounts 
of STase were detected in the medium during the incubation of 
hepatocytes in KRB. However in both jejunal and hepatocyte 
incubations addition of heat-inactivated 
antiproteases to the incubation medium resulted in increased 
STase activity. other researchers have reported that the STase 
activity released during the incubation of hepatocytes was 
increased when the incubation medium contained HHS [VanOijk et 
aI., 1986]. The results in this thesis suggest that soluble 
STase activity is protected by trypsin and plasmin inhibitors 
some of which are present in heat-inactivated rat serum (HRS). 
This protection from proteolysis is one of the factors 
involved in the control of STase activity in serum. 
Proteinase inhibitors and proteinases are involved in the 
pathophysiology of liver disease. Proteinases inhibitors 
including A1PI, ASTI, PST! and (12 antiplasmin are acute phase 
reactants. Increased production of these inhibitors by the 
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liver during the acute phase response is thought to account 
for the increased serum concentrations during the acute phase 
response [Jonsson et al., 1982; Travis and Salvesen, 1983; 
Heidtman and Travis, 1986). Increased serum levels of these 
inhibitors have also been observed in hepatic disease 
[ Trischitta et al., 1991; Lee et al., 1992). Trypsin 
inhibitors are also present in bile [ Yamamoto et al., 1986] 
and human hepatoma cells have been shown to release a trypsin 
inhibitor [ MCKeehan et al., 1986 ] . Therefore the levels of 
proteinase inhibitors in disease conditions could well 
influence levels of enzymes such as STase in plasma. 
VI . 2.4. Function of protease inhibitors in incubation systems 
Serine proteinases are present in liver and intestine and 
have been isolated from hepatic membranes ( Tanaka et al., 
1986; Tamanoue et al., 1993]. The intestine is also rich in 
proteases (TSukamoto et al., 1982) . The inclusion of serum 
proteinase inhibitors in cell/tissue culture systems is 
believed to curtail proteolytic damage to cells (Tanaka et 
al., 1986]. The results presented in this thesis indicate that 
STase released during tissue or cell incubations can also be 
i 
damaged by proteases, indicating that prot eases can destroy 
proteins released into the incubation medium. Therefore in 
tissue and cell incubations care should be exercised in the 
interpretation of results especially if the release of 
proteins is being researched as these proteins may be the 
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targets for proteases. This was especially applicable to the 
jejunal incubation systems. 
In the case of jejunal and hepatocyte incubations low 
levels of STase were observed in buffer and increased levels 
of STase were observed when the buffer was supplemented with 
proteinase inhibitors. Thus the low STase activity detected 
when the incubations were carried out in buffer alone was due 
to the fact that the STase was being destroyed by proteases 
and not because of the rate of release. 
VI.2.5. aTase in serum 
Increased STase activity in serum has been observed in 
disease conditions including and inflammation. 
Proteinase inhibitors make up at least 10\ of the total serum 
proteins [Travis and Salvesen, 1983]. Changes in the balance 
between protease inhibitors/ proteases in serum could affect 
levels of STase. Serum STase is considered to be 
acute phase marker and during inflammation there is 
increased release of STase from the liver [Lammers and 
Jamieson 1986,1988,1990; Jamieson et al., 1993}. However 
proteinase inhibitors in blood or serum could also have a 
bearing on STase activities. In the experiments presented in 
this thesis serum STase and protease inhibitory activities 
decreased with time of incubation at 37°C [Chapter V; Figures 
5.5 and 5.6]. TBP prevented this decline in STase activity. 
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storage of plasma and blood at 22° and 3 7°C has been shown to 
increase proteolytic activity [Bode and Norris, 1992; Wallvik 
et aI., 1992]. In the experiments with serum in this thesis, 
the incubation of serum at 37° C lead to decreases in trypsin 
and plasmin inhibitory and STase activities [Chapter V; 
Figures 5.5 and 5.6]. Other studies have also indicated that 
in serum, decreased trypsin inhibitory activity 
accompanied by decreased STase activity [Kuhlenschmidt, et 
aI., 1975 ] . Therefore, there is strong evidence that the 
activity of serum STase is closely related to trypsin and/or 
plasmin inhibitory activities. 
GTase was also studied and the results presented in this 
thesis indicate that GTase was not readily inactivated by 
trypsin or plasmin and thus its activity did not depend upon 
the presence of protease inhibitors. 
VI.2.6. Protease inhibitors/proteases in serum may represent 
a means by which acti vi ties of other enzymes are controlled 
Generally, enzymes are present at higher concentrations 
in cells than in plasmal serum or other tissue fluids. Normal 
plasma levels of enzymes reflect the balance between synthesis 
.. 
and release of enzymes during normal cell turnover and their 
clearance from circulation. A number of factors contribute to 
the plasma levels of enzymes. These include the rate of 
release from cells, the degree of cell damage, induction of 
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enzyme synthesis, the extent of cell proliferation and the 
rate of enzyme clearance from plasma [ Zilva and Pannal, 1984]. 
However very little is known regarding the factors that 
actually c ontrol enzyme activities in plasma or serum . As 
mentioned above, a number of pathological conditions 
associated with alterations in the protease inhibitor and 
protease levels in plasma and other body fluids. since STase 
activity in plasma is related to the balance between levels of 
protease inhibitors and proteases and this observation may 
signify a means of control of activities of enzymes such as 
STase in incubation media and body fluids. 
VI. 3. Future perspectives 
The results presented in this thesis indicate that 
soluble STase activity was directly proportional to the level 
of trypsin and plasmin inhibitors and inversely proportional 
to trypsin and plasmin activities. More work is needed to 
further clarify this relationship. There is a need for studies 
directed towards measuring levels of STase and proteinase 
inhibitors in altered metabolic states such as pancreatitis, 
sepsis, emphysema and trauma where there is imbalance 
between protease inhibitors and protease levels in tissue 
fluids. Pancreatitis is associated with an increase in 
activation of proteases in pancreatic fluid and blood. 
Emphysema is another condition where increased tissue 
proteolysis occurs and the plasma levels of protease 
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inhibitors are altered. 
This work has concentrated on defining the role of 
proteases and protease inhibitors in stabilising soluble STase 
activity. In this thesis only serine proteinases and their 
inhibitors were studied. However blood contains other 
proteinases and inhibitors including cysteine proteinases. It 
would be interesting to determine whether other proteinase 
inhibitors influence levels of serum enzymes such as GTase, 
alkaline phosphatase and lactate dehydrogenase. 
In conclusion, the results of this study show that it is 
important to consider proteolytic degradation of soluble 
enzymes in tissue fluids when enzyme activities 
concentrations are being studied . 
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